EBNA1 inhibitors and methods using same

ABSTRACT

The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a 35 U.S.C. § 371 national phase applicationfrom, and claims priority to, International Application No.PCT/US2016/032574, filed May 14, 2016, which claims priority under 35U.S.C. § 119(e) to U.S. Provisional Application No. 62/161,490, filedMay 14, 2015, all of which applications are incorporated by referenceherein in their entireties.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under grant numbers5R43AI079928 and 2R44AI09658803 awarded by National Institutes of Health(NIAID) and grant number 1R21NS063906 awarded by National Institutes ofHealth (NINDS). The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

EBV is a human gamma-herpesvirus that infects over 90% of the adultpopulation worldwide. In combination with known and unknown cofactors,especially immunosuppression, EBV infection constitutes a highcarcinogenic risk. EBV has been classified by the World HealthOrganization as a class I human carcinogen because of its causalassociation with Burkitt's lymphoma, nasopharyngeal carcinoma, about 50%of all Hodgkin's lymphoma, gastric carcinoma, angiocentric T/NKlymphoma, and lymphoproliferative disorders of the immunosuppressed. EBVis responsible for about 1% of all human cancers, worldwide. Theoncogenic potential of EBV is readily demonstrated in vitro by itscapacity to immortalize primary B-lymphocytes in culture, and in vivo byits ability to drive infected B-cells into aggressive lymphoblasticlymphomas in immunocompromised hosts.

EBV, like other herpesviruses, has a latent and lytic replication cycle.While the EBV lytic cycle is essential for viral transmission andincreases risk of EBV-associated malignancy, it is the latent viralinfection that is oncogenic. The latent virus expresses a limited set ofviral genes that stimulate cellular proliferation and survival.Clinically available inhibitors of herpesvirus DNA polymerases,including variants of acyclovir (e.g. ganciclovir) and phosphonoaceticacid (e.g. foscarnet) have at least partial inhibitory activity againstEBV lytic replication. However, none of the available herpesvirusantivirals are effective at blocking the virus from progressing to alatent infection or eliminating latent infection. Primary infectionswith EBV can evoke a robust, sometimes debilitating immune responsereferred to as infectious mononucleosis (IM). Despite this robust immunereaction, the virus efficiently establishes latent infection inB-lymphocytes, where the virus can reside in long-lived memory B-cells.In some circumstances, latent infection can also be established inT-lymphocytes and epithelial cells. During latency, the virus does notproduce infectious particles, and viral gene expression is limited to asubset of transcripts with growth-transforming and anti-apoptoticfunctions that contribute to EBV carcinogenesis. Thus, no existinganti-viral drug or immunological response can block the establishment ofan EBV latent infection, which has the potential to drive lymphoid andepithelial cell oncogenic growth transformation.

Numerous studies have demonstrated that Epstein-Barr Nuclear Antigen 1(EBNA1) is an ideal target for elimination of latent infection andtreatment of EBV-associated disease. In one aspect, EBNA1 is expressedin all EBV-positive tumors. In another aspect, EBNA1 is required forimmortalization of primary B-lymphocytes and for the stable maintenanceof the EBV genome in latently infected cells. In yet another aspect,genetic disruption of EBNA1 blocks the ability of EBV to immortalizeprimary human B-lymphocytes and causes loss of cell viability inpreviously established EBV-positive cell lines. In yet another aspect,biochemical disruption of EBNA1 folding blocks the establishment of EBVlatent infection. HSP90 inhibitors cause the selective killing of EBV⁺B-cells and block lymphomagenesis in mouse models. In yet anotheraspect. EBNA1 is a non-cellular viral oncoprotein that is functionallyand structurally well characterized. The three-dimensional structure ofEBNA1 bound to its cognate DNA sequence has been solved by X-raycrystallography. Analysis of the DNA binding domain reveals that EBNA1protein is druggable, with several deep pockets and channels within theDNA binding domain that are predicted to disrupt DNA binding when boundto small molecules. In yet another aspect, targeting a non-selfviral-encoded protein for inhibition mitigates the potential risk ofinherent toxicity. EBNA1 has a unique structural fold that is distinctfrom all known cellular DNA binding and replication proteins. In yetanother aspect, the EBNA1 DNA binding function is essential for allknown EBNA1 functions, including genome maintenance, DNA replication,transcription regulation, and host-cell survival. These studiesdemonstrate that EBNA1-DNA binding domain is a validated target forinhibition of EBV-latent infection and treatment of EBV-associatedmalignancies.

EBV plays a causative role in the tumorigenesis for a number of cancersincluding nasopharyngeal carcinoma, gastric carcinomas, non-hodgkinlymphoma (anaplastic large-cell lymphoma, angioimmunoblastic T-celllymphoma, hepatosplenic T-cell lymphoma. B-cell lymphoma. Burkitt'slymphoma, reticuloendotheliosis, reticulosis, microglioma, diffuse largeB-cell lymphoma, extranodal T/NK lymphoma/angiocentric lymphoma,follicular lymphoma, immunoblastic lymphoma, mucosa-associated lymphatictissue lymphoma, B-cell chronic lymphocytic leukemia, mantle celllymphoma, mediastinal large B cell lymphoma, lymphoplasmactic lymphoma,nodal marginal zone B cell lymphoma, splenic marginal zone lymphoma,intravascular large B-cell lymphoma, primary effusion lymphoma,lyphomatoid granulomatosis, angioimmunoblastic lymphadenopathy),leiomyosarcomas, X-linked lymphoproliferative disease, post-transplantlymphoproliferative disorders, Hodgkin's lymphoma and breast cancer. Aninhibitor of EBNA1 would change current clinical practice and bevaluable for therapeutic treatment of EBV-associated diseases.Currently, nucleoside analogues (aciclovir, ganciclovir, foscarnet) canbe used to treat lytic EBV infection and pathologies related to lyticEBV infection. However, these general antiviral drugs are not specificfor lytic EBV infection, and carry the risk of severe adverse effects.

EBV infection and EBNA1 have also been implicated in infectiousmononucleosis, chronic fatigue syndrome (CFS), multiple sclerosis,systemic lupus erythematosus, and rheumatoid arthritis. Treatment withcompounds that prevent EBV infection and/or prevent lytic EBV infectionand/or prevent latent EBV infection and/or inhibit EBNA1 would providetherapeutic relief to patients suffering from these diseases. To date,however, no effective specific treatments exist for lytic EBV infectionand/or for pathologies related to lytic EBV infection. Further, to date,no effective treatments exist for latent EBV infection and/orpathologies related to latent EBV infection. Further, no effectivetreatments exist for the treatment of diseases associated with EBNA1.

There is a thus long felt need for novel compounds and methods using thesame, which are useful for treating EBNA1 infection and/or diseasesassociated with EBNA1. Such treatments should be useful for thetreatment of subjects afflicted with diseases and conditions associatedwith EBV infection, and/or subjects that are refractory to currenttreatments for infectious mononucleosis, chronic fatigue syndrome,multiple sclerosis, systemic lupus erythematosus and/or rheumatoidarthritis. The present invention addresses these needs.

BRIEF SUMMARY OF THE INVENTION

The invention provides a compound of formula (I), or an enantiomer,diastereomer, tautomer, salt and/or solvate thereof. The inventionfurther provides a pharmaceutical composition comprising at least onecompound of the invention and at least one pharmaceutically acceptablecarrier. The invention further provides a method of treating and/orpreventing a disease or disorder caused by EBNA1 activity in a subject.The invention further provides a method of treating and/or preventingEpstein-Barr Virus (EBV) infection, and/or a disease or disorderassociated with EBV infection, in a subject. The invention furtherprovides a method of treating and/or preventing lytic and/or latent EBVVirus infection in a subject. The invention further provides a method ofmaking compounds of the invention.

In certain embodiments, the compound is

wherein: X¹ is selected from the group consisting of CR^(4a) and N; X²is selected from the group consisting of CR^(4b) and N; X³ is selectedfrom the group consisting of CR^(4c) and N;R¹ is selected from the group consisting of

R² is selected from the group consisting of

R³ is selected from the group consisting of —CO₂R^(4d),—C(═O)NH—S(═O)₂NR⁵R⁶, —S(═O)₂NHC(═O)R⁷, —NHS(═O)₂R⁷, and1H-tetrazol-5-yl;R^(4a), R^(4b), and R^(4c) are each independently selected from thegroup consisting of F, Cl, Br, I, and H;R^(4d) is selected from the group consisting of H, optionallysubstituted C₁₋₆ linear alkyl, and optionally substituted C₃₋₆ branchedalkyl;R⁵ is selected from the group consisting of H, optionally substitutedC₁₋₆ linear alkyl, and optionally substituted C₃₋₆ branched alkyl;R⁶ is selected from the group consisting of H, optionally substitutedC₁₋₆ linear alkyl, and optionally substituted C₃₋₆ branched alkyl; or R⁵and R⁶ are taken together with the atoms to which they are connected toform a 3-, 4-, 5-, or 6-membered ring optionally containing a unitselected from the group consisting of oxygen, sulfur, SO, SO₂, CF₂, NH,N(C₁₋₆ alkyl), N(C₃₋₇ branched alkyl), N(C₃₋₆ cycloalkyl),N(heteroaryl), NCO(C₁₋₆ alkyl), NCO(C₁₋₆ branched alkyl), NCO(C₃₋₆cycloalkyl), NCO₂(C₁₋₆ alkyl), NCO₂(C₁₋₆ branched alkyl), NCO₂(C₃₋₆cycloalkyl), NCON(C₁₋₆ alkyl)₂, SO₂NH₂, NSO₂(C₁₋₆ alkyl), NSO₂(C₃₋₆branched alkyl), NSO₂(C₃₋₆ cycloalkyl), and NSO₂Aryl;R⁷ is selected from the group consisting of H, optionally substitutedC₁₋₆ linear alkyl, optionally substituted C₃₋₆ branched alkyl, C₁₋₆haloalkyl, optionally substituted phenyl, optionally substitutedpyridyl, optionally substituted heteroaryl, and —CH(R⁵)(R⁶);R^(8a), R^(8b), R^(8c), R^(8d), and R^(8e) are each independentlyselected from the group consisting of H, halogen, hydroxyl, CN,optionally substituted C₁₋₆ linear alkyl, optionally substituted C₃₋₆branched alkyl, and C₁₋₆ alkoxy;R^(9a), R^(9b), R^(9c), R^(9d), and R^(9e) are each independentlyselected from the group consisting of H, halogen, optionally substitutedC₁₋₆ linear alkyl, C₁₋₆ alkoxy, and optionally substituted C₃₋₆ branchedalkyl;R^(10a) and R^(10b) are each independently selected from the groupconsisting of H, optionally substituted C₁₋₆ linear alkyl, andoptionally substituted C₁₋₆ branched alkyl;L¹ is selected from the group consisting of —C≡C—, —CH═CH— and—(CH₂)_(n)—;L² is selected from a group consisting of NH, (CH₂)_(m), and

wherein “**” indicates the point of attachment for R²;Q¹ is selected from a group consisting of optionally substituted benzyl,—COR⁷, —SO₂R⁷

n is 0, 1, 2, or 3; m is 0, 1, 2, or 3; q is 1, 2, 3, or 4; and x is 0,1, 2, or 3.

In certain embodiments, the compound is at least one compound of formulaselected from the group consisting of formula (II)

formula (III)

formula (IV)

and formula (V)

In certain embodiments, the compound is at least one compound of formulaselected from the group consisting of formula (VI)

formula (VII)

formula (VIII)

formula (IX)

In certain embodiments, the compound is at least one compound of formulaselected from the group consisting of formula (X)

formula (XI)

Formula (XII)

formula (XIII)

In certain embodiments, the compound is at least one compound of formulaselected from the group consisting of formula (XIV)

formula (XV)

formula (XVI)

and formula (XVII)

In certain embodiments, the compound is a compound of formula (XVIII)

In certain embodiments, R¹ is at least one selected form the groupconsisting of 4-acetamidophenyl; 4-(aminomethyl)phenyl; 4-aminophenyl;4-{8-azabicyclo[3.2.1]octan-3-yl}phenyl; 3-carbamoyl-5-methoxyphenyl;4-{[(2-carboxyphenyl)formamido]methyl} phenyl; 4-{[(4-carboxyphenyl)formamido]methyl} phenyl; 4-(3-chloro-4-fluorobenzenesulfon amido)phenyl; 2,4-difluorophenyl;4-[(4,4-difluoropiperidin-1-yl)methyl]phenyl;4-{[2-(dimethylamino)ethyl]carbamoyl}phenyl;4-({[2-(dimethylamino)ethyl](methyl)amino}methyl)phenyl;1-[2-(dimethylamino)ethyl]-1H-pyrrolo[2,3-b]pyridin-3-yl;1-[3-(dimethylamino)propyl]-1H-pyrrolo[2,3-b]pyridin-3-yl;4-[(dimethylamino)methyl]phenyl;4-[(1,1-dioxo-1λ⁶-thian-4-yl)oxy]phenyl;4-[(1,1-dioxo-1λ⁶-thiomorpholin-4-yl)methyl] phenyl;4-[(4-ethylpiperazin-1-yl)methyl]phenyl;4-fluoro-3-(oxan-4-yloxy)phenyl; 4-fluorophenyl;4-{[(2-fluorophenyl)formamido]methyl)phenyl; 4-[(3-hydroxyazetidin-1-yl)methyl]phenyl;4-([4-(2-hydroxyethyl)piperidin-1-yl]methyl} phenyl;4-[(4-hydroxypiperidin-1-yl)methyl]phenyl; 4-methanesulfonamidophenyl;3-(3-methanesulfonamide phenyl)phenyl;4-(4-methoxybenzene-sulfonamido)phenyl;4-{[(2-methoxyethyl)(methyl)amino]methyl}phenyl;4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl; 4-methoxyphenyl;4-[(4-methoxypiperidin-1-yl)methyl]phenyl;4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl;4-[(4-methylpiperazin-1-yl)methyl]phenyl;2-methyl-4-oxo-3,4-dihydroquinazolin-7-yl;3-(morpholin-4-ylmethyl)phenyl; 4-(morpholin-4-ylmethyl)phenyl;1-[2-(morpholin-4-yl)ethyl]-1H-pyrrolo[2,3-b]pyridin-3-yl;1-[3-(morpholin-4-yl)propyl]-1H-pyrrolo[2,3-b]pyridin-3-yl;1-[2-(morpholin-4-yl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl;1-[2-(dimethylamino)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl;1,8-naphthyridin-2-yl; 4-(oxan-4-ylmethoxy)phenyl;4-[2-(oxan-4-yl)ethoxy]phenyl; 4-(oxan-4-yloxy)phenyl;4-(oxan-4-yloxy)-3-(trifluoromethyl)phenyl;4-oxo-3,4-dihydroquinazolin-7-yl; phenyl4-[(phenylformamido)methyl]phenyl; 4-(piperazine-1-carbonyl)phenyl;4-(pyridine-3-amido)phenyl; 2-(5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl;and 4-(thiophene-2-sulfonamido)phenyl.

In certain embodiments, R² is selected from the group consisting of1,3-benzothiazol-5-yl; 5-fluoro-indol-6-yl; 7-fluoro-indol-6-yl;Indol-6-yl; 2-methyl-1,3-benzothiazol-5-yl;1-methyl-1H-pyrrolo[2,3-b]pyridin-6-yl; 1,8-naphthyridin-2-yl;1,8-naphthyridin-3-yl; and 1H-pyrrolo[2,3-b]pyridine-5-yl.

In certain embodiments, the compound is at least one selected from thegroup consisting of2-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-indol-6-ylethynyl]-benzoicacid;3-[3-Acetylamino-4-(tetrahydro-pyran-4-yloxy)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-[4-(8-Acetyl-8-aza-bicyclo[3.2.1]oct-3-yl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-[1-(2-Dimethylamino-ethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-[1-(3-Dimethylamino-propyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-benzoicacid;2-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-pyrrolo[2,3-b]pyridin-3-ylethynyl]-benzoicacid;2-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-benzoicacid;3-{2-[3-(3,3-dimethyl-2-oxoazetidin-1-yl)phenyl]ethynyl}-2-(1H-pyrrol-1-yl)benzoicacid;3-[1-(2-Dimethylamino-ethyl)-1H-pyrrolo[2,3-b]pyridin-3-ylethynyl]-2-(H-indol-6-yl)-benzoicacid;2-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-pyrrolo[2,3-b]pyridin-3-ylethynyl]-benzoicacid;3-[1-(3-Dimethylamino-propyl)-1H-pyrrolo[2,3-b]pyridin-3-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-{1-[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-ethyl]-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl}-2-(1H-indol-6-yl)-benzoicacid;2-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-indol-5-ylethynyl]-benzoicacid;2-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-indol-5-ylethynyl]-benzoicacid;2-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-indol-6-ylethynyl]-benzoicacid;2-(1H-Indol-6-yl)-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-3-ylethynyl)-benzoicacid;2-(1H-indol-6-yl)-3-[1-(tetrahydro-pyran-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-benzoicacid;2-(1H-Indol-6-yl)-3-[1-(tetrahydro-pyran-4-ylmethyl)-1H-indol-5-ylethynyl]-benzoicacid;2-(1H-Indol-6-yl)-3-[1-(1-methanesulfonyl-piperidin-4-ylmethyl)-1H-indol-5-ylethynyl]-benzoicacid;2-(1H-Indol-6-yl)-3-[1-(1-methanesulfonyl-piperidin-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-benzoicacid;3-[1-(1,1-Dioxo-hexahydro-1λ⁶-thiopyran-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-{1-[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-ethyl]-1H-indol-5-yl-ethynyl}-2-(1H-indol-6-yl)-benzoicacid;3-{1-[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-ethyl]-1H-indol-6-ylethynyl}-2-(1H-indol-6-yl)-benzoicacid;3-{1-[3-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-propyl]-1H-indol-5-yl-ethynyl}-2-(1H-indol-6-yl)-benzoicacid;3-{1-[3-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-propyl]-1H-indol-6-yl-ethynyl}-2-(1H-indol-6-yl)-benzoicacid;3-[4-(1,1-Dioxo-hexahydro-1λ⁶-thiopyran-4-yloxymethyl)-phenyethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-benzoicacid; 2-(1H-Indol-6-yl)-3-(4-isopropoxymethyl-phenylethynyl)-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(1-oxo-hexahydro-1λ⁴-thiopyran-4-yloxy)-phenylethynyl]-benzoicacid;2-(1H-indol-6-yl)-3-(3-morpholin-4-ylmethyl-1H-indol-6-ylethynyl)-benzoicacid;2-(1H-indol-6-yl)-3-[3-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-6-ylethynyl]-benzoicacid;3-[3-(1,1-Dioxo-1λ⁶-thiomorpholin-4-ylmethyl)-1H-indol-6-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-indol-6-yl)-3-(2-morpholin-4-ylmethyl-1H-indol-6-ylethynyl)-benzoicacid;3-[2-(1,1-Dioxo-1λ₆-thiomorpholin-4-ylmethyl)-1H-indol-6-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-[1-(4-ethoxy-2-methyl-butyl)-6-fluoro-1H-indol-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-[7-fluoro-1-(tetrahydro-pyran-4-ylmethyl)-1H-indol-6-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-[1-(1,1-dioxo-hexahydro-1λ₆-thiopyran-4-ylmethyl)-7-fluoro-1H-indol-6-ylethynyl]-2-(1H-indol-1)-benzoicacid;3-[1-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-ylmethyl)-6-fluoro-1H-indol-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-(7-fluoro-3-morpholin-4-ylmethyl-1H-indol-6-ylethynyl)-2-(1H-indol-(6-yl)-benzoicacid;3-(6-fluoro-3-morpholin-4-ylmethyl-1H-indol-5-ylethynyl)-2-(1H-indol-6-yl)-benzoicacid; 3-((4-(2H-tetrazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid; 3-((3-(2H-tetrazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid; 2-(1H-indol-6-yl)-3-((4-(oxazol-5-yl)phenyl)ethynyl)benzoic acid;2-(1H-indol-6-yl)-3-((4-(6-oxo-1,6-dihydropyridazin-3-yl)phenyl)ethynyl)benzoicacid; 2-(1H-indol-6-yl)-3-((3-methoxy-4-(morpholinomethyl)phenyl)ethynyl)benzoic acid;3-((3-hydroxy-4-(morpholine-4-carbonyl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid;2-(1H-Indol-6-yl)-3-[3-methoxy-4-(4-morpholin-4-yl-piperidin-1-ylmethyl)-phenylethynyl]-benzoicacid;3-((4-((4,4-difluoropiperidin-1-yl)methyl)-3-methoxyphenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid;3-((4-((4-(dimethylcarbamoyl)piperidin-1-yl)methyl)-3-methoxyphenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid;3-((3-hydroxy-4-(4-morpholinopiperidine-1-carbonyl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid;3-((4-(4,4-difluoropiperidine-1-carbonyl)-3-hydroxyphenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid;2-(1H-indol-(i-yl)-3-((4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenyl)ethynyl)benzoic acid;2-(1H-indol-6-yl)-3-((4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)methyl)phenyl)ethynyl)benzoic acid;2-(1H-indol-6-yl)-3-((4-((1-(isopropylsulfonyl)piperidin-4-yl)methyl)phenyl)ethynyl) benzoic acid;3-((4-((1-acetylpiperidin-4-yl)methyl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid; 3-((2-acetylisoindolin-5-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid;2-(1H-indol-6-yl)-3-((2-(isopropylsulfonyl)isoindolin-5-yl)ethynyl)benzoicacid;2-(1H-indol-6-yl)-3-((2-(1-(methylsulfonyl)pyrrolidin-3-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoicacid;2-(1H-indol-6-yl)-3-((2-((1-(meth)ylsulfonyl)piperidin-4-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoicacid;2-(1H-indol-6-yl)-3-((2-(1-(methylsulfonyl)azetidin-3-yl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoic acid;2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoicacid;2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoicacid;3-((2-((1-acetylpyrrolidin-3-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid;2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)azetidin-3-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoicacid; 2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)azetidin-3-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoicacid;2-(1H-indol-6-yl)-3-((2-(3-(methylsulfonamido)benzyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoicacid;2-(1H-indol-6-yl)-3-((2-(3-(methylsulfonamido)benzyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoicacid;2-(1H-indol-6-yl)-3-((2-(1-(methylsulfonyl)pyrrolidin-3-yl)isoindolin-5-yl)ethynyl)benzoicacid;2-(1H-indol-(6-yl)-3-((2-(1-(methylsulfonyl)azetidin-3-yl)isoindolin-5-yl)ethynyl)benzoicacid;2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)isoindolin-5-yl)ethynyl)benzoicacid; 2-(1H-indol-(6-yl)-3-((2-((1methylsulfonyl)azetidin-3-yl)methyl)isoindolin-5-yl)ethynyl) benzoicacid;2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)piperidin-4-yl)methyl)isoindolin-5-yl)ethynyl)benzoicacid;2-(1H-indol-6-yl)-3-((2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoicacid;2-(1H-indol-6-yl)-3-((2-(isopropylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoicacid;2-(1H-indol-6-yl)-3-((2-propionyl-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoic acid;2-(1H-indol-6-yl)-3-((2-(methylsulfonyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl)ethynyl)benzoicacid;2-(1H-indol-6-yl)-3-((2-isopropylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoicacid;3-((2-acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid;2-(1H-indol-6-yl)-3-((2-propionyl-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoic acid;3-[4-(4-cyano-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid; 3-[4-(3-cyano-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoic acid;3-[4-(3-carbamoyl-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-indol-6-yl)-3-[4-(4-trifluoromethyl-phenoxymethyl)-phenylethynyl]-benzoicacid;2-(1H-indol-6-yl)-3-[4-(3-trifluoromethyl-phenoxymethyl)-phenylethynyl]-benzoicacid;2-(1H-indol-6-yl)-3-[4-(4-methoxy-phenoxymethyl)-phenylethynyl]-benzoicacid;3-[4-(4-carbamoyl-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-indol-6-yl)-3-[4-(3-methoxy-phenoxymethyl)-phenylethynyl]-benzoicacid; 2-(1H-indol-6-yl)-3-(4-phenoxymethyl-phenylethynyl)-benzoic acid;3-[4-(2-fluoro-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-indol-6-yl)-3-[4-(pyridin-3-yloxymethyl)-phenylethynyl]-benzoicacid;3-[4-(3-chloro-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-[4-(3,4-dichloro-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-indol-6-yl)-3-[4-(2-trifluoromethyl-phenoxymethyl)-phenylethynyl]-benzoicacid;3-[4-(2-cyano-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-indol-6-yl)-3-[4-(4-methanesulfonyl-phenoxymethyl)-phenylethynyl]-benzoicacid;2-(1H-indol-6-yl)-3-[4-(pyrimidin-5-yloxymethyl)-phenylethynyl]-benzoicacid;2-(1H-indol-6-yl)-3-[4-(2-methanesulfonyl-phenoxymethyl)-phenylethynyl]-benzoicacid; 2-(1H-indol-6-yl)-3-[4-(3-methanesulfonyl-phenoxymethyl)-phenylethynyl]-benzoic acid;2-(1H-Indol-6-yl)-3-{2-[3-(3-methanesulfonamidophenyl)phenyl]ethynyl}benzoic acid;2-(1H-Indol-6-yl)-3-{2-[6-(oxan-4-yloxy)pyridin-3-yl]ethynyl}benzoicacid;2-(1H-Indol-6-yl)-3-{2-[2-(propylcarbamoyl)-1H-indol-6-yl]ethynyl}benzoicacid;2-(1H-Indol-6-yl)-3-{2-[3-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)phenyl]ethynyl}benzoicacid;3-{2-[3-Cyano-4-(oxan-4-yloxy)phenyl]ethynyl}-2-(1H-indol-6-yl)benzoicacid;3-[2-(3-{[4-(Ethoxycarbonyl)piperazin-1-yl]methyl}phenyl)ethynyl]-2-(1H-indol-6-yl)benzoicacid;3-(2-{4-[3-(Hydroxymethyl)oxetan-3-yl]phenyl}ethynyl)-2-(1H-indol-(6-yl)benzoicacid;3-{2-[3-(5-Amino-1H-pyrazol-3-yl)phenyl]ethynyl}-2-(1H-indol-6-yl)benzoicacid; 2-(1H-Indol-(w-yl)-3-{2-[3-(1,3-oxazol-5-yl)phenyl]ethynyl}benzoicacid; 2-(1H-Indol-6-yl)-3-{2-[4-(oxane-4-carbonyl)phenyl]ethynyl}benzoicacid; 2-(7-Fluoro-1H-indol-6-yl)-3-phenylethynyl-benzoic acid;2-Benzothiazol-6-yl-3-phenylethynyl-benzoic acid;2-Benzothiazol-5-yl-3-phenylethynyl-benzoic acid;2-(2-Methyl-benzothiazol-5-yl)-3-phenylethynyl-benzoic acid;2-(5-Fluoro-1H-indol-6-yl)-3-phenylethynyl-benzoic acid;2-(6-Fluoro-1H-indol-5-yl)-3-phenylethynyl-benzoic acid;2-[1,8]Naphthyridin-3-yl-3-phenylethynyl-benzoic acid;2-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-phenylethynyl-benzoic acid;2-[1,8]Naphthyridin-2-yl-3-phenylethynyl-benzoic acid;3-Phenylethynyl-2-(1H-pyrrolo[2,3-b]pyridin-(3-yl)-benzoic acid;2-(4-methoxy-1H-indol-6-yl)-3-(2-phenylethynyl)-benzoic acid;3-(2-(4-(2-hydroxypropan-2-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid;3-(2-(4-(2-aminothiazol-4-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid; 2-(1H-Indol-6-yl)-3-(3-sulfamoyl-phenylethynyl)-benzoic acid;3-(4-Amino-3-sulfamoyl-phenylethynyl)-2-(1H-indol-6-yl)-benzoic acid;2-(1H-indol-6-yl)-3-(Spiro[2H-1-benzopyran-2,1′-4-piperidine-1-t-butylcarboxylate]-4(3H)-one)ethynyl)benzoicacid;3-(2-(3-(2-aminothiazol-4-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid;3-(2-(4-(5-(methoxycarbonyl)-2-aminothiazol-4-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid;3-(2-(4-(5-amino-1,3,4-thiadiazol-2-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid;3-(2-(4-(3-amino-1H-pyrazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid;2-Amino-4-{4-[3-carboxy-2-(1H-indol-6-yl)-phenylethynyl]-phenyl}-thiazole-5-carboxylicacid;3-(2-(4-(2-aminooxazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(2-methanesulfonylamino-thiazol-4-yl)-phenylethynyl]-benzoicacid;2-(1H-Indol-6-yl)-3-[3-(2-methanesulfonylamino-thiazol-4-yl)-phenylethynyl]-benzoicacid;3-(2-(1,4-dihydro-2-((4-methoxypiperidin-1-yl)methyl)-4-oxoquinazolin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid;3-(2-(1,4-dihydro-2-((4-thiomorpholine-1,1dioxide-1-yl)methyl)-4-oxoquinazolin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid;3-(2-(2-(trifluoromethyl)-3,4-dihydro-4-oxoquinazolin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid;3-(2-(3,4-dihydro-3-(2-methoxyethyl)-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid; 2-(1H-Indol-6-yl)-3-[3-(2-methoxy-6-methyl-phenylcarbamoyl)-phenylethynyl]-benzoic acid;3-{3-[4-(1,1-Dioxo-1-thiomorpholin-4-yl)-phenylcarbamoyl]-phenylethynyl}-2-(1H-indol-6-yl)-benzoic acid;3-Phenylethynyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoic acid;3-(4-Fluoro-phenylethynyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid;3-(4-Methoxy-phenylethynyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid;2-(1H-Pyrrolo[2,3-b]pyridin-5-yl)-3-[4-(tetrahydro-pyran-4-yloxy)-phenylethynyl]-benzoicacid;2-(1H-Indol-(6-yl)-3-{4-[2-(tetrahydro-pyran-4-yl)-ethoxyl]-phenylethynyl}-benzoicacid;3-[4-(1,1-Dioxo-hexahydro-1-thiopyran-4-yloxy)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid; 2-(1H-Indol-6-yl)-3-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoicacid;3-[4-(4-Ethyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid;3-[4-(1,1-Dioxo-thiomorpholin-4-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid; 3-(4-{[(2-Dimethylamino-ethyl)-methyl-amino]-methyl}-phenylethynyl)-2-(1H-indol-6-yl)-benzoic acid;3-(4-[4-(2-Hydroxy-ethyl)-piperidin-1-ylmethyl]-phenylethynyl)-2-(1H-indol-6-yl)-benzoicacid;3-[4-(4-Hydroxymethyl-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(4-methyl-[1,4]diazepan-1-ylmethyl)-phenylethynyl]-benzoicacid;3-[4-(3-Hydroxy-azetidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-[4-(4-Hydroxy-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(4-methoxy-piperidin-1-ylmethyl)-phenylethynyl]-benzoicacid; 3-(4-Dimethylaminomethyl-phenylethynyl)-2-(1H-indol-(6-yl)-benzoicacid;2-(1H-Indol-6-yl)-3-4{[(2-methoxy-ethyl)-methyl-amino]-methyl}-phenylethynyl)-benzoicacid;3-[4-(4,4-Difluoro-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-[4-(3,3-Difluoro-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-[4-(3,4-Dihydro-1H-isoquinolin-2-)ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid; 2-(1H-Indol-6-yl)-3-[4-(4-methanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoic acid;2-(1H-Indol-6-yl)-3-[4-(3-trifluoromethyl-piperidin-1-ylmethyl)-phenylethynyl]-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(3-methoxy-pyrrolidin-1-ylmethyl)-phenylethynyl]-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(4-isopropyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid;3-[4-(4-Cyclohexyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid; 3-[4-(4-Cyclopropanecarbonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoic acid;2-(1H-Indol-6-yl)-3-(4-piperazin-1-ylmethyl-phenylethynyl)-benzoic acid;3-[4-(4-Benzenesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoic acid;3-{4-[(1,1-Dioxo-hexahydro-1-thiopyran-4-ylamino)-methyl]-phenylethynyl}-2-(1H-indol-6-yl)-benzoicacid;3-[4-(4-Cyclopentyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-[4-(4-Dimethylcarbamoyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(2,3,5,6-tetrahydro-[1,2′]bipyrazinyl-4-ylmethyl)-phenylethynyl]-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(4-thiazol-2-yl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid;3-{4-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylamino)-methyl]-phenylethynyl}-2-(1H-indol-6-yl)-benzoicacid;3-{4-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylamino)-methyl]-phenylethynyl}-2-(1H-indol-6-yl)-benzoicacid;3-[4-(4-Methyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid;3-[4-(4-Methoxy-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid;2-(1H-Indol-5-yl)-3-[4-(4-methoxy-piperidin-1-ylmethyl)-phenylethynyl]-benzoicacid;2-(1H-Indol-5-yl)-3-[4-(4-methanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid;3-[4-(4-Methanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid;3-[4-(4,4-Difluoro-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-5-yl)-benzoicacid;2-(1H-Indol-5-yl)-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid;3-[4-(4-Ethanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-[4-(1,1-Dioxo-hexahydro-1-thiopyran-4-yloxy)-phenylethynyl]-2-(1H-indol-5-yl)-benzoicacid;3-[4-(1,1-Dioxo-hexahydro-thiopyran-4-yloxy)-phenylethynyl]-2-(1H-indazol-6-yl)-benzoicacid;3-[2-Fluoro-4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-[4-(1,1-Dioxo-hexahydro-1-thiopyran-4-)yloxymethyl)-2-fluoro-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(2-methanesulfonyl-2,7-diaza-spiro[3.5]non-7-ylmethyl)-phenylethynyl]-benzoic acid;2-(1H-Indol-(6-yl)-3-[4-(5-methanesulfonyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-ylmethyl)-phenylethynyl]-benzoicacid; 3-[4-(4-Cyclopropanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoic acid;2-(1H-Indol-(w-yl)-3-{4-[4-(propane-2-sulfonyl)-piperazin-1-ylmethyl]-phenylethynyl}-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(7-methanesulfonyl-2,7-diaza-spiro[3.5]non-2-ylmethyl)-phenylethynyl]-benzoicacid;2-(1H-Indol-5-yl)-3-[4-(tetrahydro-pyran-4-yloxy)-phenylethynyl]-benzoicacid;N—(N,N-dimethylsulfamoyl)-2-(1H-indol-6-yl)-3-((4-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)phenyl)ethynyl)benzamide;2-(1H-indol-6-yl)-N-(methylsulfonyl)-3-((4-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)phenyl)ethynyl)benzamide;6-[2-[4-(Tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-6-(1H-tetrazol-5-yl)-phenyl]-1H-indole;3-[4-(Benzoylamino-methyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-Indol-6-yl)-3-(4-{[(4-oxo-cyclohexanecarbonyl)-amino]-methyl}-phenylethynyl)-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(4-oxo-cyclohexylcarbamoyl)-phenylethynyl]-benzoicacid;3-[4-(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylcarbamoyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;3-[4-(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylcarbamoyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(4-methyl-piperazine-1-carbonyl)-phenylethynyl]-benzoicacid;2-(1H-Indol-6-yl)-3-[4-(4-methoxy-piperidine-1-carbonyl)-phenylethynyl]-benzoicacid;2-(1H-Indazol-6-yl)-3-[4-(4-methanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid; and2-(1H-Indol-6-yl)-3-[4-(4-sulfamoyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid.

In certain embodiments, the pharmaceutical composition further comprisesat least one additional antiviral and/or anticancer agent.

In certain embodiments, the method comprises administering to thesubject a therapeutically effective amount of at least one compoundand/or composition of the invention.

In certain embodiments, the disease or disorder is at least one selectedfrom the group consisting of cancer, infectious mononucleosis, chronicfatigue syndrome, multiple sclerosis, systemic lupus erythematosus, andrheumatoid arthritis.

In certain embodiments, the cancer is at least one selected from thegroup consisting of nasopharyngeal carcinoma, gastric carcinomas,non-hodgkin lymphoma, anaplastic large-cell lymphoma, angioimmunoblasticT-cell lymphoma, hepatosplenic T-cell lymphoma, B-cell lymphoma,Burkitt's lymphoma, reticuloendotheliosis, reticulosis, microglioma,diffuse large B-cell lymphoma, extranodal T/NK lymphoma/angiocentriclymphoma, follicular lymphoma, immunoblastic lymphoma, mucosa-associatedlymphatic tissue lymphoma. B-cell chronic lymphocytic leukemia, mantlecell lymphoma, mediastinal large B cell lymphoma, lymphoplasmacticlymphoma, nodal marginal zone B cell lymphoma, splenic marginal zonelymphoma, intravascular large B-cell lymphoma, primary effusionlymphoma, lyphomatoid granulomatosis, angioimmunoblasticlymphadenopathy, leiomyosarcomas. X-linked lymphoproliferative disease,post-transplant lymphoproliferative disorders, Hodgkin's lymphoma andbreast cancer.

In certain embodiments, the compound is administered to the subject byat least one route selected from the group consisting of oral, nasal,inhalational, topical, buccal, rectal, pleural, peritoneal, vaginal,intramuscular, subcutaneous, transdermal, epidural, intratracheal, otic,intraocular, intrathecal, and intravenous routes. In other embodiments,the compound is administered as part of a pharmaceutical compositionfurther comprising at least one pharmaceutically acceptable carrier

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates in part to the unexpected discovery ofnovel EBNA1 inhibitors, and compositions comprising the same. Thecompounds and compositions of the invention are useful for treatingand/or preventing: diseases or disorders caused by EBNA1 activity,diseases or disorders associated with EBNA1 activity, EBV infections,diseases or disorders associated with EBV infections, lytic EBVinfections, latent EBV infections, diseases or disorders associated withlytic EBV infections, and diseases or disorders associated with latentEBV infection.

Definitions

Throughout the description, where compositions are described as having,including, or comprising specific components, or where processes aredescribed as having, including, or comprising specific process steps, itis contemplated that compositions of the present teachings also consistessentially of, or consist of, the recited components, and that theprocesses of the present teachings also consist essentially of, orconsist of, the recited processing steps.

In the application, where an element or component is said to be includedin and/or selected from a list of recited elements or components, itshould be understood that the element or component can be any one of therecited elements or components and can be selected from a groupconsisting of two or more of the recited elements or components.

As used herein, unless defined otherwise, all technical and scientificterms generally have the same meaning as commonly understood by one ofordinary skill in the art to which this invention belongs. Generally,the nomenclature used herein and the laboratory procedures in organicchemistry, virology, biochemistry and pharmaceutical sciences are thosewell-known and commonly employed in the art.

As used herein, the articles “a” and “an” refer to one or to more thanone (i.e, to at least one) of the grammatical object of the article. Byway of example, “an element” means one element or more than one element.

As used herein, the term “about” will be understood by persons ofordinary skill in the art and will vary to some extent on the context inwhich it is used. As used herein, “about” when referring to a measurablevalue such as an amount, a temporal duration, and the like, is meant toencompass variations of ±20%, ±10%, ±5%, ±1%, or ±0.1% from thespecified value, as such variations are appropriate to perform thedisclosed methods.

For the purposes of the present invention the terms “compound,”“analog.” and “composition of matter” stand equally well for the prodrugagent described herein, including all enantiomeric forms, diastereomericforms, salts, and the like, and the terms “compound,” “analog,” and“composition of matter” are used interchangeably throughout the presentspecification.

As used herein, a “disease” is a state of health of a subject whereinthe subject cannot maintain homeostasis, and wherein if the disease isnot ameliorated then the subject's health continues to deteriorate.

As used herein, a “disorder” in a subject is a state of health in whichthe subject is able to maintain homeostasis, but in which the subject'sstate of health is less favorable than it would be in the absence of thedisorder. Left untreated, a disorder does not necessarily cause afurther decrease in the subject's state of health.

As used herein, the term “EBNA1 inhibitor” refers a compound thatinhibits EBNA1.

As used herein, the term “EBV” refers to Epstein-Barr virus.

As used herein, the term “ED₅₀” or “ED50” refers to the effective doseof a formulation that produces about 50% of the maximal effect insubjects that are administered that formulation.

As used herein, an “effective amount,” “therapeutically effectiveamount” or “pharmaceutically effective amount” of a compound is thatamount of compound that is sufficient to provide a beneficial effect tothe subject to which the compound is administered.

“Instructional material,” as that term is used herein, includes apublication, a recording, a diagram, or any other medium of expressionthat can be used to communicate the usefulness of the composition and/orcompound of the invention in a kit. The instructional material of thekit may, for example, be affixed to a container that contains thecompound and/or composition of the invention or be shipped together witha container that contains the compound and/or composition.Alternatively, the instructional material may be shipped separately fromthe container with the intention that the recipient uses theinstructional material and the compound cooperatively. Delivery of theinstructional material may be, for example, by physical delivery of thepublication or other medium of expression communicating the usefulnessof the kit, or may alternatively be achieved by electronic transmission,for example by means of a computer, such as by electronic mail, ordownload from a website.

The term “low toxicity” for a compound towards a cell or tissue, as usedherein, refers to a CC₅₀ (concentration that is cytotoxic to 50% cells)of 50 μM or less for that compound towards that cell or tissue. Incertain embodiments, these characteristics ensure that these compoundsdo not affect the healthy cells of the patient and permit more effectivetreatment.

As used herein, the term “pharmaceutical composition” or “composition”refers to a mixture of at least one compound useful within the inventionwith a pharmaceutically acceptable carrier. The pharmaceuticalcomposition facilitates administration of the compound to a subject.

As used herein, the term “pharmaceutically acceptable” refers to amaterial, such as a carrier or diluent, which does not abrogate thebiological activity or properties of the compound useful within theinvention, and is relatively non-toxic, i.e., the material may beadministered to a subject without causing undesirable biological effectsor interacting in a deleterious manner with any of the components of thecomposition in which it is contained.

As used herein, the term “pharmaceutically acceptable carrier” means apharmaceutically acceptable material, composition or carrier, such as aliquid or solid filler, stabilizer, dispersing agent, suspending agent,diluent, excipient, thickening agent, solvent or encapsulating material,involved in carrying or transporting a compound useful within theinvention within or to the subject such that it may perform its intendedfunction. Typically, such constructs are carried or transported from oneorgan, or portion of the body, to another organ, or portion of the body.Each carrier must be “acceptable” in the sense of being compatible withthe other ingredients of the formulation, including the compound usefulwithin the invention, and not injurious to the subject. Some examples ofmaterials that may serve as pharmaceutically acceptable carriersinclude: sugars, such as lactose, glucose and sucrose; starches, such ascorn starch and potato starch; cellulose, and its derivatives, such assodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate;powdered tragacanth; malt; gelatin; talc; excipients, such as cocoabutter and suppository waxes; oils, such as peanut oil, cottonseed oil,safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols,such as propylene glycol; polyols, such as glycerin, sorbitol, mannitoland polyethylene glycol; esters, such as ethyl oleate and ethyl laurate;agar; buffering agents, such as magnesium hydroxide and aluminumhydroxide; surface active agents; alginic acid; pyrogen-free water;isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffersolutions; and other non-toxic compatible substances employed inpharmaceutical formulations.

As used herein, “pharmaceutically acceptable carrier” also includes anyand all coatings, antibacterial and antifungal agents, and absorptiondelaying agents, and the like that are compatible with the activity ofthe compound useful within the invention, and are physiologicallyacceptable to the subject. Supplementary active compounds may also beincorporated into the compositions. The “pharmaceutically acceptablecarrier” may further include a pharmaceutically acceptable salt of thecompound useful within the invention. Other additional ingredients thatmay be included in the pharmaceutical compositions used in the practiceof the invention are known in the art and described, for example inRemington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co.,1985, Easton, Pa.), which is incorporated herein by reference.

As used herein, the language “pharmaceutically acceptable salt” refersto a salt of the administered compound prepared from pharmaceuticallyacceptable non-toxic acids and bases, including inorganic acids,inorganic bases, organic acids, inorganic bases, solvates, hydrates, andclathrates thereof.

The term “prevent,” “preventing” or “prevention,” as used herein, meansavoiding or delaying the onset of symptoms associated with a disease orcondition in a subject that has not developed such symptoms at the timethe administering of an agent or compound commences. Disease, conditionand disorder are used interchangeably herein.

As used herein, a “patient” or “subject” may be a human or non-humanmammal or a bird. Non-human mammals include, for example, livestock andpets, such as ovine, bovine, porcine, canine, feline and murine mammals.In certain embodiments, the subject is human.

The term “treat,” “treating” or “treatment,” as used herein, meansreducing the frequency or severity with which symptoms of a disease orcondition are experienced by a subject by virtue of administering anagent or compound to the subject.

As used herein, unless otherwise noted, “alkyl” and “aliphatic” whetherused alone or as part of a substituent group refers to straight andbranched carbon chains having 1 to 20 carbon atoms or any number withinthis range, for example 1 to 6 carbon atoms or 1 to 4 carbon atoms.Designated numbers of carbon atoms (e.g. C₁₋₆) shall refer independentlyto the number of carbon atoms in an alkyl moiety or to the alkyl portionof a larger alkyl-containing substituent. Non-limiting examples of alkylgroups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl,iso-butyl, tert-butyl, and the like. Alkyl groups can be optionallysubstituted. Non-limiting examples of substituted alkyl groups includehydroxymethyl, chloromethyl, trifluoromethyl, aminomethyl,1-chloroethyl, 2-hydroxyethyl, 1,2-difluoroethyl, 3-carboxypropyl, andthe like. In substituent groups with multiple alkyl groups such as (C₁₋₆alkyl)₂ amino, the alkyl groups may be the same or different.

The term “alkoxy” refers to the group —O-alkyl, wherein the alkyl groupis as defined above. Alkoxy groups optionally may be substituted. Theterm C₃-C₆ cyclic alkoxy refers to a ring containing 3 to 6 carbon atomsand at least one oxygen atom (e.g., tetrahydrofuran,tetrahydro-2H-pyran). C₃-C₆ cyclic alkoxy groups optionally may besubstituted.

The term “aryl,” wherein used alone or as part of another group, isdefined herein as an unsaturated, aromatic monocyclic ring of 6 carbonmembers or to an unsaturated, aromatic polycyclic ring of from 10 to 14carbon members. Aryl rings can be, for example, phenyl or naphthyl ringeach optionally substituted with one or more moieties capable ofreplacing one or more hydrogen atoms. Non-limiting examples of arylgroups include: phenyl, naphthylen-1-yl, naphthylen-2-yl,4-fluorophenyl, 2-hydroxyphenyl, 3-methylphenyl, 2-amino-4-fluorophenyl,2-(N,N-diethylamino)phenyl, 2-cyanophenyl, 2,6-di-tert-butylphenyl,3-methoxyphenyl, 8-hydroxynaphthylen-2-yl 4,5-dimethoxynaphthylen-1-yl,and 6-cyano-naphthylen-1-yl. Aryl groups also include, for example,phenyl or naphthyl rings fused with one or more saturated or partiallysaturated carbon rings (e.g., bicyclo[4.2.0]octa-1,3,5-trienyl,indanyl), which can be substituted at one or more carbon atoms of thearomatic and/or saturated or partially saturated rings.

The term “arylalkyl” or “aralkyl” refers to the group -alkyl-aryl, wherethe alkyl and aryl groups are as defined herein. Aralkyl groups of thepresent invention are optionally substituted. Examples of arylalkylgroups include, for example, benzyl, 1-phenylethyl, 2-phenylethyl,3-phenylpropyl, 2-phenylpropyl, fluorenylmethyl and the like.

As used herein, “cycloalkyl,” whether used alone or as part of anothergroup, refers to a non-aromatic carbon-containing ring includingcyclized alkyl, alkenyl, and alkynyl groups, e.g., having from 3 to 14ring carbon atoms, preferably from 3 to 7 or 3 to 6 ring carbon atoms,or even 3 to 4 ring carbon atoms, and optionally containing one or more(e.g., 1, 2, or 3) double or triple bond. Cycloalkyl groups can bemonocyclic (e.g., cyclohexyl) or polycyclic (e.g., containing fused,bridged, and/or spiro ring systems), wherein the carbon atoms arelocated inside or outside of the ring system. Any suitable ring positionof the cycloalkyl group can be covalently linked to the defined chemicalstructure. Cycloalkyl rings can be optionally substituted. Nonlimitingexamples of cycloalkyl groups include: cyclopropyl,2-methyl-cyclopropyl, cyclopropenyl, cyclobutyl,2,3-dihydroxycyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl,cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctanyl,decalinyl, 2,5-dimethylcyclopentyl, 3,5-dichlorocyclohexyl,4-hydroxycyclohexyl, 3,3,5-trimethylcyclohex-1-yl, octahydropentalenyl,octahydro-1H-indenyl, 3a,4,5,6,7,7a-hexahydro-3H-inden-4-yl,decahydroazulenyl; bicyclo[6.2.0]decanyl, decahydronaphthalenyl, anddodecahydro-1H-fluorenyl. The term “cycloalkyl” also includescarbocyclic rings which are bicyclic hydrocarbon rings, non-limitingexamples of which include, bicyclo-[2.1.1]hexanyl,bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl,1,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl, andbicyclo[3.3.3]undecanyl.

“Haloalkyl” is intended to include both branched and straight-chainsaturated aliphatic hydrocarbon groups having the specified number ofcarbon atoms, substituted with 1 or more halogen. Haloalkyl groupsinclude perhaloalkyl groups, wherein all hydrogens of an alkyl grouphave been replaced with halogens (e.g., —CF₃, CF₂CF₃). Haloalkyl groupscan optionally be substituted with one or more substituents in additionto halogen. Examples of haloalkyl groups include, but are not limitedto, fluoromethyl, dichloroethyl, trifluoromethyl, trichloromethyl,pentafluoroethyl, and pentachloroethyl groups.

As used herein, the term “halogen” shall mean chlorine, bromine,fluorine and iodine.

The term “heteroaryl,” whether used alone or as part of another group,is defined herein as one or more rings having from 5 to 20 atoms whereinat least one atom in at least one ring is a heteroatom chosen fromnitrogen (N), oxygen (O), or sulfur (S), and wherein further at leastone of the rings that includes a heteroatom is aromatic. In heteroarylgroups that include 2 or more fused rings, the non-heteroatom bearingring may be a carbocycle (e.g., 6,7-dihydro-5H-cyclopentapyrimidine) oraryl (e.g., benzofuranyl, benzothiophenyl, indolyl). Exemplaryheteroaryl groups have from 5 to 14 ring atoms and contain from 1 to 5ring heteroatoms independently selected from nitrogen (N), oxygen (O),or sulfur (S). One or more N or S atoms in a heteroaryl group can beoxidized. Heteroaryl groups can be substituted. Non-limiting examples ofheteroaryl rings containing a single ring include: 1,2,3,4-tetrazolyl,[1,2,3]triazolyl, [1,2,4]triazolyl, triazinyl, thiazolyl, 1H-imidazolyl,oxazolyl, furanyl, thiophenyl, pyrimidinyl, 2-phenylpyrimidinyl,pyridinyl, 3-methylpyridinyl, and 4-dimethylaminopyridinyl. Non-limitingexamples of heteroaryl rings containing 2 or more fused rings include:benzofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl,benztriazolyl, cinnolinyl, naphthyridinyl, phenanthridinyl, 7H-purinyl,9H-purinyl, 6-amino-9H-purinyl, 5H-pyrrolo[3,2-d]pyrimidinyl,7H-pyrrolo[2,3-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl,benzo[d]thiazolyl, 1H-indolyl, 4,5,6,7-tetrahydro-1-H-indolyl,quinoxalinyl, 5-methylquinoxalinyl, quinazolinyl, quinolinyl,8-hydroxy-quinolinyl, and isoquinolinyl.

The terms “heterocyclic” and/or “heterocycle” and/or “heterocycyl,”whether used alone or as part of another group, are defined herein asone or more ring having from 3 to 20 atoms wherein at least one atom inat least one ring is a heteroatom selected from nitrogen (N), oxygen(O), or sulfur (S), and wherein further the ring that includes theheteroatom is non-aromatic. In heterocycle groups that include 2 or morefused rings, the non-heteroatom bearing ring may be aryl (e.g.,indolinyl, tetrahydroquinolinyl, chromanyl). Exemplary heterocyclegroups have from 3 to 14 ring atoms of which from 1 to 5 are heteroatomsindependently selected from nitrogen (N), oxygen (O), or sulfur (S). Oneor more N or S atoms in a heterocycle group can be oxidized. Heterocyclegroups can be optionally substituted.

Non-limiting examples of heterocyclic units having a single ringinclude: diazirinyl, aziridinyl, urazolyl, azetidinyl, pyrrolyl,thiophenyl, furanyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl,isoxazolinyl, isoxazolyl, thiazolidinyl, isothiazolyl, isothiazolinyloxathiazolidinonyl, oxazolidinonyl, hydantoinyl, tetrahydrofuranyl,pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl,tetrahydropyranyl, piperidin-2-onyl (valerolactam),2,3,4,5-tetrahydro-1H-azepinyl, 2,3-dihydro-1H-indole, and1,2,3,4-tetrahydro-quinoline. Non-limiting examples of heterocyclicunits having 2 or more rings include: hexahydro-1H-pyrrolizinyl,3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazolyl,3a,4,5,6,7,7a-hexahydro-1H-indolyl, 1,2,3,4-tetrahydroquinolinyl,chromanyl, isochromanyl, indolinyl, isoindolinyl, anddecahydro-1H-cycloocta[b]pyrrolyl.

Unless otherwise noted, when two substituents are taken together to forma ring having a specified number of ring atoms (e.g., R² and R³ takentogether with the nitrogen (N) to which they are attached to form a ringhaving from 3 to 7 ring members), the ring can have carbon atoms andoptionally one or more (e.g., 1 to 3) additional heteroatomsindependently selected from nitrogen (N), oxygen (O), or sulfur (S). Thering can be saturated or partially saturated and can be optionallysubstituted.

For the purposes of the present invention, fused ring units, as well asspirocyclic rings, bicyclic rings and the like, which comprise a singleheteroatom will be considered to belong to the cyclic familycorresponding to the heteroatom containing ring. For example,1,2,3,4-tetrahydroquinoline having the formula:

is, for the purposes of the present invention, considered a heterocyclicunit, 6,7-Dihydro-5H-cyclopentapyrimidine having the formula:

is, for the purposes of the present invention, considered a heteroarylunit. When a fused ring unit contains heteroatoms in both a saturatedand an aryl ring, the aryl ring will predominate and determine the typeof category to which the ring is assigned. For example,1,2,3,4-tetrahydro-[1,8]naphthyridine having the formula:

is, for the purposes of the present invention, considered a heteroarylunit.

Whenever a term or either of their prefix roots appear in a name of asubstituent, the name is to be interpreted as including thoselimitations provided herein. For example, whenever the term “alkyl” or“aryl” or either of their prefix roots appear in a name of a substituent(e.g., arylalkyl, alkylamino) the name is to be interpreted as includingthose limitations given above for “alkyl” and “aryl.”

The term “substituted” is used throughout the specification. The term“substituted” is defined herein as a moiety, whether acyclic or cyclic,which has one or more hydrogen atoms replaced by a substituent orseveral (e.g., 1 to 10) substituents as defined herein below. Thesubstituents are capable of replacing one or two hydrogen atoms of asingle moiety at a time. In addition, these substituents can replace twohydrogen atoms on two adjacent carbons to form said substituent, newmoiety or unit. For example, a substituted unit that requires a singlehydrogen atom replacement includes halogen, hydroxyl, and the like. Atwo hydrogen atom replacement includes carbonyl, oximino, and the like.A two hydrogen atom replacement from adjacent carbon atoms includesepoxy, and the like. The term “substituted” is used throughout thepresent specification to indicate that a moiety can have one or more ofthe hydrogen atoms replaced by a substituent. When a moiety is describedas “substituted” any number of the hydrogen atoms may be replaced. Forexample, difluoromethyl is a substituted C₁ alkyl; trifluoromethyl is asubstituted C₁ alkyl; 4-hydroxyphenyl is a substituted aromatic ring;(N,N-dimethyl-5-amino)octanyl is a substituted C₈ alkyl;3-guanidinopropyl is a substituted C₃ alkyl; and 2-carboxypyridinyl is asubstituted heteroaryl.

The variable groups defined herein, e.g., alkyl, cycloalkyl, alkoxy,aryloxy, aryl, heterocycle and heteroaryl groups defined herein, whetherused alone or as part of another group, can be optionally substituted.Optionally substituted groups will be so indicated.

The following are non-limiting examples of substituents which cansubstitute for hydrogen atoms on a moiety: halogen (chlorine (Cl),bromine (Br), fluorine (F) and iodine(I)), —CN, —NO₂, oxo (═O), —OR¹¹,—SR¹¹, —N(R¹¹)₂, —NR¹¹C(O)R¹¹, —SO₂R¹¹, —SO₂OR¹¹, —SO₂N(R¹¹)₂, —C(O)R¹¹,—C(O)OR¹¹, —C(O)N(R¹¹)₂, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₂₋₈alkenyl, C₂₋₈ alkynyl, C₃₋₁₄ cycloalkyl, aryl, heterocycle, orheteroaryl, wherein each of the alkyl, haloalkyl, alkenyl, alkynyl,alkoxy, cycloalkyl, aryl, heterocycle, and heteroaryl groups isoptionally substituted with 1-10 (e.g., 1-6 or 1-4) groups selectedindependently from halogen, —CN, —NO₂, oxo, and R¹¹; wherein R¹¹, ateach occurrence, independently is H, —OR¹², —SR¹², —C(O)R¹², —C(O)OR¹²,—C(O)N(R¹²)₃, —SO₂R¹², —S(O)₂OR¹², —N(R¹²)₂, —NR¹²C(O)R¹², C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cycloalkyl (e.g., C₃₋₆cycloalkyl), aryl, heterocycle, or heteroaryl, or two R¹¹ units takentogether with the atom(s) to which they are bound form an optionallysubstituted carbocycle or heterocycle wherein said carbocycle orheterocycle has 3 to 7 ring atoms; wherein R¹², at each occurrence,independently is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₈ alkenyl, C₂₋₈alkynyl, cycloalkyl (e.g., C₃₋₆ cycloalkyl), aryl, heterocycle, orheteroaryl, or two R¹² units taken together with the atom(s) to whichthey are bound form an optionally substituted carbocycle or heterocyclewherein said carbocycle or heterocycle preferably has 3 to 7 ring atoms.

In certain embodiments, the substituents are selected from the groupconsisting of: —OR¹³; for example, —OH, —OCH₃, —OCH₂CH₃, —OCH₂CH₂CH₃;—C(O)R¹³; for example, —COCH₃, —COCH₂CH₃, —COCH₂CH₂CH₃; —C(O)OR¹³; forexample, —CO₂CH₃, —CO₂CH₂CH₃, —CO₂CH₂CH₂CH₃; —C(O)N(R¹³)₂; for example,—CONH₂, —CONHCH₃, —CON(CH₃)₂; —N(R¹³)₂; for example, —NH₂, —NHCH₃,—N(CH₃)₂, —NH(CH₂CH₃); halogen; —F, —Cl, —Br, and —I; —CH_(e)X_(g);wherein X is halogen, m is from 0 to 2, e+g=3, for example, —CH₂F,—CHF₂, —CF₃, —CCl₃, or —CBr₃; —SO₂R¹³; for example, —SO₂H; —SO₂CH₃,—SO₂C₆H₅; C₁-C₆ linear, branched, or cyclic alkyl; Cyano; Nitro;N(R¹³)C(O)R¹³; Oxo (═O); Heterocycle; and Heteroaryl, wherein each R¹³is independently H, optionally substituted C₁-C₆ linear or branchedalkyl (e.g., optionally substituted C₁-C₄ linear or branched alkyl), oroptionally substituted C₃-C₆ cycloalkyl (e.g optionally substitutedC₃-C₄ cycloalkyl); or two R¹³ units can be taken together to form a ringcomprising 3-7 ring atoms. In certain aspects, each R¹³ is independentlyH, C₁-C₆ linear or branched alkyl optionally substituted with halogen orC₃-C₆ cycloalkyl or C₃-C₆ cycloalkyl.

When any variable occurs more than one time in any constituent or in anyformula, its definition in each occurrence is independent of itsdefinition at every other occurrence (e.g., in N(R¹⁰)₂, each R¹⁰ may bethe same or different than the other). Combinations of substituentsand/or variables are permissible only if such combinations result instable compounds.

At various places in the present specification, substituents ofcompounds are disclosed in groups or in ranges. It is specificallyintended that the description include each and every individualsubcombination of the members of such groups and ranges. For example,the term “C₁₋₆ alkyl” is specifically intended to individually discloseC₁, C₂, C₃, C₄, C₅, C₆, C₁-C₆, C₁-C₅, C₁-C₄, C₁-C₃, C₁-C₂, C₂-C₆, C₂-C₅,C₂-C₄, C₂-C₃, C₃-C₆, C₃-C₅, C₃-C₄, C₄-C₆, C₄-C₅, and C₅-C₆, alkyl.

Throughout this disclosure, various aspects of the invention may bepresented in a range format. It should be understood that thedescription in range format is merely for convenience and brevity andshould not be construed as an inflexible limitation on the scope of theinvention. Accordingly, the description of a range should be consideredto have specifically disclosed all the possible sub-ranges as well asindividual numerical values within that range and, when appropriate,partial integers of the numerical values within ranges. For example,description of a range such as from 1 to 6 should be considered to havespecifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well asindividual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5,5.3, and 6. This applies regardless of the breadth of the range.

Compounds

The EBNA1 inhibitors of the present invention include a compound offormula (I), or any enantiomer, diastereomer, tautomer, salt and/orsolvate thereof:

wherein:X¹ is selected from the group consisting of CR^(4a) and N;X² is selected from the group consisting of CR^(4b) and N;X³ is selected from the group consisting of CR^(4c) and N;R¹ is selected from the group consisting of

R² is selected from the group consisting of

R³ is selected from the group consisting of —CO₂R^(4d),—C(═O)NH—S(═O)₂NR⁵R⁶, —S(═O)₂NHC(═O)R⁷, —NHS(═O)₂R⁷, and1H-tetrazol-5-yl;R^(4a), R^(4b), and R^(4c) are each independently selected from thegroup consisting of fluorine, chlorine, bromine, iodine, and H:R^(4d) is selected from the group consisting of H, optionallysubstituted C₁₋₆ linear alkyl, and optionally substituted C₃₋₆ branchedalkyl;R⁵ is selected from the group consisting of H, optionally substitutedC₁₋₆ linear alkyl, and optionally substituted C₃₋₆ branched alkyl;R⁶ is selected from the group consisting of H, optionally substitutedC₁₋₆ linear alkyl, and optionally substituted C₃₋₆ branched alkyl; or R⁵and R⁶ are taken together with the atoms to which they are connected toform a 3-, 4-, 5-, or 6-membered ring optionally containing a unitselected from the group consisting of oxygen, sulfur, SO, SO₂, CF₂, NH,N(C₁₋₆ alkyl), N(C₃₋₇ branched alkyl), N(C₃₋₆ cycloalkyl),N(heteroaryl), NCO(C₁₋₆alkyl), NCO(C₁₋₆ branched alkyl), NCO(C₃₋₆cycloalkyl), NCO₂(C₁₋₆ alkyl), NCO₂(C₁₋₆ branched alkyl), NCO₂(C₃₋₆cycloalkyl), NCON(C₁₋₆ alkyl)₂, SO₂NH₂, NSO₂(C₁₋₆ alkyl), NSO₂(C₃₋₆branched alkyl), NSO₂(C₃₋₆ cycloalkyl), and NSO₂Aryl;R⁷ is selected from the group consisting of H, optionally substitutedC₁₋₆ linear alkyl, optionally substituted C₃₋₆ branched alkyl, C₁₋₆haloalkyl, optionally substituted phenyl, optionally substitutedpyridyl, optionally substituted heteroaryl, and —CH(R⁵)(R⁶);R^(8a), R^(8b), R^(8c), R^(8d), and R^(8e) are each independentlyselected from the group consisting of H, halogen, hydroxyl, CN,optionally substituted C₁₋₆ linear alkyl, optionally substituted C₃₋₆branched alkyl, and C₁₋₆ alkoxy;R^(9a), R^(9b), R^(9c), R^(9d) and R^(9e) are each independentlyselected from the group consisting of H, halogen, optionally substitutedC₁₋₆ linear alkyl, C₁₋₆ alkoxy, and optionally substituted C₃₋₆ branchedalkyl;R^(10a) and R^(10b) are each independently selected from the groupconsisting of H, optionally substituted C₁₋₆ linear alkyl, andoptionally substituted C₁₋₆ branched alkyl;L¹ is selected from the group consisting of —C≡C—, —CH═CH— and—(CH₂)_(n)—;L² is selected from a group consisting of NH, (CH₂)_(m), and

wherein “**” indicates the point of attachment for R²:Q¹ is selected from a group consisting of optionally substituted benzyl,COR⁷, SO₂R⁷

n is 0, 1, 2, or 3; m is 0, 1, 2, or 3; q is 1, 2, 3, or 4; and x is 0,1, 2, or 3.

In certain embodiments, compound (I) is compound (II):

In certain embodiments, compound (I) is compound (III):

In certain embodiments, compound (I) is compound (IV):

In certain embodiments, compound (I) is compound (V):

In certain embodiments, compound (I) is compound (VI):

In certain embodiments, compound (I) is compound (VII):

In certain embodiments, compound (I) is compound (VII)

In certain embodiments, compound (I) is compound (IX):

In certain embodiments, compound (I) is compound (XI):

In certain embodiments, compound (I) is compound (XI):

In certain embodiments, compound (I) is compound (XII):

In certain embodiments, compound (I) is compound (XIII):

In certain embodiments, compound (I) is compound (XIV):

In certain embodiments, compound (I) is compound (XV):

In certain embodiments, compound (I) is compound (XVI):

In certain embodiments, compound (I) is compound (XVII):

In certain embodiments, X¹ is CR⁴a. In certain embodiments, X¹ is N. Incertain embodiments, X¹ is CR^(4a). In certain embodiments, X² is N. Incertain embodiments, X³ is CR^(4a). In certain embodiments, X³ is N. Incertain embodiments, R¹ is further optionally substituted phenyl. Incertain embodiments, R¹ is further optionally substituted heteroaryl. Incertain embodiments, R¹ is further optionally substituted benzyl. Incertain embodiments, R¹ is further optionally substituted heteroarylmethyl.

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

On certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R² is further H. In certain embodiments, R² isfurther NR^(10a)R^(10b). In certain embodiments. R² is further fluorine.In certain embodiments, R² is further optionally substituted phenyl. Incertain embodiments, R² is further optionally substituted heteroaryl. Incertain embodiments, R² is

In certain embodiments, R² is

In certain embodiments, R² is

In certain embodiments, R² is

In certain embodiments, R² is

In certain embodiments, R² is

In certain embodiments, R² is

In certain embodiments, R² is

In certain embodiments, R² is

In certain embodiments, R² is

In certain embodiments, R² is

In certain embodiments, R² is

In certain embodiments, R² is

In certain embodiments, R² is

In certain embodiments, R² is

In certain embodiments, R³ is CO₂R^(4d). In certain embodiments, R³ is—C(═O)NHS(═O)₂NR⁵R⁶. In certain embodiments, R³ is —S(═O)₂NHC(═O)R⁷. Incertain embodiments, R³ is —NHS(═O)R⁷. In certain embodiments, R³ is1H-tetrazol-5-yl.

In certain embodiments, R^(4a) is H. In certain embodiments, R^(4a) isfluorine. In certain embodiments, R^(4a) is chlorine. In certainembodiments, R^(4a) is bromine. In certain embodiments. R^(4a) isiodine. In certain embodiments, R^(4b) is H. In certain embodiments,R^(4b) is fluorine. In certain embodiments, R^(4b) is chlorine. Incertain embodiments, R^(4b) is bromine. In certain embodiments, R^(4b)is iodine. In certain embodiments, R^(4c) is H. In certain embodiments,R^(4b) is fluorine. In certain embodiments, R^(4c) is chlorine. Incertain embodiments, R^(4c) is bromine. In certain embodiments, R^(4c)is iodine. In certain embodiments, R^(4d) is H. In certain embodiments,R^(4d) is optionally substituted C₁₋₆ linear alkyl. In certainembodiments, R^(4d) is optionally substituted C₃, branched alkyl.

In certain embodiments, R⁵ is H, In certain embodiments, R⁵ isoptionally substituted C₁₋₆ linear alkyl. In certain embodiments, R⁵ isoptionally substituted C₃₋₆ branched alkyl.

In certain embodiments, R⁶ is H. In certain embodiments, R⁶ isoptionally substituted C₁₋₆ linear alkyl. In certain embodiments, R⁶ isoptionally substituted C₃₋₆ branched alkyl.

In certain embodiments, R⁵ and R⁶ are taken together with the atoms towhich they are connected to form a 3, 4, 5, or 6 membered ringoptionally containing a unit selected from the group consisting ofoxygen, sulfur, SO, SO₂, CF₂, NH, N(C₁₋₆ alkyl), N(C₃₋₇ branched alkyl),N(C₃₋₆ cycloalkyl), N(heteroaryl), NCO(C₁₋₆ alkyl), NCO(C₃₋₆ branchedalkyl), NCO(C₃₋₆ cycloalkyl), NCO₂(C₁₋₆ alkyl), NCO₂(C₁₋₆ branchedalkyl), NCO₂(C₃₋₆ cycloalkyl), NCON(C₁₋₆ alkyl)₂, SO₂NH₂, NSO₂(C₁₋₆alkyl), NSO₂(C₃₋₆ branched alkyl), NSO₂(C₃₋₆ cycloalkyl), and NSO₂Aryl.

In certain embodiments, R⁷ is H. In certain embodiments, R⁷ isoptionally substituted C₁₋₆ linear alkyl. In certain embodiments, R⁷ isoptionally substituted C₃₋₆ branched alkyl. In certain embodiments, R⁷is C₁₋₆ haloalkyl. In certain embodiments, R⁷ is optionally substitutedphenyl. In certain embodiments, R⁷ is optionally substituted pyridyl. Incertain embodiments, R⁷ is optionally substituted heteroaryl. In certainembodiments, R⁷ is —CH(R⁵)(R⁶).

In certain embodiments, R^(8a) is H. In certain embodiments, R^(8a) isoptionally substituted C₁₋₆ linear alkyl. In certain embodiments, R^(8a)is optionally substituted C₃₋₆ branched alkyl. In certain embodiments,R^(8a) is halogen. In certain embodiments, R^(8a) is hydroxyl. Incertain embodiments, R^(8a) is CN. In certain embodiments, R^(8a) isC₁₋₆ alkoxy. In certain embodiments, R^(8a) is —(CH₂)_(q)NR⁵R⁶. Incertain embodiments. R^(8b) is H. In certain embodiments, R^(8b) isoptionally substituted C₁₋₆ linear alkyl. In certain embodiments, R^(8b)is optionally substituted C₃₋₆ branched alkyl. In certain embodiments,R^(8b) is halogen. In certain embodiments, R^(8b) is hydroxyl. Incertain embodiments, R^(8b) is CN. In certain embodiments, R^(8b) isC₁₋₆ alkoxy. In certain embodiments, R^(8b) is —(CH₂)_(q)NR⁵R⁶. Incertain embodiments, R^(8c) is H. In certain embodiments, R^(8c) isoptionally substituted C₁₋₆ linear alkyl. In certain embodiments, R^(8c)is optionally substituted C₃₋₆ branched alkyl. In certain embodiments,R^(8c) is halogen. In certain embodiments, R^(8c) is hydroxyl. Incertain embodiments, R^(8c) is CN. In certain embodiments. R^(8c) isC₁₋₆ alkoxy. In certain embodiments, R^(8d) is H. In certainembodiments, R^(8c) is optionally substituted C₁₋₆ linear alkyl. Incertain embodiments, R^(8d) is optionally substituted C₃₋₆ branchedalkyl.

In certain embodiments, R^(9a) is H. In certain embodiments, R^(9a) isoptionally substituted C₁₋₆ linear alkyl. In certain embodiments, R^(9a)is optionally substituted C₃₋₆ branched alkyl. In certain embodiments,R^(9a) is halogen. In certain embodiments, R^(9a) is C₁₋₆ alkoxy. Incertain embodiments, R^(9b) is H. In certain embodiments, R^(9b) isoptionally substituted C₁₋₆ linear alkyl. In certain embodiments, R^(9b)is optionally substituted C₃₋₆ branched alkyl. In certain embodiments,R^(9b) is halogen. In certain embodiments, R^(9b) is C₁₋₆ alkoxy. Incertain embodiments, R^(9c) is H. In certain embodiments, R^(9c) isoptionally substituted C₁₋₆ linear alkyl. In certain embodiments, R^(9c)is optionally substituted C₃₋₆ branched alkyl. In certain embodiments,R^(9c) is halogen. In certain embodiments, R^(9c) is C₁₋₆ alkoxy. Incertain embodiments, R^(9d) is H. In certain embodiments, R^(9d) isoptionally substituted C₁₋₆ linear alkyl. In certain embodiments, R^(9d)is optionally substituted C₃₋₆ branched alkyl. In certain embodiments,R^(9d) is halogen. In certain embodiments. R^(9d) is C₁₋₆ alkoxy. Incertain embodiments, R^(9e) is H. In certain embodiments, R^(9e) isoptionally substituted C₁₋₆ linear alkyl. In certain embodiments, R^(9e)is optionally substituted C₃₋₆ branched alkyl. In certain embodiments,R^(9e) is halogen. In certain embodiments, R^(9e) is C₁₋₆alkoxy.

In certain embodiments, R^(10a) is H. In certain embodiments, R^(10a) isoptionally substituted C₁₋₆ linear alkyl. In certain embodiments,R^(10a) is optionally substituted C₁₋₆ branched alkyl. In certainembodiments, R^(10b) is H. In certain embodiments, R^(10b) is optionallysubstituted C₁₋₆ linear alkyl. In certain embodiments, R^(10b) isoptionally substituted C₁₋₆ branched alkyl.

In certain embodiments, L¹ is —C≡C—. In certain embodiments, L¹ is—CH═CH—. In certain embodiments, L¹ is (CH₂)_(n). In certainembodiments, L² is NH. In certain embodiments, L² is (CH₂)_(m). Incertain embodiments. L² is

In certain embodiments, Q¹ is

In certain embodiments, Q¹ is

In certain embodiments, Q¹ is

In certain embodiments, Q¹ is

In certain embodiments, n is 0. In certain embodiments, n is 1. Incertain embodiments, n is 2. In certain embodiments, n is 3. In certainembodiments, m is 0. In certain embodiments, m is 1. In certainembodiments, m is 2. In certain embodiments, m is 3. In certainembodiments, q is 1. In certain embodiments, q is 2. In certainembodiments, q is 3. In certain embodiments, q is 4. In certainembodiments, x is 0. In certain embodiments, x is 1. In certainembodiments, x is 2. In certain embodiments, x is 3.

In certain embodiments, compound (I) is compound (XVIII) or apharmaceutically acceptable salt form thereof:

wherein non-limiting examples of R¹, R², and m are defined in Table 1.

TABLE 1 Entry R¹ R² m 1 phenyl 1H-pyrrolo[2,3-b]pyridine-5-yl 0 24-fluorophenyl 1H-pyrrolo[2,3-b]pyridine-5-yl 0 3 4-(oxan-4-yloxy)phenyl1H-pyrrolo[2,3-b]pyridine-5-yl 0 4 4-methoxyphenyl1H-pyrrolo[2,3-b]pyridine-5-yl 0 5 3-carbamoyl-5-methoxyphenyl1H-pyrrolo[2,3-b]pyridine-5-yl 0 6 2,4-difluorophenyl1H-pyrrolo[2,3-b]pyridine-5-yl 0 7 4-acetamidophenyl1H-pyrrolo[2,3-b]pyridine-5-yl 0 84-(4-methoxybenzene-sulfonamido)phenyl 1H-pyrrolo[2,3-b]pyridine-5-yl 09 4-(thiophene-2-sulfonamido)phenyl 1H-pyrrolo[2,3-b]pyridine-5-yl 0 104-(pyridine-3-amido)phenyl 1H-pyrrolo[2,3-b]pyridine-5-yl 0 114-methanesulfonamidophenyl 1H-pyrrolo[2,3-b]pyridine-5-yl 0 124-aminophenyl 1H-pyrrolo[2,3-b]pyridine-5-yl 0 134-(4-methoxybenzene-sulfonamido)phenyl Indol-6-yl 0 144-(thiophene-2-sulfonamido)phenyl Indol-6-yl 0 154-(pyridine-3-amido)phenyl Indol-6-yl 0 16 4-methanesulfonamidophenylIndol-6-yl 0 17 4-(3-chloro-4-fluorobenzenesulfon amido) Indol-6-yl 0phenyl 18 3-carbamoyl-5-methoxyphenyl Indol-6-yl 0 19 4-[(2- Indol-6-yl0 methoxyethyl)(methyl)carbamoyl]phenyl 20 4-{[2- Indol-6-yl 0(dimethylamino)ethyl]carbamoyl}phenyl 21 4-(piperazine-1-carbonyl)phenylIndol-6-yl 0 22 4-fluoro-3-(oxan-4-yloxy)phenyl Indol-6-yl 0 234-{[(4-carboxyphenyl)formamido]methyl} Indol-6-yl 0 phenyl 234-[(3-hydroxyazetidin-1-yl)methyl]phenyl Indol-6-yl 0 243-(3-methanesulfonamidophenyl)phenyl Indol-6-yl 0 254-[(4-methoxypiperidin-1-yl)methyl]phenyl Indol-6-yl 0 264-[(4,4-difluoropiperidin-1-yl)methyl]phenyl Indol-6-yl 0 274-[(4-hydroxypiperidin-1-yl)methyl]phenyl Indol-6-yl 0 284-[(phenylformamido)methyl]phenyl Indol-6-yl 0 294-(oxan-4-ylmethoxy)phenyl Indol-6-yl 0 30 4-[2-(oxan-4-yl)ethoxy]phenylIndol-6-yl 0 31 4-{[(2- Indol-6-yl 0fluorophenyl)formamido]methyl}phenyl 32 4-[(dimethylamino)methyl]phenylIndol-6-yl 0 33 4-(aminomethyl)phenyl Indol-6-yl 0 344-{[(2-methoxyethyl)(methyl)amino]methyl} Indol-6-yl 0 phenyl 354-{[(2-carboxyphenyl)formamido]methyl} Indol-6-yl 0 phenyl 363-(morpholin-4-ylmethyl)phenyl Indol-6-yl 0 374-[(1,1-dioxo-1λ⁶-thian-4-yl)oxy]phenyl Indol-6-yl 0 384-oxo-3,4-dihydroquinazolin-7-yl Indol-6-yl 0 392-methyl-4-oxo-3,4-dihydroquinazolin-7-yl Indol-6-yl 0 404-(morpholin-4-ylmethyl)phenyl Indol-6-yl 0 414-[(4-ethylpiperazin-1-yl)methyl]phenyl Indol-6-yl 0 424-[(4-methylpiperazin-1-yl)methyl]phenyl Indol-6-yl 0 434-[(1,1-dioxo-1λ⁶-thiomorpholin-4-yl)methyl] Indol-6-yl 0 phenyl 444-({[2-(dimethylamino)ethyl](meyhyl)amino} Indol-6-yl 0 methyl)phenyl 454-{[4-(2-hydroxyethyl)piperidin-1-yl]methyl} Indol-6-yl 0 phenyl 464-(oxan-4-yloxy)-3-(trifluoromethyl)phenyl Indol-6-yl 0 474-[(4-methyl-1,4-diazepan-1- Indol-6-yl 0 yl)methyl]phenyl 48 phenyl5-fluoro-indol-6-yl 0 49 phenyl 7-fluoro-indol-6-yl 0 50 phenyl1,3-benzothiazol-5-yl 0 51 phenyl 2-methyl-1,3-benzothiazol-5-yl 0 52phenyl 1-methyl-1H-pyrrolo[2,3-b] 0 pyridin-6-yl 53 phenyl1,8-naphthyridin-3-yl 0 54 phenyl 1,8-naphthyridin-2-yl 0 551-[3-(morpholin-4-yl)propyl]-1H-pyrrolo[2,3- Indol-6-yl 0 b]pyridin-3-yl56 1-[2-(morpholin-4-yl)ethyl]-1H-pyrrolo[2,3- Indol-6-yl 0b]pyridin-3-yl 57 1-[2-(dimethylamino)ethyl]-1H-pyrrolo[2,3- Indol-6-yl0 b]pyridin-3-yl 58 1-[3-(dimethylamino)propyl]-1H-pyrrolo[2,3-Indol-6-yl 0 b]pyridin-3-yl 591-[2-(dimethylamino)ethyl]-1H-pyrrolo[2.3- Indol-6-yl 0 b]pyridin-3-yl60 1-8-naphthyridin-2-yl Indol-6-yl 0 612-(5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl Indol-6-yl 0 621-[2-(morpholin-4-yl)ethyl]-1H-pyrrolo[2,3- Indol-6-yl 0 b]pyridin-5-yl63 1-[2-(dimethylamino)ethyl]-1H-pyrrolo[2,3- Indol-6-yl 0b]pyridin-5-yl 64 4-{8-azabicyclo[3.2.1]octan-3-yl}phenyl Indol-6-yl 0

In certain embodiments, R¹ is at least one selected form the groupconsisting of: 4-acetamidophenyl; 4-(aminomethyl)phenyl; 4-aminophenyl;4-{8-azabicyclo[3.2.1]octan-3-yl}phenyl; 3-carbamoyl-5-methoxyphenyl;4-{[(2-carboxyphenyl)formamido]methyl} phenyl; 4-{[(4-carboxyphenyl)formamido]methyl} phenyl; 4-(3-chloro-4-fluorobenzenesulfon amido)phenyl; 2,4-difluorophenyl;4-[(4,4-difluoropiperidin-1-yl)methyl]phenyl;4-{[2-(dimethylamino)ethyl]carbamoyl} phenyl;4-({[2-(dimethylamino)ethyl](methyl)amino}methyl)phenyl;1-[2-(dimethylamino)ethyl]-1H-pyrrolo[2,3-b]pyridin-3-yl;1-[3-(dimethylamino) propyl]-1H-pyrrolo[2,3-b]pyridin-3-yl;4-[(dimethylamino)methyl]phenyl;4-[(1,1-dioxo-1λ⁶-thian-4-yl)oxy]phenyl;4-[(1,1-dioxo-1λ⁶-thiomorpholin-4-yl)methyl] phenyl;4-[(4-ethylpiperazin-1-yl)methyl]phenyl;4-fluoro-3-(oxan-4-yloxy)phenyl; 4-fluorophenyl; 4-{[(2-fluorophenyl)formamido]methyl}phenyl; 4-[(3-hydroxy azetidin-1-yl)methyl]phenyl;4-{[4-(2-hydroxyethyl) piperidin-1-yl]methyl} phenyl;4-[(4-hydroxypiperidin-1-yl)methyl]phenyl; 4-methanesulfonamidophenyl;3-(3-methanesulfonamide phenyl)phenyl;4-(4-methoxybenzene-sulfonamido)phenyl;4-{[(2-methoxyethyl)(methyl)amino] methyl}phenyl;4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl; 4-methoxyphenyl;4-[(4-methoxypiperidin-1-yl)methyl]phenyl;4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl;4-[(4-methylpiperazin-1-yl)methyl]phenyl;2-methyl-4-oxo-3,4-dihydroquinazolin-7-yl;3-(morpholin-4-ylmethyl)phenyl; 4-(morpholin-4-ylmethyl)phenyl;1-[2-(morpholin-4-yl)ethyl]-1H-pyrrolo[2,3-b]pyridin-3-yl;1-[3-(morpholin-4-yl)propyl]-1H-pyrrolo[2,3-b]pyridin-3-yl;1-[2-(morpholin-4-yl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl;1-[2-(dimethylamino)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl,1,8-naphthyridin-2-yl; 4-(oxan-4-ylmethoxy)phenyl;4-[2-(oxan-4-yl)ethoxy]phenyl; 4-(oxan-4-yloxy)phenyl;4-(oxan-4-yloxy)-3-(trifluoromethyl)phenyl;4-oxo-3,4-dihydroquinazolin-7-yl; phenyl4-[(phenylformamido)methyl]phenyl; 4-(piperazine-1-carbonyl)phenyl;4-(pyridine-3-amido)phenyl; 2-(5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl;and 4-(thiophene-2-sulfonamido)phenyl.

In certain embodiments, R² is at least one selected from the groupconsisting of: 1,3-benzothiazol-5-yl; 5-fluoro-indol-6-yl;7-fluoro-indol-6-yl; Indol-6-yl; 2-methyl-1,3-benzothiazol-5-yl;1-methyl-1H-pyrrolo[2,3-b]pyridin-6-yl; 1,8-naphthyridin-2-yl;1,8-naphthyridin-3-yl; and 1H-pyrrolo[2,3-b]pyridine-5-yl.

As defined herein, a compound depicted by the racemic formula furtherstands for either of the two enantiomers or mixtures thereof, or in thecase where a second chiral center is present, all possiblediastereomers.

For the purposes of demonstrating the manner in which the compounds ofthe present invention are named and referred to herein, the compound offormula:

has the chemical name3-(2-phenylethynyl)-2-(H-pyrrolo[2,3-b]pyridin-5-yl)benzoic acid.

For the purposes of demonstrating the manner in which the compounds ofthe present invention are named and referred to herein, the compound offormula:

has the chemical name 2-(5-fluoro-1H-indol-6-yl)-3-(2-phenylethynyl)benzoic acid.

As defined herein, a compound depicted by a racemic formula furtherstands for either of the two enantiomers having the formula or mixturesthereof, or in the case where a second chiral center is present, allpossible diastereomers.

The compounds described herein may form salts with acids and/or bases,and such salts are included in the present invention. In certainembodiments, the salts are pharmaceutically acceptable salts. The term“salts” embraces addition salts of free acids and/or bases that areuseful within the methods of the invention. The term “pharmaceuticallyacceptable salt” refers to salts that possess toxicity profiles within arange that affords utility in pharmaceutical applications.Pharmaceutically unacceptable salts may nonetheless possess propertiessuch as high crystallinity, which have utility in the practice of thepresent invention, such as for example utility in process of synthesis,purification or formulation of compounds useful within the methods ofthe invention.

Suitable pharmaceutically acceptable acid addition salts may be preparedfrom an inorganic acid or from an organic acid. Examples of inorganicacids include sulfate, hydrogen sulfate, hemisulfate, hydrochloric,hydrobromic, hydriodic, nitric, carbonic, sulfuric, and phosphoric acids(including hydrogen phosphate and dihydrogen phosphate). Appropriateorganic acids may be selected from aliphatic, cycloaliphatic, aromatic,araliphatic, heterocyclic, carboxylic and sulfonic classes of organicacids, examples of which include formic, acetic, propionic, succinic,glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic,glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic,anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic),methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic,trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-toluenesulfonic,sulfanilic, cyclohexylaminosulfonic, stearic, alginic, β-hydroxybutyric,salicylic, galactaric, galacturonic acid, glycerophosphonic acids andsaccharin (e.g., saccharinate, saccharate).

Suitable pharmaceutically acceptable base addition salts of compounds ofthe invention include, for example, metallic salts including alkalimetal, alkaline earth metal and transition metal salts such as, forexample, calcium, magnesium, potassium, sodium and zinc salts.Pharmaceutically acceptable base addition salts also include organicsalts made from basic amines such as, for example, ammonium,N,N′-dibenzylethylene-diamine, chloroprocaine, choline, diethanolamine,ethylenediamine, meglumine (N-methylglucamine) and procaine.

All of these salts may be prepared from the corresponding compound byreacting, for example, the appropriate acid or base with the compound.Salts may be comprised of a fraction of less than one, one, or more thanone molar equivalent of acid or base with respect to any compound of theinvention.

In certain embodiments, the at least one compound of the invention is acomponent of a pharmaceutical composition further including at least onepharmaceutically acceptable carrier.

The compounds of the invention may possess one or more stereocenters,and each stereocenter may exist independently in either the (R) or (S)configuration. In certain embodiments, compounds described herein arepresent in optically active or racemic forms. The compounds describedherein encompass racemic, optically-active, regioisomeric andstereoisomeric forms, or combinations thereof that possess thetherapeutically useful properties described herein. Preparation ofoptically active forms is achieved in any suitable manner, including byway of non-limiting example, by resolution of the racemic form withrecrystallization techniques, synthesis from optically-active startingmaterials, chiral synthesis, or chromatographic separation using achiral stationary phase. In certain embodiments, a mixture of one ormore isomer is utilized as the therapeutic compound described herein. Inother embodiments, compounds described herein contain one or more chiralcenters. These compounds are prepared by any means, includingstereoselective synthesis, enantioselective synthesis and/or separationof a mixture of enantiomers and/or diastereomers. Resolution ofcompounds and isomers thereof is achieved by any means including, by wayof non-limiting example, chemical processes, enzymatic processes,fractional crystallization, distillation, and chromatography.

The methods and formulations described herein include the use ofN-oxides (if appropriate), crystalline forms (also known as polymorphs),solvates, amorphous phases, and/or pharmaceutically acceptable salts ofcompounds having the structure of any compound of the invention, as wellas metabolites and active metabolites of these compounds having the sametype of activity. Solvates include water, ether (e.g., tetrahydrofuran,methyl tert-butyl ether) or alcohol (e.g., ethanol) solvates, acetatesand the like. In certain embodiments, the compounds described hereinexist in solvated forms with pharmaceutically acceptable solvents suchas water, and ethanol. In other embodiments, the compounds describedherein exist in unsolvated form.

In certain embodiments, the compounds of the invention exist astautomers. All tautomers are included within the scope of the compoundsrecited herein.

In certain embodiments, compounds described herein are prepared asprodrugs. A “prodrug” is an agent converted into the parent drug invivo. In certain embodiments, upon in vivo administration, a prodrug ischemically converted to the biologically, pharmaceutically ortherapeutically active form of the compound. In other embodiments, aprodrug is enzymatically metabolized by one or more steps or processesto the biologically, pharmaceutically or therapeutically active form ofthe compound.

In certain embodiments, sites on, for example, the aromatic ring portionof compounds of the invention are susceptible to various metabolicreactions. Incorporation of appropriate substituents on the aromaticring structures may reduce, minimize or eliminate this metabolicpathway. In certain embodiments, the appropriate substituent to decreaseor eliminate the susceptibility of the aromatic ring to metabolicreactions is, by way of example only, a deuterium, a halogen, or analkyl group.

Compounds described herein also include isotopically-labeled compoundswherein one or more atoms is replaced by an atom having the same atomicnumber, but an atomic mass or mass number different from the atomic massor mass number usually found in nature. Examples of isotopes suitablefor inclusion in the compounds described herein include and are notlimited to ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ³⁶Cl, ¹⁸F, ¹²³I, ¹²⁵I, ¹³N, ¹⁵N, ¹⁵O,¹⁷O, ¹⁸O, ³²P, and ³²S. In certain embodiments, isotopically-labeledcompounds are useful in drug and/or substrate tissue distributionstudies. In other embodiments, substitution with heavier isotopes suchas deuterium affords greater metabolic stability (for example, increasedin vivo half-life or reduced dosage requirements). In yet otherembodiments, substitution with positron emitting isotopes, such as ¹¹C,¹⁸F, ¹⁵O and ¹³N, is useful in Positron Emission Topography (PET)studies for examining substrate receptor occupancy. Isotopically-labeledcompounds are prepared by any suitable method or by processes using anappropriate isotopically-labeled reagent in place of the non-labeledreagent otherwise employed.

In certain embodiments, the compounds described herein are labeled byother means, including, but not limited to, the use of chromophores orfluorescent moieties, bioluminescent labels, or chemiluminescent labels.

Methods of Making

The compounds described herein, and other related compounds havingdifferent substituents are synthesized using techniques and materialsdescribed herein and as described, for example, in Fieser & Fieser'sReagents for Organic Synthesis, Vol. 1-17 (John Wiley and Sons, 1991);Rodd's Chemistry of Carbon Compounds, Vol. 1-5 and Supplementals(Elsevier Science Publishers, 1989); Organic Reactions, Vol. 1-40 (JohnWiley and Sons, 1991), Larock's Comprehensive Organic Transformations(VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4^(th)Ed., (Wiley 1992); Carey & Sundberg, Advanced Organic Chemistry, 4^(th)Ed., Vols. A and B (Plenum 2000, 2001), and Green & Wuts, ProtectiveGroups in Organic Synthesis 3rd Ed., (Wiley 1999) (all of which areincorporated by reference for such disclosure). General methods for thepreparation of compound as described herein are modified by the use ofappropriate reagents and conditions, for the introduction of the variousmoieties found in the formula as provided herein.

The processes described herein can be monitored according to anysuitable method known in the art. For example, product formation can bemonitored by spectroscopic means, such as nuclear magnetic resonancespectroscopy (e.g., ¹H or ¹³C), infrared spectroscopy, spectrophotometry(e.g., UV-visible), mass spectrometry, or by chromatography such as highpressure liquid chromatography (HPLC), gas chromatography (GC),gel-permeation chromatography (GPC), or thin layer chromatography (TLC).

The reactions or the processes described herein can be carried out insuitable solvents which can be readily selected by one skilled in theart of organic synthesis. Suitable solvents typically are substantiallynonreactive with the reactants, intermediates, and/or products at thetemperatures at which the reactions are carried out, i.e., temperaturesthat can range from the solvent's freezing temperature to the solvent'sboiling temperature. A given reaction can be carried out in one solventor a mixture of more than one solvent. Depending on the particularreaction step, suitable solvents for a particular reaction step can beselected.

Reagents used in the preparation of the compounds of this invention canbe either commercially obtained or can be prepared by standardprocedures described in the literature. In a non-limitingexemplification, compounds of the invention may be produced by one ofthe following reaction schemes.

Suitably substituted compound (1) is reacted with suitably substitutedcompound (2) in the presence of an acid such as hydrochloric acid,sulfuric acid, trifluoroacetic acid, and the like, in an organic solventsuch as methanol, ethanol, N,N-dimethylformamide, tetrahydrofuran,1,4-dioxane, methylene chloride and the like, optionally heated,optionally heated with microwave irradiation, to provide compound (3).Alternatively, compound (1) may be reacted withtrimethylsilyldiazomethane in an organic solvent such as methylenechloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane,N,N-dimethylformamide, and the like to provide compound (3). Compound(3) is then reacted with compound (4) in the presence of a catalyst,such as 4-chloropyridine hydrochloride, in an organic solvent such asmethylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane.N,N-dimethylformamide, and the like, optionally heated, optionallyheated with microwave irradiation, to provide compound (5).Alternatively, compound (3) is reacted with compound (6), in thepresence of an acid such as hydrochloric acid, sulfuric acid,trifluoroacetic acid, acetic acid, and the like, in an organic solventsuch as methanol, ethanol, N,N-dimethylformamide, tetrahydrofuran,1,4-dioxane, methylene chloride, 1,2-dichloroethane, and the like,optionally heated, optionally heated with microwave irradiation, toprovide compound (5).

Compound (5) is reacted with compound (7), in the presence of a basesuch as triethylamine, diisopropylethylamine, pyridine,2,6-dimethylpyridine, and the like in the presence of a palladiumcatalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation, to provide compound (8).Alternatively, compound (5) is reacted with trimethylsilyl acetylene inthe presence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-dimethylpyridine, and the like in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (9).Compound (9) is then deprotected by removal of the trimethylsily moietyby reacting compound (9) with a fluoride source such astetrabutylammonium fluoride, and the like in an organic solvent such astetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane,and the like to provide compound (10). Compound (10) is reacted withcompound (11), wherein X is a chloride, bromide, iodide,methanesulfonate, trifluoromethanesulfonate, tosylate, and the like inthe presence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-dimethylpyridine, and the like in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine) palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile) dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (8).Compound (8) is reacted with a base such as sodium hydroxide, lithiumhydroxide, potassium hydroxide, sodium carbonate, lithium carbonate,potassium carbonate, and the like, in an organic solvent such asmethanol, ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,and the like, optionally heated, optionally heated with microwaveirradiation to provide compound (12).

Compound (13) is reacted with compound (7) in the presence of a basesuch as triethylamine, diisopropylethylamine, pyridine,2,6-dimethylpyridine, and the like in the presence of a palladiumcatalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (14).Alternatively, compound (13) is reacted with trimethylsilyl acetylene inthe presence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-dimethylpyridine, and the like in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine) palladium(0), dichlorobis(triphenylphosphine) palladium(II), palladium on carbon,bis(acetonitrile) dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (15).Compound (15) is then deprotected by removal of the trimethylsily moietyusing a fluoride source such as tetrabutylammonium fluoride, the like inan organic solvent such as tetrahydrofuran, 1,4-dioxane, methylenechloride, 1,2-dichloroethane, and the like to provide compound (16).Compound (16) is reacted with compound (11), wherein X is a chloride,bromide, iodide, methanesulfonate, trifluoromethanesulfonate, tosylate,and the like in the presence of a base such as triethylamine,diisopropylethylamine, pyridine, 2,6-dimethylpyridine, and the like inthe presence of a palladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine) palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile) dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (14).Compound (14) is reacted with a base such as sodium hydroxide, lithiumhydroxide, potassium hydroxide, sodium carbonate, lithium carbonate,potassium carbonate, and the like, in an organic solvent such asmethanol, ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,and the like, optionally heated, optionally heated with microwaveirradiation to provide compound (17).

Compound (18) is reacted with sodium nitrite in the presence of an acidsuch as hydrochloric acid, sulfuric acid, acetic acid, trifluoroaceticacid, and the like, in an organic solvent such as methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, and the like,optionally heated, optionally heated with microwave irradiation. Furtherreaction with compound (19) wherein M is a metal such as sodium,potassium, and the like in an organic solvent such as methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, and the like,optionally heated, optionally heated with microwave irradiation toprovide compound (20). Compound (20) is reacted with suitablysubstituted compound (2) in the presence of an acid such as hydrochloricacid, sulfuric acid, trifluoroacetic acid, and the like, in an organicsolvent such as methanol, ethanol, N,N-dimethyl formamide,tetrahydrofuran, 1,4-dioxane, methylene chloride and the like,optionally heated, optionally heated with microwave irradiation toprovide compound (21). Alternatively, compound (20) may be reacted withtrimethylsilyldiazomethane in an organic solvent such as methylenechloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane,N,N-dimethylformamide, and the like to provide compound (21). Compound(21) is reacted with compound (22) in the presence of a palladiumcatalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile) dichloropalladium(II), and the like, in the presenceof a base such as triethylamine, diisopropylethyl amine, pyridine,2,6-dimethylpyridine, sodium hydroxide, lithium hydroxide, potassiumhydroxide, sodium carbonate, lithium carbonate, potassium carbonate, andthe like, in an organic solvent such as methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethaneand the like, optionally heated, optionally heated with microwaveirradiation to provide compound (23).

Compound (24) is reacted with suitably substituted compound (2) in thepresence of an acid such as hydrochloric acid, sulfuric acid,trifluoroacetic acid, and the like, in an organic solvent such asmethanol, ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride and the like, optionally heated, optionally heatedwith microwave irradiation to provide compound (25). Alternatively,compound (24) may be reacted with trimethylsilyldiazomethane in anorganic solvent such as methylene chloride, 1,2-dichloroethane,tetrahydrofuran, 1,4-dioxane, N,N-dimethyl formamide, and the like toprovide compound (25). Compound (25) is reacted with compound (7) in thepresence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-dimethylpyridine, and the like in the presence of apalladium catalyst such as palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (26).Alternatively, compound (25) is reacted with trimethylsilyl acetylene inthe presence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-dimethylpyridine, and the like in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile) dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (27).Compound (27) is then deprotected by removal of the trimethylsily moietyusing a fluoride source such as tetrabutylammonium fluoride, and thelike in an organic solvent such as tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like to provide compound(28). Compound (28) is reacted with compound (11) wherein X is achloride, bromide, iodide, methanesulfonate, trifluoromethanesulfonate,tosylate, and the like in the presence of a base such as triethylamine,diisopropylethylamine, pyridine, 2,6-dimethylpyridine, and the like inthe presence of a palladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (26).

Compound (26) is reacted with compound (22) in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0),dichlorobis(triphenylphosphine) palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in the presence ofa base such as triethylamine, diisopropylethylamine, pyridine,2,6-dimethylpyridine, sodium hydroxide, lithium hydroxide, potassiumhydroxide, sodium carbonate, lithium carbonate, potassium carbonate, andthe like, in an organic solvent such as methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethaneand the like, optionally heated, optionally heated with microwaveirradiation to provide compound (29). Compound (29) is reacted with abase such as sodium hydroxide, lithium hydroxide, potassium hydroxide,sodium carbonate, lithium carbonate, potassium carbonate, and the like,in an organic solvent such as methanol, ethanol. N,N-dimethylformamide,tetrahydrofuran, 1,4-dioxane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (30).

Compound (31) is reacted with suitably substituted compound (2) in thepresence of an acid such as hydrochloric acid, sulfuric acid,trifluoroacetic acid, and the like, in an organic solvent such asmethanol, ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride and the like, optionally heated, optionally heatedwith microwave irradiation to provide compound (32). Alternatively,compound (31) may be reacted with trimethylsilyldiazomethane in anorganic solvent such as methylene chloride, 1,2-dichloroethane,tetrahydrofuran, 1,4-dioxane, N,N-dimethyl formamide, and the like toprovide compound (32). Compound (32) is reacted with compound (22) inthe presence of a palladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine) palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile) dichloropalladium(II), and the like, in the presenceof a base such as triethylamine, diisopropylethylamine, pyridine,2,6-dimethylpyridine, sodium hydroxide, lithium hydroxide, potassiumhydroxide, sodium carbonate, lithium carbonate, potassium carbonate, andthe like, in an organic solvent such as methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethaneand the like, optionally heated, optionally heated with microwaveirradiation to provide compound (33).

Compound (33) is reacted with hydrogen in the presence of a catalystsuch as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in an organicsolvent such as methanol, ethanol, N,N-dimethylformamide,tetrahydrofuran, 1,4-dioxane, and the like to provide compound (34).Compound (34) is reacted with sodium nitrite in the presence of an acidsuch as hydrochloric acid, sulfuric acid, acetic acid, trifluoroaceticacid, and the like in an organic solvent such as methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, and the like,optionally heated, optionally heated with microwave irradiation. Furtherreaction with compound (19) wherein M is a metal such as sodium,potassium, and the like in an organic solvent such as methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, and the like,optionally heated, optionally heated with microwave irradiation toprovide compound (35). Compound (35) is reacted with compound (7) in thepresence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-dimethylpyridine, and the like in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (36).Alternatively, compound (35) is reacted with trimethylsilyl acetylene inthe presence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-dimethylpyridine, and the like in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine) palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile) dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (37).Compound (37) is then deprotected by removal of the trimethylsily moietyusing a fluoride source such as tetrabutylammonium fluoride, and thelike in an organic solvent such as tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like to provide compound(38). Compound (38) is reacted with compound (11) wherein X is achloride, bromide, iodide, methanesulfonate, trifluoromethanesulfonate,tosylate, and the like in the presence of a base such as triethylamine,diisopropylethylamine, pyridine, 2,6-dimethylpyridine, and the like inthe presence of a palladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (36).

Compound (39) is reacted with compound (40) wherein PG istert-butyldimethylsilyl, tert-butyldiphenylsilyl, acetyl, benzoyl andthe like, in the presence of a base such as triethylamine,diisopropylethylamine, pyridine, 2,6-dimethylpyridine, and the like, inan organic solvent such as N,N-dimethylformamide, tetrahydrofuran,1,4-dioxane, methylene chloride, 1,2-dichloroethane, and the like, toprovide compound (41). Compound (41) is reacted with compound (7) in thepresence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-dimethylpyridine, and the like in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine) palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile) dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (42).Alternatively, compound (41) is reacted with trimethylsilyl acetylene inthe presence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-dimethylpyridine, and the like in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (43).Compound (43) is then deprotected by removal of the trimethylsily moietyusing a fluoride source such as tetrabutylammonium fluoride, and thelike in an organic solvent such as tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like to provide compound(44). Compound (44) is reacted with compound (11), wherein X is achloride, bromide, iodide, methanesulfonate, trifluoromethanesulfonate,tosylate, and the like in the presence of a base such as triethylamine,diisopropylethylamine, pyridine, 2,6-dimethylpyridine, and the like inthe presence of a palladium catalyst such as palladium (II) acetate,tetrakis (triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (42).

Compound (42) is deprotected by a fluoride source such astetrabutylammonium fluoride and the like or a base such as aqueoussodium carbonate, potassium carbonate, cesium carbonate and the like, inan organic solvent such as methanol, ethanol, in an organic solvent suchas tetrahydrofuran, 1,4-dioxane, and the like to provide compound (44).Compound (44) is reacted with trifluoromethanesulfonic anhydride, in anorganic solvent such as tetrahydrofuran, 1,4-dioxane, methylenechloride, 1,2-dichloroethane, N,N-dimethylformamide, and the like,optionally in the presence of a base such as triethylamine,diisopropylethylamine, pyridine, 2,6-dimethylpyridine, and the like, toprovide compound (45). Compound (45) is reacted with compound (22) inthe presence of a palladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile) dichloropalladium(II), and the like, in the presenceof a base such as triethylamine, diisopropylethyl amine, pyridine,2,6-dimethylpyridine, sodium hydroxide, lithium hydroxide, potassiumhydroxide, sodium carbonate, lithium carbonate, potassium carbonate, andthe like, in an organic solvent such as methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethaneand the like, optionally heated, optionally heated with microwaveirradiation to provide compound (46). Compound (46) is then reacted withan acid such as hydrochloric acid, sulfuric acid, and the like, in asolvent such as water, N,N-dimethylformamide, tetrahydrofuran,1,4-dioxane, and the like, optionally heated, optionally heated withmicrowave irradiation to provide compound (47). Alternatively, compound(46) is reacted with a base such as sodium hydroxide, lithium hydroxide,potassium hydroxide, and the like, in a solvent such as water, methanol,ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, and thelike, optionally heated, optionally heated with microwave irradiation toprovide compound (47).

Compound (48) is reacted with compound (22a) in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0),dichlorobis(triphenylphosphine) palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in the presence ofa base such as triethylamine, diisopropylethylamine, pyridine,2,6-dimethylpyridine, sodium hydroxide, lithium hydroxide, potassiumhydroxide, sodium carbonate, lithium carbonate, potassium carbonate, andthe like, in an organic solvent such as methanol, ethanol.N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, and the like,optionally heated, optionally heated with microwave irradiation toprovide compound (49). Compound (49) is reacted with a base such assodium hydroxide, lithium hydroxide, potassium hydroxide, sodiumcarbonate, lithium carbonate, potassium carbonate, and the like, in anorganic solvent such as methanol, ethanol, N,N-dimethylformamide,tetrahydrofuran, 1,4-dioxane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (50).

Compound (49) is reacted with compound (51) in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0),dichlorobis(triphenylphosphine) palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in the presence ofa base such as triethylamine, diisopropylethylamine, pyridine,2,6-dimethylpyridine, sodium hydroxide, lithium hydroxide, potassiumhydroxide, sodium carbonate, lithium carbonate, potassium carbonate, andthe like, in an organic solvent such as methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, and the like,optionally heated, optionally heated with microwave irradiation toprovide compound (52). Compound (52) is reacted with a base such assodium hydroxide, lithium hydroxide, potassium hydroxide, sodiumcarbonate, lithium carbonate, potassium carbonate, and the like, in anorganic solvent such as methanol, ethanol, N,N-dimethyl formamide,tetrahydrofuran, 1,4-dioxane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (53).Alternatively, compound (52) is reacted with hydrogen in the presence ofa catalyst such as palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladiumon carbon, bis(acetonitrile) dichloropalladium(II), and the like, in anorganic solvent such as methanol, ethanol, N,N-dimethylformamide,tetrahydrofuran, 1,4-dioxane, and the like to provide compound (54).Compound (54) is reacted with a base such as sodium hydroxide, lithiumhydroxide, potassium hydroxide, sodium carbonate, lithium carbonate,potassium carbonate, and the like, in an organic solvent such asmethanol, ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,and the like, optionally heated, optionally heated with microwaveirradiation to provide compound (55).

Compound (56) is reacted with chlorosulfonylisocyanate and tert-butanolin the presence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-dimethylpyridine, and the like in a solvent such asmethylene chloride, 1,2-dichloroethane, N,N-dimethylformamide,tetrahydrofuran, 1,4-dioxane, and the like, and then deprotected bytreatment with an acid such as hydrogen chloride, trifluoroacetic acid,and the like in an organic solvent such as ethyl acetate, methylenechloride and the like to provide compound (57). Compound (57) is reactedwith compound (58) in the presence of coupling agent such as1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, N,N′-Dicyclohexylcarbodiimide,O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate.O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate,Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphoniumhexafluorophosphate, benzotriazol-1-yl-oxytripyrrolidino phosphoniumhexafluorophosphate, and the like, in an organic solvent such astetrahydrofuran, 1,4-dioxane, dimethylformamide, methylene chloride,dichloroethane, methanol, ethanol, and the like, optionally in thepresence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-lutidine, and the like, optionally in the presence of4-N,N-dimethylaminopyridine, to provide compound (59).

Alternatively, compound (58) is reacted with compound (60) in thepresence of coupling agent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, N,N′-Dicyclohexyl carbodiimide,O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate,O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate,Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphoniumhexafluorophosphate, benzotriazol-1-yl-oxytripyrrolidinophosphoniumhexafluorophosphate, and the like, in an organic solvent such astetrahydrofuran, 1,4-dioxane, dimethylformamide, methylene chloride,dichloroethane, methanol, ethanol, and the like, optionally in thepresence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-lutidine, and the like, optionally in the presence of4-N,N-dimethylaminopyridine, to provide compound (61).

Compound (62) is reacted with chlorosulfonylisocyanate in the presenceof aluminum trichloride in nitroethane to provide compound (63).Compound (63) is reacted with an acid such as hydrochloric acid,sulfuric acid, trifluoroacetic acid, acetic acid, and the like,optionally in an organic solvent such as tetrahydrofuran, 1,4-dioxane,dimethylformamide, methylene chloride, dichloroethane, methanol,ethanol, and the like, to provide compound (64). Compound (64) isreacted with compound (65) in the presence of pyridine hydrochloride,optionally in an organic solvent such as tetrahydrofuran, 1,4-dioxane,dimethylformamide, methylene chloride, 1,2-dichloroethane, methanol,ethanol, and the like, optionally heated, optionally heated withmicrowave irradiation to provide compound (66). Compound (66) is reactedwith compound (7), in the presence of a base such as triethylamine,diisopropylethylamine, pyridine, 2,6-dimethylpyridine, and the like inthe presence of a palladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile) dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (67).Compound (67) is reacted with compound (68) in the presence of couplingagent such as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide,N,N′-Dicyclohexylcarbodiimide,O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate,O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate,Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphoniumhexafluorophosphate, benzotriazol-1-yl-oxytripyrrolidinophosphoniumhexafluorophosphate, and the like, in an organic solvent such astetrahydrofuran, 1,4-dioxane, dimethylformamide, methylene chloride,dichloroethane, methanol, ethanol, and the like, optionally in thepresence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-lutidine, and the like, optionally in the presence of4-N,N-dimethylaminopyridine, to provide compound (69).

Compound (70) is reacted with compound (71), wherein X is a chloride,bromide, iodide, methanesulfonate, trifluoromethanesulfonate, tosylate,and the like in the presence of a base such as triethylamine,diisopropylethylamine, pyridine, 2,6-dimethylpyridine, and the like, inan organic solvent such as tetrahydrofuran, 1,4-dioxane,dimethylformamide, methylene chloride, 1,2-dichloroethane, and the like,to provide compound (72). Compound (72) is reacted with a base such assodium hydroxide, lithium hydroxide, potassium hydroxide, sodiumcarbonate, lithium carbonate, potassium carbonate, and the like, in anorganic solvent such as methanol, ethanol, N,N-dimethylformamide,tetrahydrofuran, 1,4-dioxane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (73).

Compound (74) is reacted with compound (75), wherein X is a chloride,bromide, iodide, methanesulfonate, trifluoromethanesulfonate, tosylate,and the like in the presence of a base such as triethylamine,diisopropylethylamine, pyridine, 2,6-dimethylpyridine, and the like, inan organic solvent such as tetrahydrofuran, 1,4-dioxane,dimethylformamide, methylene chloride, 1,2-dichloroethane, and the like,to provide compound (76). Compound (76) is then reacted with an acidsuch as hydrochloric acid, sulfuric acids, and the like, in a solventsuch as water, methanol, ethanol, N,N-dimethylformamide,tetrahydrofuran, 1,4-dioxane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (77).Alternatively, compound (76) is reacted with a base such as sodiumhydroxide, lithium hydroxide, potassium hydroxide, and the like, in asolvent such as water, methanol, ethanol, N,N-dimethylformamide,tetrahydrofuran, 1,4-dioxane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (77).

Compound (78) is reacted with sodium nitrite in the presence of an acidsuch as hydrochloric acid, sulfuric acid, tetrafluoroboric acid, and thelike, optionally in a solvent such as water, methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, and the like,followed by reaction with sodium azide in a solvent such as water,methanol, ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,and the like to provide compound (79). Compound (79) is reacted withcompound (80) in the presence of a catalyst such as sodium ascorbate andcopper sulfate and the like, in an organic solvent such as methanol,ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, and thelike, optionally heated, optionally heated with microwave irradiation toprovide compound (81). Compound (81) is reacted with compound (7) in thepresence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-dimethylpyridine, and the like in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloro palladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (82).Compound (82) is reacted with a base such as sodium hydroxide, lithiumhydroxide, potassium hydroxide, sodium carbonate, lithium carbonate,potassium carbonate, and the like, in an organic solvent such asmethanol, ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,and the like, optionally heated, optionally heated with microwaveirradiation to provide compound (83).

Compound (84) is reacted with compound (7), in the presence of a basesuch as pyridine, triethylamine, diisopropylethylamine,2,6-dimethylpyridine, and the like, in the presence of a palladiumcatalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloro palladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (85).Alternatively, compound (84) is reacted with trimethylsilyl acetylene inthe presence of a base such as triethylamine, diisopropylethyl amine,pyridine, 2,6-dimethylpyridine, and the like in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0),dichlorobis(triphenylphosphine) palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (86).Compound (86) is then deprotected by removal of the trimethylsily moietyusing a fluoride source such as tetrabutylammonium fluoride, and thelike in an organic solvent such as tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane. N,N-dimethylformamide, and thelike to provide compound (87). Alternatively, compound (86) is reactedwith hydrogen fluoride in the presence of a base such as pyridine,2,6-dimethylpyridine, triethyl amine, and the like, optionally in asolvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride,1,2-dichloroethane, N,N-dimethylformamide, and the like to providecompound (87). Alternatively, compound (86) is reacted with a base suchas aqueous sodium hydroxide, potassium hydroxide, lithium hydroxide andthe like, in a solvent such as tetrahydrofuran, 1,4-dioxane, methylenechloride, 1,2-dichloroethane, N,N-dimethylformamide, and the like,optionally heated, optionally heated with microwave irradiation toprovide compound (87). Compound (87) is reacted with compound (11),wherein X is a leaving group such as chloride, bromide, iodide,methanesulfonate, trifluoromethanesulfonate, tosylate, and the like inthe presence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-dimethylpyridine, and the like in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (85).

Compound (88) is reacted with compound (89), in the presence of couplingagent such as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide,N,N′-Dicyclohexylcarbodiimide,O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate,O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate,Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphoniumhexafluorophosphate, benzotriazol-1-yl-oxytripyrrolidinophosphoniumhexafluorophosphate, and the like, in an organic solvent such astetrahydrofuran, 1,4-dioxane, dimethylformamide, methylene chloride,dichloroethane, methanol, ethanol, and the like, optionally in thepresence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-lutidine, and the like, optionally in the presence of4-N,N-dimethylaminopyridine, to provide compound (90). Compound (90) isreacted with a base such as sodium hydroxide, lithium hydroxide,potassium hydroxide, sodium carbonate, lithium carbonate, potassiumcarbonate, and the like, in an organic solvent such as methanol,ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, and thelike, optionally heated, optionally heated with microwave irradiation toprovide compound (91). Alternatively, compound (90) is reacted with anacid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, andthe like, optionally in the presence of a solvent such as methanol,ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, methylenechloride and the like, optionally heated, optionally heated withmicrowave irradiation to provide compound (91).

Compound (26) is reacted with compound (92), in the presence of a basesuch as potassium phosphate, cesium carbonate, potassium carbonatesodium carbonate, sodium tert-butoxide and the like in the presence of acopper (I) catalyst such as copper iodide and the like, or a palladiumcatalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine) palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,toluene, 1,2-dichloroethane, and the like, optionally heated, optionallyheated with microwave irradiation to provide compound (93).

Compound (94) is reacted with compound (22) in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0),dichlorobis(triphenylphosphine) palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in the presence ofa base such as triethylamine, diisopropylethylamine, pyridine,2,6-dimethylpyridine, sodium hydroxide, lithium hydroxide, potassiumhydroxide, sodium carbonate, lithium carbonate, potassium carbonate, andthe like, in an organic solvent such as methanol, ethanol.N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethaneand the like, optionally heated, optionally heated with microwaveirradiation to provide compound (95). Compound (95) is then deprotectedby removal of the trimethylsily moiety using a fluoride source such astetrabutylammonium fluoride, and the like in an organic solvent such astetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane,and the like to provide compound (96). Compound (96) is reacted withcompound (97), wherein X is a chloride, bromide, iodide,methanesulfonate, trifluoromethanesulfonate, tosylate, and the like inthe presence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-dimethylpyridine, and the like in the presence of apalladium catalyst such as palladium (II) acetate,tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, in an organicsolvent such as N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,methylene chloride, 1,2-dichloroethane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (98).Compound (98) is reacted with a base such as sodium hydroxide, lithiumhydroxide, potassium hydroxide, sodium carbonate, lithium carbonate,potassium carbonate, and the like, in an organic solvent such asmethanol, ethanol. N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,and the like, optionally heated, optionally heated with microwaveirradiation to provide compound (99).

Compound (100) is reacted with compound (101), in the presence ofcoupling agent such as S-ethyl-3-(3-dimethylaminopropyl) carbodiimide,N,N′-Dicyclohexylcarbodiimide,O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate,O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate,Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphoniumhexafluorophosphate, benzotriazol-1-yl-oxytripyrrolidinophosphoniumhexafluorophosphate, and the like, in an organic solvent such astetrahydrofuran, 1,4-dioxane, dimethylformamide, methylene chloride,dichloroethane, methanol, ethanol, and the like, optionally in thepresence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-lutidine, and the like, optionally in the presence of4-N,N-dimethylaminopyridine, to provide compound (102). Alternatively, acompound of formula (100) is reacted with acyl chloride (103) in thepresence of a base such as trimethylamine, diisopropylethylamine,N-methylmorpholine, pyridine and the like in a solvent such asdichloromethane, tetrahydrofuran and the like to provide compound (102).Compound (102) is reacted with a base such as sodium hydroxide, lithiumhydroxide, potassium hydroxide, sodium carbonate, lithium carbonate,potassium carbonate, and the like, in an organic solvent such asmethanol, ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,and the like, optionally heated, optionally heated with microwaveirradiation to provide compound (104). Alternatively, compound (102) isreacted with an acid such as trifluoroacetic acid, hydrochloric acid,sulfuric acid, and the like, optionally in the presence of a solventsuch as methanol, ethanol, N,N-dimethylformamide, tetrahydrofuran,1,4-dioxane, methylene chloride and the like, optionally heated,optionally heated with microwave irradiation to provide compound (104).

Compound (105) is converted to compound (106) according to Scheme 24,using appropriate reagents, starting materials and purification methodsknown to those skilled in the art.

Compound (107) is converted to compound (108) according to Scheme 25,using appropriate reagents, starting materials and purification methodsknown to those skilled in the art.

Compound (109) is reacted with compound (110), in the presence ofcoupling agent such as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide,N,N′-Dicyclohexylcarbodiimide,O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate,O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate,Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphoniumhexafluorophosphate, benzotriazol-1-yl-oxytripyrrolidinophosphoniumhexafluorophosphate, and the like, in an organic solvent such astetrahydrofuran, 1,4-dioxane, dimethylformamide, methylene chloride,dichloroethane, methanol, ethanol, and the like, optionally in thepresence of a base such as triethylamine, diisopropylethylamine,pyridine, 2,6-lutidine, and the like, optionally in the presence of4-N,N-dimethylaminopyridine, to provide compound (111). Compound (111)is reacted with a base such as sodium hydroxide, lithium hydroxide,potassium hydroxide, sodium carbonate, lithium carbonate, potassiumcarbonate, and the like, in an organic solvent such as methanol,ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, and thelike, optionally heated, optionally heated with microwave irradiation toprovide compound (112). Alternatively, compound (111) is reacted with anacid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, andthe like, optionally in the presence of a solvent such as methanol,ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, methylenechloride and the like, optionally heated, optionally heated withmicrowave irradiation to provide compound (112).

Compound (113) is converted to compound (114) according to Scheme 27,using appropriate reagents, starting materials and purification methodsknown to those skilled in the art.

Compound (115) is converted to compound (116) according to Scheme 28,using appropriate reagents, starting materials and purification methodsknown to those skilled in the art.

Compound (117) is reacted with compound (118), in the presence of areducing agent such as sodium cyanoborohydride, sodiumtriacetoxyborohydride, and the like, in an organic solvent such astetrahydrofuran, 1,4-dioxane, methanol, ethanol, and the like, toprovide compound (119). Compound (119) is reacted with a base such assodium hydroxide, lithium hydroxide, potassium hydroxide, sodiumcarbonate, lithium carbonate, potassium carbonate, and the like, in anorganic solvent such as methanol, ethanol, N,N-dimethylformamide,tetrahydrofuran, 1,4-dioxane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (120).Alternatively, compound (119) is reacted with an acid such astrifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like,optionally in the presence of a solvent such as methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, methylene chlorideand the like, optionally heated, optionally heated with microwaveirradiation to provide compound (120).

Compound (121) is converted to compound (122) according to Scheme 30,using appropriate reagents, starting materials and purification methodsknown to those skilled in the art.

Compound (123) is convened to compound (124) according to Scheme 31,using appropriate reagents, starting materials and purification methodsknown to those skilled in the art.

Compound (125) is reacted with a reducing agent such as sodiumborohydride lithium aluminum hydride and the like, in an organic solventsuch as tetrahydrofuran, 1,4-dioxane, methanol, ethanol, and the like,to provide compound (126). Compound (126) is reacted under Mitsunobuconditions with compound (127), in the presence of an agent such asdiethylazodicarboxylate, diisopropylazodicarboxylate and the like, and aphosphine such as triphenylphosphine, and the like, in an organicsolvent such as tetrahydrofuran, 1,4-dioxane, dichloromethane, and thelike, to provide compound (128). Alternatively, compound (126) isreacted with compound (129), in which X is a leaving group such as ahalogen, mesylate, tosylate and the like, in the presence of a base suchas triethylamine, diisopropylethylamine, pyridine, sodium carbonate,potassium carbonate, sodium hydride, and the like, in a solvent such astetrahydrofuran, dimethylformamide, and the like to provide compound(128). Alternatively, compound (126) is reacted with an activatinggroup, which converts the hydroxy into a leaving group, such asmethanesulfonyl chloride, tosyl chloride, and the like, in the presenceof a base such as triethylamine, diisopropylethylamine, pyridine, sodiumcarbonate, potassium carbonate, sodium hydride, and the like, in asolvent such as tetrahydrofuran, dimethylformamide, and the like toprovide compound (131), which is then treated with compound (127), inthe presence of base such as triethylamine, diisopropylethylamine,pyridine, sodium carbonate, potassium carbonate, sodium hydride, and thelike, in a solvent such as tetrahydrofuran, dimethylformamide, and thelike to provide compound (128). A compound of formula (128) is reactedwith a base such as sodium hydroxide, lithium hydroxide, potassiumhydroxide, sodium carbonate, lithium carbonate, potassium carbonate, andthe like, in an organic solvent such as methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, and the like,optionally heated, optionally heated with microwave irradiation toprovide compound (130). Alternatively, compound (128) is reacted with anacid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, andthe like, optionally in the presence of a solvent such as methanol,ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, methylenechloride and the like, optionally heated, optionally heated withmicrowave irradiation to provide compound (130).

Compound (132) is converted to compound (133) according to Scheme 33,using appropriate reagents, starting materials and purification methodsknown to those skilled in the art.

Compound (134) is converted to compound (135) according to Scheme 34,using appropriate reagents, starting materials and purification methodsknown to those skilled in the art.

Compound (136) is reacted with a sulfonyl chloride of formula (137), inthe presence of base such as triethylamine, diisopropylethylamine,pyridine, sodium carbonate, potassium carbonate, sodium hydride, and thelike, in a solvent such as tetrahydrofuran, dimethylformamide, and thelike to provide compound (128). A compound of formula (138) is reactedwith a base such as sodium hydroxide, lithium hydroxide, potassiumhydroxide, sodium carbonate, lithium carbonate, potassium carbonate, andthe like, in an organic solvent such as methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, and the like,optionally heated, optionally heated with microwave irradiation toprovide compound (139).

Compound (140) is converted to compound (141) according to Scheme 36,using appropriate reagents, starting materials and purification methodsknown to those skilled in the art.

Compound (142) is converted to compound (143) according to Scheme 36,using appropriate reagents, starting materials and purification methodsknown to those skilled in the art.

Compound (144) is reacted with compound (145), wherein PG is aprotecting group such as a carboxylbenzy (Cbz), tert-butyloxycarbonyl(Boc), Fluorenylmethyloxycarbonyl (FMoc), and the like, in the presenceof coupling agent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, N,N′-Dicyclohexylcarbodiimide,O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate,O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyl uroniumhexafluorophosphate,Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate, benzotriazol-1-yl-oxytripyrrolidinophosphoniumhexafluorophosphate, and the like, in an organic solvent such astetrahydrofuran, 1,4-dioxane, dimethylformamide, methylene chloride,dichloroethane, methanol, ethanol, and the like, optionally in thepresence of a base such as triethylamine, diisopropylethyl amine,pyridine, 2,6-lutidine, and the like, optionally with heating,optionally with microwave irradiation, to provide compound (146).Compound (146) is reacted with a coupling agent such asdiethylazodicarboxylate, diisopropylazodicarboxylate,di-tert-butyldicarboxylate and the like and a phoshine such astriphenylphosphine, tri-n-butylphosphine and the like, in the presenceof compound (147), a suitably protected silyl azide, such astrimethylsilyl azide, in an organic solvent such as tetrahydrofuran,1,4-dioxane, dimethylformamide, methylene chloride, dichloroethane, andthe like, optionally with heating, optionally with microwaveirradiation, to provide compound (148).

Compound (148) is reacted with a base such as sodium hydroxide, lithiumhydroxide, potassium hydroxide, sodium carbonate, lithium carbonate,potassium carbonate, triethlamine, diisopropylethylamine,N-methylpyrrolidine (NMP), 2,6-lutidine, pyridine, and the like, in anorganic solvent such as methanol, ethanol, N,N-dimethylformamide,tetrahydrofuran, 1,4-dioxane, and the like, optionally heated,optionally heated with microwave irradiation to provide compound (149).Alternatively, compound (148) is reacted with an acid such astrifluoroacetic acid, acetic acid, formic acid, hydrochloric acid,hydrobromic acid, and the like, in a solvent such as methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, methylene chloride,and the like, optionally heated, optionally heated with microwaveirradiation to provide compound (149). Alternatively, compound (148) isreacted with hydrogen in the presence of a palladium catalyst such aspalladium on carbon, palladium (II) acetate,tetrakis(triphenylphosphine) palladium(0), dichlorobis(triphenylphosphine)palladium(II),bis(acetonitrile)dichloropalladium(II), and the like, in a solvent suchas methanol, ethanol, tetrahydrofuran, 1,4-dioxane, and the like toprovide compound (149).

Compound (150) is reacted with a boronate source, such asbis(pinacolato)diboron 4,4,5,5-Tetramethyl-1,3,2-dioxaborolane, and thelike, in the presence of a palladium catalyst such as palladium (II)acetate, tetrakis(triphenylphosphine)palladium(0),dichlorobis(triphenylphosphine) palladium(II), palladium on carbon,bis(acetonitrile)dichloropalladium(II), and the like, and a coppercatalyst, such as copper (I) iodide and the like, in the presence of abase such as triethylamine, diisopropylethylamine, pyridine,2,6-dimethylpyridine, sodium hydroxide, lithium hydroxide, potassiumhydroxide, sodium carbonate, lithium carbonate, potassium carbonate, andthe like, in an organic solvent such as methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethaneand the like, optionally heated, optionally heated with microwaveirradiation to provide compound (151) wherein Y1 is selected from thegroup consisting of pinacolato and (OH)₂. Compound (151) is reacted withcompound (152), wherein Y is selected from the group consisting ofchlorine, bromine, iodine, and trifluoromethanesulfonate, in thepresence of a palladium catalyst such as [1,1′-bis (diphenylphosphino)ferrocene]palladium (II) dichloride dichloromethane adduct, palladium(II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon,bis(acetonitrile)dichloro palladium(II), and the like, in the presenceof a base such as triethylamine, diisopropylethylamine, pyridine,2,6-dimethylpyridine, sodium hydroxide, lithium hydroxide, potassiumhydroxide, sodium acetate, potassium acetate, sodium carbonate, lithiumcarbonate, potassium carbonate, and the like, in an organic solvent suchas methanol, ethanol, N,N-dimethylformamide, tetrahydrofuran,1,4-dioxane, 1,2-dimethoxyethane and the like, optionally heated,optionally heated with microwave irradiation to provide compound (153).Compound (153) is reacted with a base such as sodium hydroxide, lithiumhydroxide, potassium hydroxide, sodium carbonate, lithium carbonate,potassium carbonate, and the like, in an organic solvent such asmethanol, ethanol. N,N-dimethylformamide, tetrahydrofuran, 1,4-dioxane,and the like, optionally heated, optionally heated with microwaveirradiation to provide compound (154).

Combination Therapies

The compounds identified using the methods described here are useful inthe methods of the invention in combination with one or more additionalagents useful for treating EBV infection and/or EBV-associated cancer.These additional agents may comprise compounds identified herein oragents, e.g., commercially available agents, known to treat, prevent, orreduce the symptoms of EBV infection and/or EBV-associated cancer.

One or more compounds of the invention described herein may beadministered to a patient in need thereof with one or more of theseagents. In certain embodiments, the compound of the invention iscombined with one or more of agents, i.e., delivered to the patientconcurrently. In other embodiment, the compound of the invention isdelivered to the patient concurrently therewith one or more of theseagents. In yet other embodiments, the compound of the invention isdelivered prior to one or more of these agents. In yet otherembodiments, the compound of the invention is delivered subsequent toone or more of these agents.

As used herein, combination of two or more compounds/agents may refer toa composition wherein the individual compounds/agents are physicallymixed or wherein the individual compounds/agents are physicallyseparated. A combination therapy encompasses administering thecomponents/agents separately to produce the desired additive,complementary or synergistic effects. In certain embodiments, thecompound and the agent are physically mixed in the composition. In otherembodiments, the compound and the agent are physically separated in thecomposition.

In certain embodiments, an agent is administered prior to, concurrentlywith, or subsequent to the compound.

In certain embodiments, the agent is a chemotherapeutic. One of skill inthe art would readily be able to select a chemotherapeutic foradministration with one or more of the compound of the invention, basedon the cancer being treated, patient physical condition, among othersfactors. In certain embodiment, the chemotherapeutic is selected fromthe group consisting of cisplatin, doxorubicin, 5-fluorouracil,cyclophosphamide, vincristine and prednisone.

In certain embodiments, the agent is an antiviral agent. In certainembodiments, the antiviral agent is selected from the group consistingof ganciclovir, acyclovir, valganciclovir, vidarabine, brivudine,cytarabine, idoxuridine, penciclovir, and famciclovir. In otherembodiments, the antiviral agent is ganciclovir.

In certain embodiments, the agent is a histone deacetylase inhibitor. Incertain embodiments, the histone deactylase inhibitor is selected fromthe group consisting of arginine butyrate, sodium butyrate,suberoylanilide hydroxamic acid (SAHA), and valproic acid.

In certain embodiments, the agent is a DNA methylation inhibitor. Incertain embodiments, the DNA methylation inhibitor is 5′-azacytidine.

In certain embodiments, the agent is a proteasome inhibitor. In certainembodiments, the proteasome inhibitor is bortezamib.

In certain embodiments, the agent is an immunotherapy and/or vaccine.Desirably, the immunotherapy and/or vaccines are tailored to the patientand specific disease/conditions being treated. In certain embodiments,the immunotherapy and/or vaccine are tailored to the patient andspecific cancer being treated. In certain embodiments, the immunotherapyis a patient derived (autologous) EBV specific T-cell or a non-patientderived EBV-specific T-cell (CART cells). In certain embodiments, theagent is an immunomodulator. In certain embodiments, the immunomodulatoris at least one selected from Rituximab, PD1, PD-L1, CTLA4, antibodiesto B-cells and modulators of regulatory T-cells and NK cells.

In certain embodiments, chemotherapy and/or radiation therapy bolsterthe effects of the EBV-activating therapy described herein. In otherembodiments, immune-based therapies eradicate residual disease andactivate endogenous immune responses. In yet other embodiments, suchcombination approaches (surgery plus chemotherapy/radiation plusimmunotherapy) are anticipated to be successful in the treatment of manycancers along with the methods described herein.

The compounds identified using the methods described here are useful inthe methods of the invention in combination with one or more additionaltreatment protocol useful for treating EBV infection and/orEBV-associated cancer. These additional treatment protocols may comprisetreatment protocols known to treat, prevent, or reduce the symptoms ofEBV infection and/or EBV-associated cancer.

In certain embodiments, adjunctive therapies for use with the methodsand compositions described herein include acupuncture. In otherembodiments, the non-chemical treatment protocol is surgery. In yetother embodiments, the non-chemical treatment protocol is chiropracticcare. In yet other embodiments, the non-chemical treatment protocol ispassive or active immunotherapy. In yet other embodiments, thenon-chemical treatment protocol includes X-rays. In yet otherembodiments, the non-chemical treatment protocol includes ultrasounds,among others. In other embodiments, adjunctive treatment protocolsinclude diagnostic assessments, e.g., blood testing, to determine ormonitor the progress of the infection, the course or status of thedisease, relapse or any need for booster administrations of thecompositions.

These additional treatment protocols may be administered prior to,concurrently with, or subsequent to administration of the compound ofthe invention. In certain embodiments, radiation is administered priorto, concurrently with, or subsequent to the compound.

Doses of the compound of the invention within the ranges describedelsewhere herein may be used when the compound of the invention isadministered in combination with an additional pharmacologically activereagent or in an additional treatment protocol. In other embodiments,lower doses of the compound of the invention are useful whenadministered in combination with an additional pharmacologically activereagent. In yet other embodiments, combination of the compound of theinvention with another pharmacological agent or treatment protocolpermits lower than usual dosages of the additional pharmacological agentor adjustment of the additional protocol regimen and/or lower doses ofthe compound of the invention to achieve the desired therapeutic effect.

A synergistic effect may be calculated, for example, using suitablemethods such as, for example, the Sigmoid-E_(max) equation (Holford &Scheiner, 19981, Clin. Pharmacokinet. 6: 429-453), the equation of Loeweadditivity (Loewe & Muischnek, 1926, Arch. Exp. Pathol Pharmacol. 114:313-326) and the median-effect equation (Chou & Talalay, 1984, Adv.Enzyme Regul. 22: 27-55). Each equation referred to above may be appliedto experimental data to generate a corresponding graph to aid inassessing the effects of the drug combination. The corresponding graphsassociated with the equations referred to above are theconcentration-effect curve, isobologram curve and combination indexcurve, respectively.

Kits

Also provided are kits or packages of pharmaceutical formulationscontaining (i) at least one compound of the invention; and (ii) anantiviral and/or anticancer agent. In certain embodiments, the compoundof the invention and the antiviral and/or anticancer agent areformulated for the desired delivery vehicle and route. In certainembodiments, the kit is also includes a chemotherapeutic agent describedherein. In other embodiments, the compound and antiviral and/oranticancer agent are formulated for any suitable route, such as for oralor parenteral, for example, transdermal, transmucosal (e.g, sublingual,lingual, (trans)buccal, (trans)urethral, vaginal (e.g., trans- andperivaginally), (intra)nasal and (trans)rectal), intravesical,intrapulmonary, intraduodenal, intragastrical, intrathecal,subcutaneous, intramuscular, intradermal, intra-arterial, intravenous,intrabronchial, inhalation, and topical administration. In yet otherembodiments, the kit is designed for delivery at home. The kit may thusinclude tubes or other containers, applicators, needles, syringes, andother appropriate packaging and instructions for use.

Methods

The invention provides a method of treating and/or preventing a diseaseor disorder caused by EBNA1 activity in a subject. The invention furtherprovides a method of treating and/or preventing Epstein-Barr Virus (EBV)infection, and/or a disease or disorder associated with EBV infection,in a subject. The invention further provides a method of treating and/orpreventing lytic and/or latent EBV Virus infection in a subject.

In certain embodiments, the disease or disorder is at least one selectedfrom the group consisting of cancer, infectious mononucleosis, chronicfatigue syndrome, multiple sclerosis, systemic lupus erythematosus, andrheumatoid arthritis. In certain embodiments, the cancer is at least oneselected from the group consisting of nasopharyngeal carcinoma, gastriccarcinomas, non-hodgkin lymphoma, anaplastic large-cell lymphoma,angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma,B-cell lymphoma, Burkitt's lymphoma, reticuloendotheliosis, reticulosis,microglioma, diffuse large B-cell lymphoma, extranodal T/NKlymphoma/angiocentric lymphoma, follicular lymphoma, immunoblasticlymphoma, mucosa-associated lymphatic tissue lymphoma, B-cell chroniclymphocytic leukemia, mantle cell lymphoma, mediastinal large B celllymphoma, lymphoplasmactic lymphoma, nodal marginal zone B celllymphoma, splenic marginal zone lymphoma, intravascular large B-celllymphoma, primary effusion lymphoma, lyphomatoid granulomatosis,angioimmunoblastic lymphadenopathy, leiomyosarcomas, X-linkedlymphoproliferative disease, post-transplant lymphoproliferativedisorders, Hodgkin's lymphoma and breast cancer.

In certain embodiments, the methods of the invention compriseadministering a therapeutically effective amount of a compound and/orcomposition of the invention to the subject in need thereof. In otherembodiments, the compound of the invention is part of a pharmaceuticalcomposition further comprising at least one pharmaceutically acceptablecarrier. In yet other embodiments, the compound and/or composition isadministered to the subject by at least one route selected from thegroup consisting of oral, nasal, inhalational, topical, buccal, rectal,pleural, peritoneal, vaginal, intramuscular, subcutaneous, transdermal,epidural, intratracheal, otic, intraocular, intrathecal, and intravenousroutes. In yet other embodiments, the compound is administered as partof a pharmaceutical composition. In yet other embodiments, the subjectis a mammal. In yet other embodiments, the mammal is human.

Administration/Dosage/Formulations

The regimen of administration may affect what constitutes an effectiveamount. The therapeutic formulations may be administered to the subjecteither prior to or after the onset of a disease or disorder contemplatedin the invention. Further, several divided dosages, as well as staggereddosages may be administered daily or sequentially, or the dose may becontinuously infused, or may be a bolus injection. Further, the dosagesof the therapeutic formulations may be proportionally increased ordecreased as indicated by the exigencies of the therapeutic orprophylactic situation.

Administration of the compositions of the present invention to apatient, preferably a mammal, more preferably a human, may be carriedout using known procedures, at dosages and for periods of time effectiveto treat a disease or disorder contemplated in the invention. Aneffective amount of the therapeutic compound necessary to achieve atherapeutic effect may vary according to factors such as the state ofthe disease or disorder in the patient; the age, sex, and weight of thepatient; and the ability of the therapeutic compound to treat a diseaseor disorder contemplated in the invention. Dosage regimens may beadjusted to provide the optimum therapeutic response. For example,several divided doses may be administered daily or the dose may beproportionally reduced as indicated by the exigencies of the therapeuticsituation. A non-limiting example of an effective dose range for atherapeutic compound of the invention is from about 1 and 5,000 mg/kg ofbody weight/per day. The pharmaceutical compositions useful forpracticing the invention may be administered to deliver a dose of from 1ng/kg/day and 100 mg/kg/day. One of ordinary skill in the art would beable to study the relevant factors and make the determination regardingthe effective amount of the therapeutic compound without undueexperimentation.

Actual dosage levels of the active ingredients in the pharmaceuticalcompositions of this invention may be varied so as to obtain an amountof the active ingredient that is effective to achieve the desiredtherapeutic response for a particular patient, composition, and mode ofadministration, without being toxic to the patient.

In particular, the selected dosage level depends upon a variety offactors including the activity of the particular compound employed, thetime of administration, the rate of excretion of the compound, theduration of the treatment, other drugs, compounds or materials used incombination with the compound, the age, sex, weight, condition, generalhealth and prior medical history of the patient being treated, and likefactors well known in the medical arts.

A medical doctor, e.g., physician or veterinarian, having ordinary skillin the art may readily determine and prescribe the effective amount ofthe pharmaceutical composition required. For example, the physician orveterinarian could start doses of the compounds of the inventionemployed in the pharmaceutical composition at levels lower than thatrequired in order to achieve the desired therapeutic effect andgradually increase the dosage until the desired effect is achieved.

In particular embodiments, it is advantageous to formulate the compoundin dosage unit form for ease of administration and uniformity of dosage.Dosage unit form as used herein refers to physically discrete unitssuited as unitary dosages for the patients to be treated; each unitcontaining a predetermined quantity of therapeutic compound calculatedto produce the desired therapeutic effect in association with therequired pharmaceutical vehicle. The dosage unit forms of the inventionare dictated by and directly dependent on (a) the unique characteristicsof the therapeutic compound and the particular therapeutic effect to beachieved, and (b) the limitations inherent in the art ofcompounding/formulating such a therapeutic compound for the treatment ofa disease or disorder contemplated in the invention.

In certain embodiments, the compositions of the invention are formulatedusing one or more pharmaceutically acceptable excipients or carriers. Inother embodiments, the pharmaceutical compositions of the inventioncomprise a therapeutically effective amount of a compound of theinvention and a pharmaceutically acceptable carrier. In yet otherembodiments, the compound of the invention is the only biologicallyactive agent in the composition. In yet other embodiments, the compoundof the invention is the only biologically active agent intherapeutically effective amounts in the composition.

The carrier may be a solvent or dispersion medium containing, forexample, water, ethanol, polyol (for example, glycerol, propyleneglycol, and liquid polyethylene glycol, and the like), suitable mixturesthereof, and vegetable oils. The proper fluidity may be maintained, forexample, by the use of a coating such as lecithin, by the maintenance ofthe required particle size in the case of dispersion and by the use ofsurfactants. Prevention of the action of microorganisms may be achievedby various antibacterial and antifungal agents, for example, parabens,chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In manycases, it is preferable to include isotonic agents, for example, sugars,sodium chloride, or polyalcohols such as mannitol and sorbitol, in thecomposition. Prolonged absorption of the injectable compositions may bebrought about by including in the composition an agent which delaysabsorption, for example, aluminum monostearate or gelatin.

In certain embodiments, the compositions of the invention areadministered to the patient in dosages that range from one to five timesper day or more. In other embodiments, the compositions of the inventionare administered to the patient in range of dosages that include, butare not limited to, once every day, every two days, every three days toonce a week, and once every two weeks. It is readily apparent to oneskilled in the art that the frequency of administration of the variouscombination compositions of the invention varies from individual toindividual depending on many factors including, but not limited to, age,disease or disorder to be treated, gender, overall health, and otherfactors. Thus, the invention should not be construed to be limited toany particular dosage regime and the precise dosage and composition tobe administered to any patient is determined by the attending physicaltaking all other factors about the patient into account.

Compounds of the invention for administration may be in the range offrom about 1 μg to about 10,000 mg, about 20 μg to about 9,500 mg, about40 μg to about 9.000 mg, about 75 μg to about 8,500 mg, about 150 μg toabout 7,500 mg, about 200 μg to about 7,000 mg, about 3050 μg to about6,000 mg, about 500 μg to about 5,000 mg, about 750 μg to about 4,000mg, about 1 mg to about 3,000 mg, about 10 mg to about 2,500 mg, about20 mg to about 2.000 mg, about 25 mg to about 1,500 mg, about 30 mg toabout 1,000 mg, about 40 mg to about 900 mg, about 50 mg to about 800mg, about 60 mg to about 750 mg, about 70 mg to about 600 mg, about 80mg to about 500 mg, and any and all whole or partial incrementstherebetween.

In certain embodiments, the dose of a compound of the invention is fromabout 1 mg and about 2,500 mg. In certain embodiments, a dose of acompound of the invention used in compositions described herein is lessthan about 10.000 mg, or less than about 8,000 mg, or less than about6,000 mg, or less than about 5.000 mg, or less than about 3,000 mg, orless than about 2,000 mg, or less than about 1.000 mg, or less thanabout 500 mg, or less than about 200 mg, or less than about 50 mg.Similarly, in certain embodiments, a dose of a second compound asdescribed herein is less than about 1,000 mg, or less than about 800 mg,or less than about 600 mg, or less than about 500 mg, or less than about400 mg, or less than about 300 mg, or less than about 200 mg, or lessthan about 100 mg, or less than about 50 mg, or less than about 40 mg,or less than about 30 mg, or less than about 25 mg, or less than about20 mg, or less than about 15 mg, or less than about 10 mg, or less thanabout 5 mg, or less than about 2 mg, or less than about 1 mg, or lessthan about 0.5 mg, and any and all whole or partial increments thereof.

In certain embodiments, the present invention is directed to a packagedpharmaceutical composition comprising a container holding atherapeutically effective amount of a compound of the invention, aloneor in combination with a second pharmaceutical agent; and instructionsfor using the compound to treat, prevent, or reduce one or more symptomsof a disease or disorder contemplated in the invention.

Formulations may be employed in admixtures with conventional excipients,i.e., pharmaceutically acceptable organic or inorganic carriersubstances suitable for oral, parenteral, nasal, intravenous,subcutaneous, enteral, or any other suitable mode of administration,known to the art. The pharmaceutical preparations may be sterilized andif desired mixed with auxiliary agents, e.g., lubricants, preservatives,stabilizers, wetting agents, emulsifiers, salts for influencing osmoticpressure buffers, coloring, flavoring and/or aromatic substances and thelike. They may also be combined where desired with other active agents.

Routes of administration of any of the compositions of the inventioninclude oral, nasal, rectal, intravaginal, parenteral, buccal,sublingual or topical. The compounds for use in the invention may beformulated for administration by any suitable route, such as for oral orparenteral, for example, transdermal, transmucosal (e.g., sublingual,lingual, (trans)buccal, (trans)urethral, vaginal (e.g, trans- andperivaginally), (intra)nasal and (trans)rectal), intravesical,intrapulmonary, intraduodenal, intragastrical, intrathecal,subcutaneous, intramuscular, intradermal, intra-arterial, intravenous,intrabronchial, inhalation, and topical administration.

Suitable compositions and dosage forms include, for example, tablets,capsules, caplets, pills, gel caps, troches, dispersions, suspensions,solutions, syrups, granules, beads, transdermal patches, gels, powders,pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs,suppositories, liquid sprays for nasal or oral administration, drypowder or aerosolized formulations for inhalation, compositions andformulations for intravesical administration and the like. It should beunderstood that the formulations and compositions that would be usefulin the present invention are not limited to the particular formulationsand compositions that are described herein.

Oral Administration

For oral application, particularly suitable are tablets, dragees,liquids, drops, suppositories, or capsules, caplets and gelcaps. Thecompositions intended for oral use may be prepared according to anymethod known in the art and such compositions may contain one or moreagents selected from the group consisting of inert, non-toxicpharmaceutically excipients that are suitable for the manufacture oftablets. Such excipients include, for example an inert diluent such aslactose; granulating and disintegrating agents such as cornstarch;binding agents such as starch; and lubricating agents such as magnesiumstearate. The tablets may be uncoated or they may be coated by knowntechniques for elegance or to delay the release of the activeingredients. Formulations for oral use may also be presented as hardgelatin capsules wherein the active ingredient is mixed with an inertdiluent.

For oral administration, the compounds of the invention may be in theform of tablets or capsules prepared by conventional means withpharmaceutically acceptable excipients such as binding agents (e.g.,polyvinylpyrrolidone, hydroxypropylcellulose orhydroxypropylmethylcellulose); fillers (e.g, cornstarch, lactose,microcrystalline cellulose or calcium phosphate); lubricants (e.g.,magnesium stearate, talc, or silica); disintegrates (e.g., sodium starchglycollate); or wetting agents (e.g., sodium lauryl sulphate). Ifdesired, the tablets may be coated using suitable methods and coatingmaterials such as OPADRY™ film coating systems available from Colorcon,West Point, Pa. (e.g., OPADRY™ OY Type, OYC Type, Organic Enteric OY-PType, Aqueous Enteric OY-A Type, OY-PM Type and OPADRY™ White,32K18400). Liquid preparation for oral administration may be in the formof solutions, syrups or suspensions. The liquid preparations may beprepared by conventional means with pharmaceutically acceptableadditives such as suspending agents (e.g., sorbitol syrup, methylcellulose or hydrogenated edible fats); emulsifying agent (e.g.,lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily estersor ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).

Granulating techniques are well known in the pharmaceutical art formodifying starting powders or other particulate materials of an activeingredient. The powders are typically mixed with a binder material intolarger permanent free-flowing agglomerates or granules referred to as a“granulation”. For example, solvent-using “wet” granulation processesare generally characterized in that the powders are combined with abinder material and moistened with water or an organic solvent underconditions resulting in the formation of a wet granulated mass fromwhich the solvent must then be evaporated.

Melt granulation generally consists in the use of materials that aresolid or semi-solid at room temperature (i.e., having a relatively lowsoftening or melting point range) to promote granulation of powdered orother materials, essentially in the absence of added water or otherliquid solvents. The low melting solids, when heated to a temperature inthe melting point range, liquefy to act as a binder or granulatingmedium. The liquefied solid spreads itself over the surface of powderedmaterials with which it is contacted, and on cooling, forms a solidgranulated mass in which the initial materials are bound together. Theresulting melt granulation may then be provided to a tablet press or beencapsulated for preparing the oral dosage form. Melt granulationimproves the dissolution rate and bioavailability of an active (i.e.,drug) by forming a solid dispersion or solid solution.

U.S. Pat. No. 5,169,645 discloses directly compressible wax-containinggranules having improved flow properties. The granules are obtained whenwaxes are admixed in the melt with certain flow improving additives,followed by cooling and granulation of the admixture. In certainembodiments, only the wax itself melts in the melt combination of thewax(es) and additives(s), and in other cases both the wax(es) and theadditives(s) melt.

The present invention also includes a multi-layer tablet comprising alayer providing for the delayed release of one or more compounds of theinvention, and a further layer providing for the immediate release of amedication for treatment of a disease or disorder contemplated in theinvention. Using a wax/pH-sensitive polymer mix, a gastric insolublecomposition may be obtained in which the active ingredient is entrapped,ensuring its delayed release.

Parenteral Administration

As used herein, “parenteral administration” of a pharmaceuticalcomposition includes any route of administration characterized byphysical breaching of a tissue of a subject and administration of thepharmaceutical composition through the breach in the tissue. Parenteraladministration thus includes, but is not limited to, administration of apharmaceutical composition by injection of the composition, byapplication of the composition through a surgical incision, byapplication of the composition through a tissue-penetrating non-surgicalwound, and the like. In particular, parenteral administration iscontemplated to include, but is not limited to, subcutaneous,intravenous, intraperitoneal, intramuscular, intrasternal injection, andkidney dialytic infusion techniques.

Formulations of a pharmaceutical composition suitable for parenteraladministration comprise the active ingredient combined with apharmaceutically acceptable carrier, such as sterile water or sterileisotonic saline. Such formulations may be prepared, packaged, or sold ina form suitable for bolus administration or for continuousadministration. Injectable formulations may be prepared, packaged, orsold in unit dosage form, such as in ampules or in multidose containerscontaining a preservative. Formulations for parenteral administrationinclude, but are not limited to, suspensions, solutions, emulsions inoily or aqueous vehicles, pastes, and implantable sustained-release orbiodegradable formulations. Such formulations may further comprise oneor more additional ingredients including, but not limited to,suspending, stabilizing, or dispersing agents. In one embodiment of aformulation for parenteral administration, the active ingredient isprovided in dry (i.e., powder or granular) form for reconstitution witha suitable vehicle (e.g., sterile pyrogen-free water) prior toparenteral administration of the reconstituted composition.

The pharmaceutical compositions may be prepared, packaged, or sold inthe form of a sterile injectable aqueous or oily suspension or solution.This suspension or solution may be formulated according to the knownart, and may comprise, in addition to the active ingredient, additionalingredients such as the dispersing agents, wetting agents, or suspendingagents described herein. Such sterile injectable formulations may beprepared using a non-toxic parenterally-acceptable diluent or solvent,such as water or 1,3-butanediol, for example. Other acceptable diluentsand solvents include, but are not limited to, Ringer's solution,isotonic sodium chloride solution, and fixed oils such as syntheticmono- or di-glycerides. Other parentally-administrable formulationswhich are useful include those which comprise the active ingredient inmicrocrystalline form, in a liposomal preparation, or as a component ofa biodegradable polymer system. Compositions for sustained release orimplantation may comprise pharmaceutically acceptable polymeric orhydrophobic materials such as an emulsion, an ion exchange resin, asparingly soluble polymer, or a sparingly soluble salt.

Controlled Release Formulations and Drug Delivery Systems

In certain embodiments, the formulations of the present invention maybe, but are not limited to, short-term, rapid-offset, as well ascontrolled, for example, sustained release, delayed release andpulsatile release formulations.

The term sustained release is used in its conventional sense to refer toa drug formulation that provides for gradual release of a drug over anextended period of time, and that may, although not necessarily, resultin substantially constant blood levels of a drug over an extended timeperiod. The period of time may be as long as a month or more and shouldbe a release which is longer that the same amount of agent administeredin bolus form.

For sustained release, the compounds may be formulated with a suitablepolymer or hydrophobic material that provides sustained releaseproperties to the compounds. As such, the compounds useful within themethods of the invention may be administered in the form ofmicroparticles, for example by injection, or in the form of wafers ordiscs by implantation.

In one embodiment of the invention, the compounds of the invention areadministered to a patient, alone or in combination with anotherpharmaceutical agent, using a sustained release formulation.

The term delayed release is used herein in its conventional sense torefer to a drug formulation that provides for an initial release of thedrug after some delay following drug administration and that may,although not necessarily, includes a delay of from about 10 minutes upto about 12 hours.

The term pulsatile release is used herein in its conventional sense torefer to a drug formulation that provides release of the drug in such away as to produce pulsed plasma profiles of the drug after drugadministration.

The term immediate release is used in its conventional sense to refer toa drug formulation that provides for release of the drug immediatelyafter drug administration.

As used herein, short-term refers to any period of time up to andincluding about 8 hours, about 7 hours, about 6 hours, about 5 hours,about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40minutes, about 20 minutes, about 10 minutes, or about 1 minute and anyor all whole or partial increments thereof after drug administrationafter drug administration.

As used herein, rapid-offset refers to any period of time up to andincluding about 8 hours, about 7 hours, about 6 hours, about 5 hours,about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40minutes, about 20 minutes, about 10 minutes, or about 1 minute and anyand all whole or partial increments thereof after drug administration.

Dosing

The therapeutically effective amount or dose of a compound of thepresent invention depends on the age, sex and weight of the patient, thecurrent medical condition of the patient and the progression of adisease or disorder contemplated in the invention. The skilled artisanis able to determine appropriate dosages depending on these and otherfactors.

A suitable dose of a compound of the present invention may be in therange of from about 0.01 mg to about 5,000 mg per day, such as fromabout 0.1 mg to about 1,000 mg, for example, from about 1 mg to about500 mg, such as about 5 mg to about 250 mg per day. The dose may beadministered in a single dosage or in multiple dosages, for example from1 to 5 or more times per day. When multiple dosages are used, the amountof each dosage may be the same or different. For example, a dose of 1 mgper day may be administered as two 0.5 mg doses, with about a 12-hourinterval between doses.

It is understood that the amount of compound dosed per day may beadministered, in non-limiting examples, every day, every other day,every 2 days, every 3 days, every 4 days, or every 5 days. For example,with every other day administration, a 5 mg per day dose may beinitiated on Monday with a first subsequent 5 mg per day doseadministered on Wednesday, a second subsequent 5 mg per day doseadministered on Friday, and so on.

In the case wherein the patient's status does improve, upon the doctor'sdiscretion the administration of the inhibitor of the invention isoptionally given continuously; alternatively, the dose of drug beingadministered is temporarily reduced or temporarily suspended for acertain length of time (i.e., a “drug holiday”). The length of the drugholiday optionally varies between 2 days and 1 year, including by way ofexample only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days,12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days,120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days,320 days, 350 days, or 365 days. The dose reduction during a drugholiday includes from 10%-100%, including, by way of example only, 10%,15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,85° %, 90%, 95%, or 100%.

Once improvement of the patient's conditions has occurred, a maintenancedose is administered if necessary. Subsequently, the dosage or thefrequency of administration, or both, is reduced, as a function of thedisease or disorder, to a level at which the improved disease isretained. In certain embodiments, patients require intermittenttreatment on a long-term basis upon any recurrence of symptoms and/orinfection.

The compounds for use in the method of the invention may be formulatedin unit dosage form. The term “unit dosage form” refers to physicallydiscrete units suitable as unitary dosage for patients undergoingtreatment, with each unit containing a predetermined quantity of activematerial calculated to produce the desired therapeutic effect,optionally in association with a suitable pharmaceutical carrier. Theunit dosage form may be for a single daily dose or one of multiple dailydoses (e.g., about 1 to 5 or more times per day). When multiple dailydoses are used, the unit dosage form may be the same or different foreach dose.

Toxicity and therapeutic efficacy of such therapeutic regimens areoptionally determined in cell cultures or experimental animals,including, but not limited to, the determination of the LD₅₀ (the doselethal to 50% of the population) and the ED₅₀ (the dose therapeuticallyeffective in 50% of the population). The dose ratio between the toxicand therapeutic effects is the therapeutic index, which is expressed asthe ratio between LD₅₀ and ED₅₀. The data obtained from cell cultureassays and animal studies are optionally used in formulating a range ofdosage for use in human. The dosage of such compounds lies preferablywithin a range of circulating concentrations that include the ED₅₀ withminimal toxicity. The dosage optionally varies within this rangedepending upon the dosage form employed and the route of administrationutilized.

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, numerous equivalents to thespecific procedures, embodiments, claims, and examples described herein.Such equivalents were considered to be within the scope of thisinvention and covered by the claims appended hereto. For example, itshould be understood, that modifications in reaction conditions,including but not limited to reaction times, reaction size/volume, andexperimental reagents, such as solvents, catalysts, pressures,atmospheric conditions, e.g., nitrogen atmosphere, andreducing/oxidizing agents, with art-recognized alternatives and using nomore than routine experimentation, are within the scope of the presentapplication.

It is to be understood that wherever values and ranges are providedherein, all values and ranges encompassed by these values and ranges,are meant to be encompassed within the scope of the present invention.Moreover, all values that fall within these ranges, as well as the upperor lower limits of a range of values, are also contemplated by thepresent application.

The following examples further illustrate aspects of the presentinvention. However, they are in no way a limitation of the teachings ordisclosure of the present invention as set forth herein.

EXAMPLES

The invention is now described with reference to the following Examples.These Examples are provided for the purpose of illustration only, andthe invention is not limited to these Examples, but rather encompassesall variations that are evident as a result of the teachings providedherein.

Materials and Methods

¹H-NMR spectra were obtained on a Varian Mercury 300-MHz NMR or a Bruker400 MHz NMR. Purity (%) and mass spectral data were determined with aWaters Alliance 2695 HPLC/MS (Waters Symmetry C18, 4.6×75 mm, 3.5 μm)with a 2996 diode array detector from 210-400 nm or with an AgilentTechnologies-Ion-trap mass spectrometer-LC-MSD TRAPXCT PLUS.

Example 12-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-indol-6-ylethynyl]-benzoicacid

2-Bromo-3-iodo-benzoic acid methyl ester: To a stirring solution of2-bromo-3-iodobenzoic acid (50.0 g, 0.15 mol) in methanol (125 mL) wasadded thionyl chloride (12.2 mL, 0.168 mol) over a period of 10 minutesat ice bath temperature. The reaction mixture was allowed to stir at 60°C. over a period of 12 hours. The resulting reaction mixture was allowedto reach room temperature, diluted with ethyl acetate (500 mL), washedwith sodium bicarbonate (250 mL), water (2×250 mL), brine (250 mL),dried over sodium sulfate and filtered. Silica gel (100 g, 60-120 mesh)was added to the filtrate, stirred for 30 minutes at 25-30° C., filteredand concentrated under reduced pressure to give methyl2-bromo-3-iodobenzoate as a pale yellow liquid (50.0 g, 96%). ¹H NMR(400 MHz, DMSO-d₆) δ 8.11 (dd, J=7.8, 1.5 Hz, 1H), 7.62 (dd, J=7.6, 1.5Hz, 1H), 7.23 (t, J=7.7 Hz, 1H), 3.85 (s, 3H). MS m/z (M+) 340.9, (M+2)342.9.

2-bromo-3-triethylsilanylethynyl-benzoic acid methyl ester: A solutionof methyl 2-bromo-3-iodobenzoate (400 g, 1.176 mol) in tetrahydrofuranand triethylamine (1.0 L:1.0 L) was deaerated using a argon gas over aperiod of 15 minutes. To this solution were addedbis(triphenylphosphine) palladium(II) dichloride (8.24 g, 0.0117 mol),copper (I) iodide (11.23 g, 0.058 mol) and triethyl-ethynyl-silane(253.6 mL, 1.412 mol) at ambient temperature over a period of 30minutes. The reaction mixture was allowed to stir at ambient temperatureover a period of 4 hours. The reaction mixture was concentrated underreduced pressure, diethyl ether (1.5 L) was added to the crude product,stirred for 30 minutes and filtered through celite pad. The filtrate wasthen concentrated under reduced pressure to give2-bromo-3-triethylsilanylethynyl-benzoic acid methyl ester as a lightbrown liquid (372 g, 90%). ¹H NMR (400 MHz, DMSO-d₆) δ 7.70 (ddd,J=16.6, 7.7, 1.7 Hz, 2H), 7.49 (t, J=7.7 Hz, 1H), 3.86 (s, 3H),1.01-1.05 (t, J=7.9 Hz, 9H), 0.65-0.71 (q, J=7.7 Hz, 6H). MS m/z(M+353.3, (M+2) 355.2.

2-(1H-Indol-6-yl)-3-triethylsilanyl ethynyl-benzoic acid methyl ester: Asolution of 2-bromo-3-triethylsilanylethynyl-benzoic acid methyl ester(300 g, 0.85 mol) in 1,4-dioxane:water (750 mL:750 mL) was deaeratedusing a argon gas over a period of 15 minutes. To this solution wereadded 6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indole (227.1g, 0.93 mol), [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane(6.94 g, 0.0085 mol) and potassium carbonate (235 g, 1.7 mol) at ambienttemperature. The reaction mixture was heated to 90° C. over a period of3 hours. The resultant reaction mixture was then allowed to reachambient temperature, diluted with ethyl acetate (2 L) and filteredthrough celite. The aqueous layer was separated and organic layer waswashed with water (500 mL), brine (500 mL), dried (sodium sulfate),filtered and concentrated under reduced pressure. The resultant crudeproduct was suspended with 10% ethyl acetate in hexane, stirred for 30minutes, filtered, and dried to give2-(1H-indol-6-yl)-3-triethylsilanylethynyl-benzoic acid methyl ester asa brown solid (248 g, 75%). ¹H NMR (400 MHz, DMSO-d₆) δ 11.08 (s, 1H),7.68 (ddd, J=10.9, 7.7, 1.4 Hz, 2H), 7.55-7.39 (m, 2H), 7.36 (t, J=2.7Hz, 1H), 7.32-7.25 (m, 1H), 6.84 (dd, J=8.1, 1.5 Hz, 1H), 6.43 (ddd,J=3.1, 1.9, 0.9 Hz, 1H), 3.45 (s, 3H), 0.69 (t, J=7.9 Hz, 9H), 0.36 (q,J=7.7 Hz, 6H). MS m/z (M+H) 390.2.

3-ethynyl-2-(1H-indol-6-yl)-benzoic acid methyl ester: To a stirringsolution of 2-(1H-indol-6-yl)-3-triethylsilanylethynyl-benzoic acidmethyl ester (250 g, 0.645 mol) in tetrahydrofuran (1.25 L) was added1.0 M tetrabutylammonium fluoride (838 mL, 0.838 mol) at 0-5° C. over aperiod of 30 minutes. The reaction mixture was allowed to stir atambient temperature over a period 60 minutes. Completion of the reactionwas monitored by TLC and LC-MS. The reaction mixture was concentratedunder reduced pressure. The resultant crude product was then dilutedwith ethyl acetate (2000 mL) and washed with water (2×500 mL). Organiclayer was washed with brine (600 mL), dried over sodium sulfate,filtered and concentrated under reduced pressure. The resultant crudeproduct was purified through silica gel cartridge eluting with ethylacetate/hexanes to give 3-ethynyl-2-(1H-indol-6-yl)-benzoic acid methylester as pale yellow solid (124 g, 70%). ¹H NMR (400 MHz, DMSO-d₆) δ11.16 (s, 1H), 7.74 (dd, J=7.7, 1.4 Hz, 1H), 7.68 (dd, J=7.7, 1.4 Hz,1H), 7.57-7.35 (m, 3H), 7.31 (dt, J=1.7, 0.9 Hz, 1H), 6.85 (dd, J=8.2,1.6 Hz, 1H), 6.45 (ddd, J=3.0, 1.9, 0.9 Hz, 1H), 4.03 (s, 3H), 3.44 (s,1H). MS m/z (M+H) 276.3.

2-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-indol-6-ylethynyl]-benzoicacid methyl ester: To a stirring solution of6-bromo-1-(2-morpholin-4-yl-ethyl)-1H-indole (560 mg, 1.82 mmol) intoluene:triethylamine (5:5 mL) was added cesium carbonate (1.54 g, 4.73mmol) and the reaction mixture was deaerated using an argon gas balloonfor 15 minutes. To this suspension was added palladium (II) acetonitriledichloride complex (5.0 mg, 0.0182 mmol) and2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (26 mg, 0.055mmol) at ambient temperature. The resulting reaction mixture was stirredunder inert atmosphere for 30 minutes. To the above reaction mixture,3-ethynyl-2-(1H-indol-6-yl)-benzoic acid methyl ester (500 mg, 1.82mmol) was added and the reaction mass was heated to 90° C. for a periodof 4 hours. The resultant reaction mixture was then allowed to cool toambient temperature and diluted with ethyl acetate (50 mL) and filteredthrough celite. The organic layer was washed with water (2×20 mL), brine(20 mL), dried (sodium sulfate), filtered and concentrated under reducedpressure. The resultant crude product was purified through silica gelcartridge eluting with dichloromethane/methanol to give the product2-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-indol-6-ylethynyl]-benzoicacid methyl ester as pale yellow solid in 49% yield. ¹H NMR (400 MHz,DMSO-d₆) δ 11.22 (s, 1H), 7.79 (dd. J=7.6, 1.2 Hz, 1H), 7.67 (dd, J=8.0,1.2 Hz, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.51-7.41 (m, 5H), 7.15 (s, 1H),6.99 (dd, J=8.0, 1.6 Hz, 1H), 6.82 (dd, J=8.0, 1.2 Hz, 1H), 6.50 (s,1H), 6.40 (d, J=3.2 Hz, 1H), 4.14 (t, J=6.4 Hz, 2H), 3.49-3.47 (m, 7H),2.55 (t, J=6.0 Hz, 2H), 2.35 (bs, 4H). MS m/z (M+H) 504.2.

2-(1H-indol-6-yl)-3-[l-(2-morpholin-4-yl-ethyl)-1H-indol-6-ylethynyl]-benzoicacid: To a solution of2-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-indol-6-ylethynyl]-benzoicacid methyl ester (120 mg, 0.24 mmol) in tetrahydrofuran:methanol (1:1mL) was added 2N sodium hydroxide (aq) (48 mg, 1.2 mmol) and theresulting solution was stirred for about 24 hours at ambienttemperature. The reaction mixture was then concentrated and the pHadjusted to 4 using 1 N hydrochloric acid solution. The aqueous layerwas then extracted using ethyl acetate (2×25 mL), washed with water (20mL) and brine (10 mL). The organic layers were combined, dried (sodiumsulfate), filtered and concentrated under reduced pressure. Theresulting crude product was then purified using reversed phase HPLC togive the2-(1H-indol-6-yl)-3-[l-(2-morpholin-4-yl-ethyl)-1H-indol-6-ylethynyl]-benzoicacid as pale yellow solid in 70% yield. ¹H NMR (400 MHz, DMSO-d₆) δ12.70 (brs, 1H), 11.22 (s, 1H), 7.74 (dd, J=7.6, 1.2 Hz, 1H), 7.65 (dd,J=7.6, 1.2 Hz, 1H), 7.61 (d, J=8.4 Hz, 1H), 7.48-7.44 (m, 3H), 7.42-7.40(m, 2H), 7.14 (s, 1H), 7.06 (dd, J=8.0, 1.6 Hz, 1H), 6.80 (dd, J=8.0,0.8 Hz, 1H), 6.49 (s, 1H), 6.39 (d, J=2.8 Hz, 1H), 4.14 (t, J=6.4 Hz,2H), 3.49 (t, J=4.0 Hz, 4H), 2.55 (bs, 2H), 2.35 (bs, 4H). MS m/z (M+H)490.3.

Example 23-[3-Acetylamino-4-(tetrahydro-pyran-4-yloxy)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[3-Acetylamino-4-(tetrahydro-pyran-4-yloxy)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.70 (s, 1H), 11.15 (d, J=2.6 Hz, 1H), 8.95 (s, 1H), 7.82(s, 1H), 7.73 (dd, J=7.8, 1.4 Hz, 1H), 7.66-7.54 (m, 2H), 7.48-7.34 (m,3H), 7.08-6.98 (m, 2H), 6.74 (dd, J=8.5, 2.2 Hz, 1H), 4.59 (tt, J=8.6,4.2 Hz, 1H), 3.85 (dt, J=11.6, 4.4 Hz, 2H), 3.49-3.33 (m, 3H), 2.09 (s,3H), 1.90 (dt, J=13.5, 3.9 Hz, 2H). 1.64 (dtd, J=13.0, 9.0, 4.0 Hz, 2H).MS m/z (M+H) 495.4.

Example 33-[4-(8-Acetyl-8-aza-bicyclo[3.2.1]oct-3-yl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(8-Acetyl-8-aza-bicyclo[3.2.1]oct-3-yl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 11.16 (s, 1H), 7.61-7.54 (m, 1H), 7.49 (dd, J=16.2, 7.7 Hz,3H), 7.38-7.29 (m, 2H), 7.25-7.11 (m, 2H), 7.10-7.00 (m, 3H), 6.44 (s,1H), 4.48 (d, J=5.5 Hz, 1H), 4.25-4.18 (m, 1H), 3.14 (tt, J=11.4, 6.1Hz, 1H), 1.99 (s, 4H), 2.00-1.80 (m, 2H), 1.80 (s, 2H), 1.81-1.66 (m,2H), 1.70-1.50 (m, 2H). MS m/z (M+H) 489.4.

Example 43-[1-(2-Dimethylamino-ethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[1-(2-Dimethylamino-ethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHzDMSO-d₆) δ 11.21 (s, 1H), 7.97 (d, J=1.9 Hz, 1H), 7.71 (dd. J=7.5, 1.7Hz, 2H), 7.63-7.55 (m, 3H), 7.50-7.37 (m, 3H), 7.06 (dd, J=8.1, 1.6 Hz,1H), 6.48 (s, 1H), 6.39 (d, J=3.5 Hz, 1H), 4.29 (t, J=6.5 Hz, 2H), 2.60(t, J=6.5 Hz, 2H), 2.14 (s, 6H). MS m/z (M+H) 449.2

Example 53-[1-(3-Dimethylamino-propyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[1-(3-Dimethylamino-propyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMF-d₇) δ 11.62 (d, J=2.3 Hz, 1H), 8.38 (s, 1H), 8.14 (q, J=2.9 Hz, 2H),8.07-7.96 (m, 3H), 7.90-7.78 (m, 3H), 7.47 (dd, J=8.1, 1.6 Hz, 1H), 6.89(s, 1H), 6.82 (d, J=3.5 Hz, 1H), 4.63 (t, J=7.1 Hz, 2H), 2.59 (t, J=7.0Hz, 2H), 2.54 (s, 6H), 2.28 (p, J=7.1 Hz, 2H). MS m/z (M+H) 463.2.

Example 62-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-benzoicacid

2-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.72 (s, 1H), 11.22 (d, J=2.5 Hz, 1H), 7.96 (d, J=1.9 Hz,1H), 7.79-7.56 (m, 4H), 7.51-7.38 (m, 3H), 7.05 (dd, J=8.1, 1.6 Hz, 1H),6.49 (s, 1H), 6.40 (d, J=3.5 Hz, 1H), 4.24 (t, J=7.0 Hz, 2H), 3.52 (t,J=4.6 Hz, 4H), 2.27 (s, 4H), 2.18 (t, J=7.0 Hz, 2H), 1.90 (p, J=7.0 Hz,2H). MS m/z (M+H) 505.2.

Example 72-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-pyrrolo[2,3-b]pyridin-3-ylethynyl]-benzoicacid

2-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.72 (s, 1H), 11.16 (s, 1H), 8.20 (dd, J=4.6, 1.7 Hz, 1H),7.78-7.66 (m, 2H), 7.65-7.54 (m, 2H), 7.49-7.39 (m, 3H), 6.99 (dd,J=8.1, 1.5 Hz, 1H), 6.90-6.77 (m, 2H), 6.51 (s, 1H), 4.22 (t, J=7.0 Hz,2H), 3.50 (t, J=4.6 Hz, 4H), 2.25 (s, 4H), 2.19 (t, J=6.9 Hz, 2H), 1.90(p, J=7.0 Hz, 2H). MS m/z (M+H) 505.2.

Example 82-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-benzoicacid

2-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.72 (s, 1H), 11.21 (d, J=2.4 Hz, 1H), 7.96 (d, J=2.0 Hz,1H), 7.80-7.69 (m, 2H), 7.70-7.56 (m, 3H), 7.52-7.38 (m, 3H), 7.05 (dd,J=8.1, 1.6 Hz, 1H), 6.49 (s, 1H), 6.40 (d, J=3.5 Hz, 1H), 4.33 (t, J=6.4Hz, 2H), 3.49 (t, J=4.6 Hz, 4H), 2.65 (t, J=6.5 Hz, 2H), 2.40 (d, J=4.7Hz, 4H). MS m/z (M+H) 491.3.

Example 93-[1-(2-Dimethylamino-ethyl)-1H-pyrrolo[2,3-b]pyridin-3-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[1-(2-Dimethylamino-ethyl)-1H-pyrrolo[2,3-b]pyridin-3-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.68 (bs, 1H), 11.18 (d, J=2.5 Hz, 1H), 8.20 (dd. J=4.3, 2.0Hz, 1H), 7.76 (s, 1H), 7.72 (dd, J=7.7, 1.4 Hz, 1H), 7.66-7.55 (m, 2H),7.50-7.39 (m, 3H), 6.99 (dd, J=8.1, 1.5 Hz, 1H), 6.87-6.76 (m, 2H), 6.52(ddd, J=3.0, 2.0, 0.9 Hz, 1H), 4.29 (t, J=6.3 Hz, 2H), 2.63 (t, J=6.3Hz, 2H), 2.15 (s, 6H). MS m/z (M+H) 449.4.

Example 102-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-pyrrolo[2,3-b]pyridin-3-ylethynyl]-benzoicacid

2-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-pyrrolo[2,3-b]pyridin-3-ylethynyl]-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 11.08 (s, 1H), 8.18 (d, J=4.8 Hz, 1H), 7.72 (s, 1H),7.53-7.42 (m, 2H), 7.38-7.29 (m, 2H), 7.20 (s, 2H), 7.10 (d, J=8.1 Hz,1H), 6.97 (d, J=7.8 Hz, 1H), 6.86-6.79 (m, 1H), 6.45 (s, 1H), 4.30 (t,J=6.3 Hz, 2H), 3.48 (t, =4.6 Hz, 4H), 2.64 (d, J=6.1 Hz, 2H), 2.39 (s,4H). MS m/z (M+H) 491.4.

Example 113-[1-(3-Dimethylamino-propyl)-1H-pyrrolo[2,3-b]pyridin-3-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[1-(3-Dimethylamino-propyl)-1H-pyrrolo[2,3-b]pyridin-3-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 11.17 (1, J==2.3 Hz, 1H), 8.21 (dd, J=4.5, 1.7 Hz, 1H), 7.75(s, 1H), 7.78-7.66 (m, 1H), 7.66-7.54 (m, 2H), 7.50-7.39 (m, 3H), 6.99(dd, J=8.1, 1.5 Hz, 1H), 6.90-6.78 (m, 2H), 6.52 (s, 1H), 4.20 (t, J=7.1Hz, 2H), 2.19 (t, J=7.1 Hz, 2H), 2.13 (s, 6H), 1.87 (p, J=7.1 Hz, 2H).MS m/z (M+H) 463.5.

Example 123-(1-[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl-ethyl]-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl)-2-(H-indol-6-yl)-benzoicacid

3-{1-[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-ethyl]-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl}-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.72 (s, 1H), 11.21 (s, 1H), 7.96 (d, J=1.9 Hz, 1H),7.80-7.69 (m, 2H), 7.70-7.61 (m 2H), 7.60 (d, J=8.1 Hz, 1H), 7.52-7.38(m, 3H), 7.05 (dd, J=8.2, 1.6 Hz, 1H), 6.49 (s, 1H), 6.41 (d, J=3.5 Hz,1H), 4.32 (t, =6.3 Hz, 2H), 2.98 (q, J=3.9 Hz 4H), 2.95-2.82 (m, 6H). MSnm/z (M+H) 539.3.

Example 132-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-indol-5-ylethynyl]-benzoicacid

2-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-indol-5-ylethynyl]-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.68 (s, 1H), 11.21 (d, J=2.3 Hz, 1H), 7.73 (dd, J=7.7, 1.5Hz, 1H), 7.66-7.55 (m, 2H), 7.49-7.36 (m, 4H), 7.33 (d, J=1.4 Hz, 1H),7.04 (dd, J=8.1, 1.6 Hz, 1H), 6.87 (dd, J=8.5, 1.6 Hz, 1H), 6.49 (s,1H), 6.34 (d, J=3.1 Hz, 1H), 4.24 (t, J=6.5 Hz, 2H), 3.50 (t, J=4.6 Hz,4H), 2.60 (t, J=6.5 Hz, 2H), 2.38 (s, 2H), 2.38 (d, J=9.3 Hz, 2H). MSm/z (M+H) 490.3.

Example 142-(1H-indol-6-yl)-3-[l-(3-morpholin-4-yl-propyl)-1H-indol-5-ylethynyl]-benzoicacid

2-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-indol-5-ylethynyl]-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 11.21 (t, J=2.3 Hz, 1H), 7.72 (dd, J=7.7, 1.4 Hz, 1H),7.66-7.55 (m, 2H), 7.49-7.36 (m, 6H), 7.33 (d, J=1.4 Hz, 1H), 7.04 (dd,J=8.1, 1.6 Hz, 1H), 6.86 (dd, J=8.5, 1.6 Hz, 1H), 6.49 (s, 1H), 6.35 (d,J=3.1 Hz, 1H), 4.16 (t, J=6.7 Hz, 2H), 3.55 (t, J=4.6 Hz, 4H), 2.26 (d,J=5.7 Hz, 4H), 2.11 (t, J=6.8 Hz, 2H), 1.86 (q, J=6.8 Hz, 2H). MS m/z(M+H) 504.3.

Example 152-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-indol-6-ylethynyl]-benzoicacid

2-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-indol-6-ylethynyl]-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₄) δ 11.22 (s, 1H), 7.73 (dd, J=7.7, 1.4 Hz, 1H), 7.68-7.57 (m,2H), 7.51-7.38 (m, 5H), 7.20 (s, 1H), 7.05 (dd, J=8.1, 1.5 Hz, 1H), 6.77(dd, J=8.2, 1.3 Hz, 1H), 6.49 (s, 1H), 6.41 (d, J=3.0 Hz, 1H), 4.10 (t,J=6.2 Hz, 2H), 3.58 (s, 4H), 2.28 (s, 4H), 2.09 (s, 2H), 1.84 (s, 2H).MS m/z (M+H) 504.3.

Example 162-(1H-Indol-6-yl)-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-3-ylethynyl)-benzoicacid

2-(1H-Indol-6-yl)-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-3-ylethynyl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.69 (s, 1H), 11.20 (s, 1H), 7.62 (dd, J=13.5, 7.7 Hz, 2H),7.58-7.48 (m, 2H), 7.42 (t, J=7.3 Hz, 2H), 6.96 (d, J=8.2 Hz, 1H),6.91-6.90 (m, 2H), 6.75 (s, 1H), 6.47 (t, J=2.4 Hz, 1H), 3.30-3.29 (m,2H), 3.22 (t, J=4.3 Hz, 2H), 1.69-1.67 (m, 2H). MS m/z (M+H) 394.0.

Example 172-(1H-indol-6-yl)-3-[1-(tetrahydro-pyran-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[1-(tetrahydro-pyran-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.74 (s, 1H), 11.21 (s, 1H), 7.98 (d, J=1.9 Hz, 1H),7.80-7.71 (m, 2H), 7.64 (d, J=7.6 Hz, 1H), 7.60 (s, 1H), 7.59-7.56 (m,2H), 7.50-7.42 (m, 1H), 7.41 (t, J=2.7 Hz, 1H), 7.05 (dd, J=8.1, 1.6 Hz,1H), 6.49 (t, J=2.6 Hz, 1H), 6.41 (d, J=3.5 Hz, 1H), 4.11 (d, J=7.3 Hz,2H), 3.85-3.71 (m, 2H), 3.17 (td, J=11.5, 2.5 Hz, 2H), 2.06 (ddd,J=11.4, 7.2, 4.0 Hz, 1H), 1.36-1.18 (m, 4H). MS m/z (M+H) 476.2.

Example 182-(1H-Indol-6-yl)-3-[1-(tetrahydro-pyran-4-ylmethyl)-1H-indol-5-ylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[1-(tetrahydro-pyran-4-ylmethyl)-1H-indol-5-ylethynyl]-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.68 (s, 1H), 11.21 (t, J=2.2 Hz, 1H), 7.72 (dd, J=7.7, 1.4Hz, 1H), 7.63 (dd, J=7.7, 1.4 Hz, 1H), 7.59 (d, J=8.1 Hz, 1H), 7.48-7.43(m, 2H), 7.43-7.39 (m, 2H), 7.38 (d, J=3.1 Hz, 1H), 7.34 (d, J=1.5 Hz,1H), 7.04 (dd, J=8.2, 1.6 Hz, 1H), 6.86 (dd, J=8.5, 1.6 Hz, 1H), 6.49(ddd, J=3.0, 1.9, 0.9 Hz, 1H), 6.35 (dd, J=3.1, 0.8 Hz, 1H), 4.03 (d,J=7.2 Hz, 2H), 3.85-3.73 (m, 2H), 3.16 (td, J=11.4, 2.7 Hz, 2H),2.06-1.89 (m, 1H), 1.38-1.18 (m, 4H). MS m/z (M+H) 475.2.

Example 192-(1H-Indol-6-yl)-3-[1-(1-methanesulfonyl-piperidin-4-ylmethyl)-1H-indol-5-ylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[1-(1-methanesulfonyl-piperidin-4-ylmethyl)-1H-indol-5-ylethynyl]-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.68 (s, 1H), 11.21 (s, 1H), 7.76-7.69 (m, 1H), 7.65-7.56(m, 2H), 7.50-7.33 (m, 6H), 7.04 (dd, =8.2, 1.6 Hz, 1H), 6.86 (dd,J=8.6, 1.6 Hz, 1H), 6.52-6.47 (m, 1H), 6.36 (d, J=3.1 Hz, 1H), 4.07 (d,J=7.2 Hz, 2H), 3.50 (d, J=11.7 Hz, 2H), 2.79 (s, 3H), 2.57 (td, J=12.0,2.5 Hz, 2H), 1.86 (d, J=3.8 Hz, 1H), 1.56-1.43 (m, 2H), 1.26 (dd,J=13.4, 9.5 Hz, 2H). MS m/z (M+H) 552.3.

Example 202-(1H-Indol-6-yl)-3-[1-(1-methanesulfonyl-piperidin-4-ylmethyl)-l-pyrrolo[2,3-b]pyridin-5-ylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[1-(1-methanesulfonyl-piperidin-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.71 (s, 1H), 11.21 (t, J=2.2 Hz, 1H), 7.97 (d, J=2.0 Hz,1H), 7.85-7.73 (m, 2H), 7.66 (dd, J=7.7, 1.4 Hz, 1H), 7.63-7.57 (m, 2H),7.55-7.24 (m, 3H), 7.05 (dd, J=8.2, 1.6 Hz, 1H), 6.49 (t, J=2.5 Hz, 1H),6.42 (d, J=3.4 Hz, 1H), 4.15 (d, J=7.3 Hz, 2H), 3.49 (d, J=11.8 Hz, 2H),2.73-2.52 (m, 5H), 1.97 (m, 1H), 1.49 (d, J=12.6 Hz, 2H), 1.24 (m, 2H).MS m/z (M+H) 553.2.

Example 213-[1-(1,1-Dioxo-hexahydro-1λ⁶-thiopyran-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[1-(1,1-Dioxo-hexahydro-1λ⁶-thiopyran-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.75 (s, 1H), 11.21 (d, J=2.4 Hz, 1H), 7.97 (d, J=2.0 Hz,1H), 7.75 (dt, J=3.9, 2.2 Hz, 2H), 7.65 (dd, J=7.8, 1.4 Hz, 1H),7.63-7.55 (m, 2H), 7.53-7.37 (m, 3H), 7.05 (dd, J=8.1, 1.6 Hz, 1H), 6.49(t, J=2.4 Hz, 1H), 6.43 (d, J=3.5 Hz, 1H), 4.18 (d, J=7.3 Hz, 2H), 3.02(qd, J=12.7, 9.4 Hz, 4H), 2.17 (ddt, J=12.1, 8.2, 4.1 Hz, 1H), 1.76 (d,J=13.7 Hz, 2H), 1.72-1.51 (m, 2H). MS m/z (M+H) 524.5.

Example 223-{1-[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-ethyl]-1H-indol-5-yl-ethynyl}-2-(1H-indol-6-yl)-benzoicacid

3-{1-[2-(1,1-Dioxo-λ⁶-thiomorpholin-4-yl)-ethyl]-1H-indol-5-yl-ethynyl}-2-(1H-indol-6-yl)-benzoicacid was prepared the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 11.20 (s, 1H), 7.73 (dd, J=7.6, 1.2 Hz, 1H), 7.64-7.57 (m,2H), 7.46-7.40 (m, 5H), 7.33 (d, J=0.8 Hz, 1H), 7.05 (dd, J=8.4, 1.6 Hz,1H), 6.87 (dd, J=8.4, 1.2 Hz, 1H), 6.48 (d, J=2 Hz, 1H), 6.35 (d, J=3.2Hz, 1H), 4.23 (t, J=6.4 Hz, 2H), 2.99 (d, J=5.2 Hz, 4H), 2.91 (d, J=5.6Hz, 4H), 2.81 (t, J=6.4 Hz, 2H). MS m/z (M−H) 536.3.

Example 233-{1-[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-ethyl]-1H-indol-6-ylethynyl}-2-(1H-indol-6-yl)-benzoicacid

3-{1-[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-ethyl]-1H-indol-6-ylethynyl}-2-(1H-indol-6-yl)-benzoicacid was prepared the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.68 (s, 1H), 11.21 (s, 1H), 7.74 (dd, J=8.0, 1.2 Hz, 1H),7.65 (dd, J=7.6, 1.2 Hz, 1H), 7.61 (d, J=8.0 Hz, 1H), 7.48-7.43 (m, 3H),7.43-7.40 (m, 2H), 7.16 (s, 1H), 7.05 (dd, J=8.0, 1.6 Hz, 1H), 6.79 (dd,J=8.0, 1.2 Hz, 1H), 6.50 (s, 1H), 6.40 (d, J=3.2 Hz, 1H), 4.13 (t, J=6.4Hz, 2H), 2.96 (d, J=4.0 Hz, 4H), 2.87 (d, J=5.6 Hz, 4H), 2.76 (t, J=6.4Hz, 2H). MS m/z (M+H) 538.2.

Example 243-{1-[3-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-propyl]-1H-indol-5-yl-ethynyl}-2-(1H-indol-6-yl)-benzoicacid

3-{1-[3-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-propyl]-1H-indol-5-ylethynyl}-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.64 (brs, 1H), 1.19 (s, 1H), 7.68-7.56 (m, 3H), 7.45-7.33(m, 6H), 7.05 (d, J=8.0 Hz, 1H), 6.87 (d, =7.2 Hz, 1H), 6.48 (s, 1H),6.35 (s, 1H), 4.17 (t, 2H), 3.05 (m, 4H), 2.74 (m, 4H), 2.25 (t, 2H),1.84 (t, 2H), MS m/z (M−H) 550.3.

Example 253-{1-[3-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-propyl]-1H-indol-6-yl-ethynyl}-2-(1H-indol-6-yl)-benzoicacid

3-{1-[3-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-propyl]-1H-indol-6-ylethynyl}-2-(1H-indol-6-yl)-benzoicacid was prepared the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.71 (brs, 1H), 11.21 (s, 1H), 7.74 (d, J=7.2 Hz, 1H),7.64-5.59 (m, 2H), 7.46-7.40 (m, 5H), 7.19 (s, 1H), 7.06 (d, J=8.0 Hz,1H), 6.77 (d, J=8.0 Hz, 1H), 6.50 (s, 1H), 6.40 (d, J=2.8 Hz, 1H), 4.12(t, J=6.4 Hz, 2H), 3.03 3.01 (m 4H), 2.73-2.71 (m 4H), 2.21 (t, J=6.4Hz, 2H), 1.80 (t, J=6.4 Hz, 2H). MS m/z (M−H) 550.2.

Example 263-[4-(1,1-Dioxo-hexahydro-1λ⁶-thiopyran-4-yloxymethyl)-phenyethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(1,1-Dioxo-hexahydro-1λ⁶-thiopyran-4-yloxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ12.70 (brs, 1H), 11.20 (s, 1H, NH), 7.74 (dd, J=6.8, 0.8 Hz,1H), 7.68 (dd, J=7.6, 1.2 Hz, 1H), 7.58 (d, J=8.4 Hz, 1H), 7.46 (t, J=8Hz, 1H), 7.41-7.38 (m, 2H), 7.27 (d, J=8 Hz, 2H), 7.12 (d, J=8.4 Hz,2H), 7.03 (dd, J=8.4, 1.6 Hz, 1H), 6.47 (s, 1H), 4.48 (s, 2H), 3.68-3.64(m, 1H), 3.13-2.99 (m, 4H), 2.13-2.04 (m, 4H). MS m/z (M+H) 500.1.

Example 272-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-benzoicacid was prepared the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ12.76 (brs, 1H), 11.18 (s, 11-, NH), 7.73 (dd, J=7.6, 1.2 Hz,1H), 7.65 (dd, J=7.6, 1.2 Hz, 1H), 7.57 (d, J=8.0 Hz, 1H), 7.46-7.42 (m,2H), 7.39 (t, J=2.4 Hz, 2H), 7.24 (d, J=8 Hz, 2H), 7.11 (d, J=8.0 Hz,2H), 7.03 (dd, J=8.4, 1.6 Hz, 1H), 6.46 (s, 1H), 4.47 (s, 1H), 3.81-3.76(m, 2H), 3.51 (q, J=4.4 Hz, 1H), 3.32-3.28 (m, 2H), 1.78-1.73 (m, 2H),1.46-1.42 (m, 2H). MS m/z (M−H) 450.2.

Example 282-(1H-Indol-6-yl)-3-(4-isopropoxymethyl-phenylethynyl)-benzoic acid

2-(1H-indol-6-yl)-3-(4-isopropoxymethyl-phenylethynyl)-benzoic acid wasprepared by the same procedure as Example 1.2-(1H-indol-6-yl)-3-(4-isopropoxymethyl-phenylethynyl)-benzoic acidmethyl ester. ¹H NMR (400 MHz, DMSO-d₆) δ 12.75 (s, 1H), 11.19 (s, 1H),7.73 (d, J=7.7 Hz, 1H), 7.65 (d, J=7.7 Hz, 1H), 7.57 (d, J=8.2 Hz, 1H),7.49-7.36 (m, 3H), 7.22 (d, J=8.2 Hz, 2H), 7.09 (d, J=8.2 Hz, 2H), 7.02(dd, J=8.2, 1.6 Hz, 1H), 6.47 (s, 1H), 4.41 (s, 2H), 3.59 (p, J=6.1 Hz,1H), 1.11 (d, J=6.1 Hz, 6H). MS m/z (M−H) 408.3.

Example 292-(1H-Indol-6-yl)-3-[4-(1-oxo-hexahydro-1λ⁴-thiopyran-4-yloxy)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(1-oxo-hexahydro-1λ⁴-thiopyran-4-yloxy)-phenylethynyl]-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.70 (s, 1H), 11.19 (s, 1H), 7.71 (dd, J=7.7, 1.4 Hz, 1H),7.64 (dd, J=7.7, 1.4 Hz, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.45 (t J=7.7 Hz,1H), 7.42-7.34 (m, 2H), 7.12-7.04 (m, 2H), 7.02 (dd, J=8.2, 1.6 Hz, 1H),6.97-6.89 (m, 2H), 6.47 (t, J=2.7 Hz, 1H), 4.69 (dt, J=5.6, 2.8 Hz, 1H),2.90 (td, J=12.9, 11.9, 3.1 Hz, 2H), 2.68 (ddd, J=12.9, 5.1, 2.5 Hz,2H), 2.31 (ddt, J=14.7, 12.0, 2.9 Hz, 2H), 1.88-1.74 (m, 2H). MS m/z(M+H) 470.1.

Example 302-(1H-indol-6-yl)-3-(3-morpholin-4-ylmethyl-1H-indol-6-ylethynyl)-benzoicacid

2-(1H-indol-6-yl)-3-(3-morpholin-4-ylmethyl-1H-indol-6-ylethynyl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.64 (s, 1H), 11.20 (s, 1H), 11.08 (d, J=2.4 Hz, 1H), 7.75(dd, J=7.8, 1.4 Hz, 1H), 7.66-7.56 (m, 2H), 7.52 (d, J=8.2 Hz, 1H),7.50-7.37 (m, 3H), 7.31 (d, J=2.4 Hz, 1H), 7.21 (s, 1H), 7.07 (dd,J=8.2, 1.6 Hz, 1H), 6.75 (dd, J=8.2, 1.4 Hz, 1H), 6.48 (s, 1H),3.60-3.48 (m, 6H), 2.34 (s, 4H). MS m/z (M+H) 476.2.

Example 312-(1H-indol-6-yl)-3-[3-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-6-ylethynyl]-benzoicacid

2-(1H-indol-6-yl)-3-[3-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-6-ylethynyl]-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.69 (bs, 1H), 11.20 (s, 1H), 11.10 (s, 1H), 7.75 (d, J=7.5Hz, 1H), 7.61 (dd, J=13.6, 7.9 Hz, 1H), 7.55-7.41 (m, 2H), 7.45-7.37 (m,3H), 7.32 (s, 1H), 7.22 (s, 1H), 7.07 (dd, J=8.1, 1.6 Hz, 1H), 6.75 (d,J=8.3 Hz, 1H), 6.49 (s, 1H), 3.63 (s, 2H), 3.05 (s, 4H), 2.84 (s, 3H),2.44 (s, 4H). MS m/z (M−H) 552.0.

Example 323-[3-(1,1-Dioxo-1λ⁶-thiomorpholin-4-ylmethyl)-1H-indol-6-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[3-(1,1-Dioxo-1λ⁶-thiomorpholin-4-ylmethyl)-1H-indol-6-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.61 (s, 1H), 11.19 (t, J=2.1 Hz, 1H), 11.12 (s, 1H), 7.75(dd, J=7.7, 1.4 Hz, 1H), 7.67-7.52 (m, 3H), 7.50-7.33 (m, 4H), 7.22 (s,1H), 7.07 (dd. J=8.2, 1.6 Hz, 1H), 6.74 (dd, J=8.2, 1.4 Hz, 1H), 6.48(s, 1H), 3.77 (s, 2H), 3.05 (s, 2H), 3.05 (d, J=10.7 Hz, 2H), 2.85 (d,J=4.6 Hz, 4H). MS m/z (M−H) 522.6.

Example 332-(1H-indol-6-yl)-3-(2-morpholin-4-ylmethyl-1H-indol-6-ylethynyl)-benzoicacid

2-(1H-indol-6-yl)-3-(2-morpholin-4-ylmethyl-1H-indol-6-ylethynyl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,CD3OD) δ 7.70 (ddd, J=17.5, 7.7, 1.4 Hz, 2H), 7.60 (d, J=8.2 Hz, 1H),7.49-7.34 (m, 3H), 7.28 (d J=3.2 Hz, 1H), 7.17-7.07 (m, 2H), 6.77 (dd,J=8.2, 1.4 Hz, 1H), 6.57 (s, 1H), 6.51 (dd. J=3.2, 1.0 Hz, 1H), 4.24 (s,2H), 3.81 (s, 4H), 3.06 (s, 4H). MS m/z (M−H) 474.8.

Example 343-[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-ylmethyl)-1H-indol-6-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-ylmethyl)-1H-indol-6-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.69 (s, 1H), 11.22-11.13 (m, 2H), 7.74 (dd, J=7.7, 1.4 Hz,1H), 7.65-7.56 (m, 2H), 7.48-7.40 (m, 2H), 7.42-7.31 (m, 2H), 7.20 (s,1H), 7.08 (dd, J=8.1, 1.6 Hz, 1H), 6.73 (dd, J=8.1, 1.4 Hz, 1H), 6.47(s, 1H), 6.31 (d, J=1.8 Hz, 1H), 3.81 (s, 2H), 3.11 (t, J=5.1 Hz, 4H),2.90 (dd, J=7.0, 3.6 Hz, 4H). MS m/z (M−H) 522.4.

Example 353-[1-(4-ethoxy-2-methyl-butyl)-6-fluoro-1H-indol-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[6-Fluoro-1-(tetrahydro-pyran-4-ylmethyl)-1H-indol-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 11.17 (s, 1H), 7.66 (d, J=7.6 Hz, 1H), 7.59 (d, J=7.7 Hz,1H), 7.54 (d, J=8.2 Hz, 1H), 7.50-7.34 (m, 5H), 7.20 (d, J=6.9 Hz, 1H),7.05 (dd, J=8.1, 1.5 Hz, 1H), 6.46 (s, 1H), 6.33 (d, J=3.1 Hz, 1H), 4.00(d, J=7.2 Hz, 2H), 3.83-3.73 (m, 2H), 3.17 (td, J=11.4, 2.7 Hz, 2H),1.98 (s, 1H), 1.33-1.16 (m, 4H). MS m/z (M−H) 491.4.

Example 363-[7-fluoro-1-(tetrahydro-pyran-4-ylmethyl)-1H-indol-6-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[7-fluoro-1-(tetrahydro-pyran-4-ylmethyl)-1H-indol-6-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 11.11 (s, 1H), δ 7.53 (s, 1H), 7.51-7.39 (m, 3H), 7.41-7.24(m, 3H), 7.22 (d, J=8.2 Hz, 1H), 7.13 (dd, J=8.1, 1.6 Hz, 1H), 6.67 (dd,J=8.2, 5.9 Hz, 1H), 6.43 (dt, J=18.8, 2.5 Hz, 2H), 4.11 (d, J=7.1 Hz,2H), 3.81 (dd, J=10.9, 3.6 Hz, 2H), 3.20 (m, 2H), 1.93 (bs, 1H), 1.26(dt, J=13.7, 6.5 Hz, 4H). MS m/z (M+H) 493.3.

Example 373-[1-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-ylmethyl)-7-fluoro-1H-indol-6-ylethynyl]-2-(1H-indol-yl)-benzoicacid

3-[1-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-ylmethyl)-7-fluoro-1H-indol-6-ylethynyl]-2-(1H-indol-1)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 11.12 (s, 1H), 7.55 (s, 1H), 7.52-7.37 (m, 3H), 7.30 (dd,J=5.4, 2.5 Hz, 2H), 7.27-7.12 (m, 3H), 6.68 (dd, J=8.2, 5.8 Hz, 1H),6.46 (t, J=2.7 Hz, 1H), 6.41 (t, J=2.4 Hz, 1H), 4.17 (d, J=7.2 Hz, 2H),3.28-2.87 (m, 4H), 2.05 (s, 1H), 1.71 (q, J=13.9, 11.9 Hz, 4H). MS m/z(M+H) 541.3.

Example 383-[1-(1,1-dioxo-hexahydro-11′-thiopyran-4-ylmethyl)-6-fluoro-1H-indol-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[1-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-ylmethyl)-6-fluoro-1H-indol-5-ylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.70 (s, 1H), 11.18 (s, 1H), 7.73 (d, J=7.7 Hz, 1H), 7.65(d, J=7.7 Hz, 1H), 7.60-7.34 (m, 6H), 7.22 (d, J=6.9 Hz, 1H), 7.03 (dd,J=8.1, 1.6 Hz, 1H), 6.47 (t, J=2.3 Hz, 1H), 6.35 (d, J=3.2 Hz, 1H), 4.08(d, J=7.3 Hz, 2H), 3.05-2.99 (m, 4H), 2.11-2.05 (m, 1H), 1.75 (d, J=14.0Hz, 2H), 1.65 (d, J=11.9 Hz, 2H). MS m/z (M+H) 541.3.

Example 393-(7-fluoro-3-morpholin-4-ylmethyl-1H-indol-6-ylethynyl)-2-(1H-indol-6-yl)-benzoicacid

3-(7-fluoro-3-morpholin-4-ylmethyl-1H-indol-6-ylethynyl)-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 11.65 (d, J=2.5 Hz, 1H), 11.17 (s, 1H), 7.74 (dd, J=7.7, 1.4Hz, 1H), 7.64 (dd, J=7.7, 1.4 Hz, 1H), 7.56 (d, J=8.1 Hz, 1H), 7.50-7.41(m, 2H), 7.41-7.31 (m, 3H), 7.07 (dd, J=8.2, 1.6 Hz, 1H), 6.65 (dd,J=8.2, 6.1 Hz, 1H), 6.46 (t, J=2.4 Hz, 1H), 3.56 (s, 2H), 3.52 (d, J=4.5Hz, 4H), 2.40-2.23 (m, 4H). MS m/z (M+H) 494.2.

Example 403-(6-fluoro-3-morpholin-1-ylmethyl-1H-indol-5-ylethynyl)-2-(1H-indol-6-yl)-benzoicacid

3-(6-fluoro-3-morpholin-4-ylmethyl-1H-indol-5-ylethynyl)-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (400 MHz,DMSO-d₆) δ 12.67 (s, 1H), 11.18 (d, J=2.6 Hz, 2H), δ 7.73 (dd, J=7.7,1.4 Hz, 1H), 7.67-7.57 (m 2H), 7.50-7.34 (m, 3H), 7.32-7.22 (m, 2H),7.18-7.03 (m, 2H), 6.46 (t, J=2.4 Hz, 1H), 3.56-3.46 (m, 4H), 3.39 (bs,2H), 2.30 (s, 4H). MS m/z (M+H) 494.3.

Example 413-((4-(2H-tetrazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoic acid

3-((4-(2H-tetrazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoic acidwas prepared by the same procedure as Example 1. ¹H NMR (300 MHz, CD3OD)δ ppm 7.84 (d, J=8.21 Hz, 2 H) 7.76 (d, J=7.62 Hz, 2 H) 7.59-7.64 (m, 1H) 7.42-7.50 (m, 2 H) 7.30 (d, J=2.93 Hz, 1 H) 7.19 (d, J=8.21 Hz, 2 H)7.06 (dd, J=8.06, 1.32 Hz, 1 H) 6.52 (d, J=3.22 Hz, 1 H). MS m/z (M+H)406.2.

Example 423-((3-(2H-tetrazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoic acid

3-((3-(2H-tetrazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoic acidwas prepared by the same procedure as Example 1. ¹H NMR (300 MHz, CD3OD)δ ppm 7.87 (d, J=7.04 Hz, 1 H) 7.73-7.82 (m, 3 H) 7.56-7.67 (m, 2 H)7.36-7.49 (m, 3 H) 7.25 (br, s., 1 H) 7.16 (d, J=7.92 Hz 1 H) 7.07 (d,J=7.92 Hz, 1 H) 6.47 (br, s., 1 H). MS m/z (M+H) 406.1.

Example 43 2-(1H-indol-6-yl)-3-((4-(oxazol-5-yl)phenyl)ethynyl)benzoicacid

2-(1H-indol-6-yl)-3-((4-(oxazol-5-yl)phenyl)ethynyl)benzoic acid wasprepared by the same procedure as Example 1. ¹H NMR (300 MHz, CD3OD) δppm 8.21 (s, 1 H) 7.73 (d, J=7.92 Hz, 2 H) 7.60 (d, J=8.21 Hz, 1 H) 7.53(d, J=8.21 Hz, 2 H) 7.38-7.50 (m, 3 H) 7.29 (s, 1 H) 7.00-7.15 (m, 3 H)6.51 (d, J=2.64 Hz, 1 H). MS m/z (M+H) 405.1.

Example 442-(1H-indol-6-yl)-3-((4-(6-oxo-1,6-dihydropyridazin-3-yl)phenyl)ethynyl)benzoicacid

2-(1H-indol-6-yl)-3-((4-(6-oxo-1,6-dihydropyridazin-3-yl)phenyl)ethynyl)benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,CD3OD) δ ppm 7.95 (d, J=9.97 Hz, 1 H) 7.72 (dd, J=11.87, 8.06 Hz, 4 H)7.60 (d, J=8.21 Hz, 1 H) 7.40-7.49 (m, 2 H) 7.29 (d, J=2.93 Hz, 1H)6.97-7.16 (m, 4 H) 6.51 (d, J=2.93 Hz, 1 H). MS m/z (M+H) 432.1.

Example 452-(1H-indol-6-yl)-3-((3-methoxy-4-(morpholinomethyl)phenyl)ethynyl)benzoicacid

4-(4-bromo-2-methoxybenzyl)morpholine: 4-bromo-2-methoxybenzaldehyde(214 mg, 1 mmol) and morpholine (87 mg, 1 mmol) were dissolved intetrahydrofuran at room temperature. Sodium triacetoxyborohydride (254mg, 1.2 mmol) was added to the mixture. The reaction was heated to 50°C. for 18 hours. Then, saturated sodium bicarbonate solution was addedto quench the reaction. Ethyl acetate was added to reaction mixture andlayers were separated. The organic layer was combined and concentratedto give crude product 4-(4-bromo-2-methoxybenzyl)morpholine as oil whichwas used for next step without further purification.

2-(1H-indol-6-yl)-3-((3-methoxy-4-(morpholinomethyl)phenyl)ethynyl)benzoic acid: 4-(4-Bromo-2-methoxybenzyl)morpholine and3-ethynyl-2-(1H-indol-6-yl)-benzoic acid methyl ester were reactedfollowing the same procedure as Example 1. ¹H NMR (300 MHz, CD3OD) δ ppm10.61 (br, s., 1 H) 7.74 (dd, J=11.73, 7.62 Hz, 2 H) 7.60 (d, J=8.21 Hz,1 H) 7.38-7.52 (m, 2 H) 7.19-7.31 (m, 2 H) 7.03 (dd, J=8.21, 1.17 Hz, 1H) 6.81 (d, J=7.92 Hz, 1 H) 6.36-6.57 (m, 2 H) 4.25 (s, 2 H) 3.83 (br,s., 1 H) 3.63 (s, 3 H) 3.20 (br, s., 4 H). MS m/z (M+H) 467.2.

Example 463-((3-hydroxy-4-(morpholine-4-carbonyl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid

(4-Bromo-2-hydroxyphenyl)(morpholino)methanone: 4-Bromo-2-hydroxybenzoicacid (215.9 mg, 1 mmol) morpholine (87 mg, 1 mmol) and diisopropyl ethylamine (260 mg, 2 mmol) were dissolved in N,N-dimethylformamide,1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxid hexafluorophosphate (HATU) (456 mg, 1.2 mmol) was added and thereactions were stirred at ambient temperature for 18 hours. Then thesolvent was removed under vacuum. The resulting oil was purified withcolumn chromatography (methylene chloride/methanol) to give the product(4-bromo-2-hydroxyphenyl)(morpholino)methanone as pale yellow solid.

3-((3-hydroxy-4-(morpholine-4-carbonyl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid: (4-Bromo-2-hydroxyphenyl)morpholino)methanone and3-ethynyl-2-(1H-indol-6-yl)-benzoic acid methyl ester were reactedfollowing the same procedure as Example 1. ¹H NMR (300 MHz, CD3OD) δ ppm7.65-7.74 (m, 3 H) 7.58 (d, J=8.21 Hz, 1 H) 7.42 (d, J=5.57 Hz, 3 H)7.25 (d, J=2.93 Hz, 1 H) 7.08 (d, J=9.38 Hz, 1 H) 7.01 (d, J=7.92 Hz, 1H) 6.64 (s, 1 H) 6.57 (d, J=9.09 Hz, 1 H) 6.47 (s., 1 H) 3.64 (br, s., 3H). MS m/z (M+H) 467.2.

Example 472-(1H-Indol-6-yl)-3-[3-methoxy-4-(4-morpholin-4-yl-piperidin-1-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[3-methoxy-4-(4-morpholin-4-yl-piperidin-1-ylmethyl)-phenylethynyl]-benzoicacid was prepared by the same procedure as Example 45. ¹H NMR (300 MHz,CD₃OD) δ ppm 7.75 (dd, J=13.49, 7.62 Hz, 2 H) 7.58 (d, J=8.21 Hz, 1 H)7.36-7.49 (m, 2 H) 7.27 (d, J=2.93 Hz, 1 H) 7.22 (d, J=7.62 Hz, 1 H)6.97 (d, J=8.21 Hz, 1 H) 6.76 (d, J=7.62 Hz, 1 H) 6.48 (d, J=3.22 Hz, 1H) 6.41 (s, 1 H) 4.21 (s, 2 H) 3.88 (br, s., 4 H) 3.44-3.65 (m, 1 H)3.59 (s, 3 H) 3.48-3.52 (m, 2 H) 3.22 (br, s., 3 H) 3.01 (t, J=12.31 Hz,2 H) 2.26 (d, J=12.61 Hz, 2 H) 1.95 (d, J==11.43 Hz, 2 H). MS m/z (M+H)550.4.

Example 48 3-((4-((4,4-difluoropiperidin-1-yl)methyl)-3-methoxyphenyl)ethynyl)-2-(1H-indol-6-yl)benzoic acid

3-((4-((4,4-difluoropiperidin-1-yl)methyl)-3-methoxyphenyl)ethynyl)-2-(1H-indol-6-yl)benzoic acid was prepared by the same procedure as Example 45. ¹H NMR(300 MHz CD₃OD) δ ppm 7.74 (dd, J=12.31, 7.62 Hz, 2 H) 7.60 (d, J=7.92Hz, 1 H) 7.38-7.50 (m, 2 H) 7.25 (d, J=7.62 Hz, 2 H) 7.04-7.11 (m, 1 H)7.02 (dd, J=8.21, 1.17 Hz, 1 H) 6.81 (d, J=7.04 Hz, 1 H) 6.48 (d, J=2.64Hz, 1 H) 6.43 (s, 1 H) 4.29 (s, 2 H) 3.61 (s, 3 H) 3.36 (br, s., 4 H)2.28 (br, s., 4 H). MS m/z (M+H) 501.3.

Example 49 3-((4-((4-(dimethylcarbamoyl)piperidin-1-yl)methyl)-3-methoxyphenyl) ethynyl)-2-(1H-indol-6-yl)benzoic acid

3-((4-((4-(dimethylcarbamoyl)piperidin-1-yl)methyl)-3-methoxyphenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid was prepared by the same procedure as Example 45. ¹H NMR (300 MHz,CD₃OD) δ ppm 7.75 (dd, J=13.05, 7.77 Hz, 2 H) 7.60 (d, J=8.21 Hz, 1 H)7.38-7.51 (m, 2 H) 7.20-7.33 (m, 2 H) 7.03 (d, J=8.21 Hz, 1 H) 6.82 (d,J=7.62 Hz, 1 H) 6.48 (d, J=2.93 Hz, 1 H) 6.44 (s, 1 H) 4.20 (s, 2 H)3.62 (s, 3 H) 3.45 (d, J=12.90 Hz, 1 H) 3.09 (s, 4 H) 2.99 (d, J=14.07Hz, 2 H) 2.91 (s, 4 H) 1.79-1.96 (m, 3 H). MS m/z (M+H) 536.3.

Example 503-((3-hydroxy-4-(4-morpholinopiperidine-1-carbonyl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid

3-((3-hydroxy-4-(4-morpholinopiperidine-1-carbonyl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoic acid was prepared by the same procedure as Example 46. ¹H NMR(300 MHz, CD₃OD) 5 ppm 7.71 (d, J=7.62 Hz, 3 H) 7.57 (d, J=8.21 Hz, 1 H)7.32-7.46 (m, 2 H) 7.25 (br, s., 1 H) 7.06 (d, J=8.21 Hz, 1 H) 7.00 (d,J=7.92 Hz, 1 H) 6.66 (s, 1 H) 6.57 (d, J=7.62 Hz, 1 H) 6.47 (br, s., 1H) 3.41 (d, J=11.43 Hz, 4 H) 1.64 (d, J=8.80 Hz, 4 H). MS mm/z (M+H)550.2.

Example 51 3-((4-(4,4-difluoropiperidine-1-carbonyl)-3-hydroxyphenyl)ethynyl)-2-(1H-indol-6-yl)benzoic acid

3-((4-(4,4-difluoropiperidine-1-carbonyl)-3-hydroxyphenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid was prepared by the same procedure as Example 46. ¹H NMR (300 MHz,CD₃OD) δ ppm 7.72 (d, J=7.62 Hz, 2 H) 7.58 (d, J=8.21 Hz, 1 H) 7.37-7.49(m, 2 H) 7.26 (d, J=2.64 Hz, 1 H) 7.04 (dd, J=11.87, 8.06 Hz, 2 H) 6.65(s, 1 H) 6.57 (d, J=7.92 Hz, 1 H) 6.48 (d, J=3.22 Hz, 1 H) 2.00 (br, s.,4 H). MS m/z (M+H) 501.2.

Example 522-(1H-indol-1-yl)-3-((4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenyl)ethynyl) benzoic acid

4-(4-Bromo-benzyl)-1-methanesulfonyl-piperidine: To a dichloromethane (2mL) solution of 4-(4-bromobenzyl)piperidine (253 mg, 1 mmol) andtriethylamine (80 mg, 1.2 mmol) at 0° C., methanesulfonyl chloride (171mg, 1.5 mmol) was added slowly. The reaction was warmed up to roomtemperature and stirred for 16 hours. Water (2 mL) was added and thelayers were separated. The water layer was extracted 2×3 mLdichloromethane. The combined solvent was dried with sodium sulfate,filtered and removed under vacuum. The crude material used in next stepwithout further purification.

2-(1H-indol-6-yl)-3-((4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenyl)ethynyl) benzoic acid:4-(4-Bromo-benzyl)-1-methanesulfonyl-piperidine and3-ethynyl-2-(1H-indol-6-yl)-benzoic acid methyl ester were reactedfollowing the same procedure as Example 1. ¹H NMR (300 MHz, CDCl₃) δ ppm8.27 (br, s., 1 H) 7.68-7.85 (m, 3 H) 7.64 (d, J=8.21 Hz, 1 H) 7.31-7.43(m, 2 H) 7.09-7.20 (m, 2 H) 6.55 (br, s., 1 H) 6.11 (br, s., 2 H) 3.71(d, =12.02 Hz, 2 H) 2.71 (s, 3 H) 2.37-2.61 (m, 5 H) 1.64 (d, J=12.90Hz, 2 H) 1.44-1.57 (m, 1 H) 1.17-1.39 (m, 2 H). MS m/z (M+H) 513.1.

Example 532-(1H-indol-6-yl)-3-((4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)methyl)phenyl)ethynyl)benzoic acid

2-(1H-indol-6-yl)-3-((4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)methyl)phenyl)ethynyl)benzoic acid was prepared by the same procedure asExample 52. ¹H NMR (300 MHz, CDCl₃) δ ppm 8.21 (br, s., 1 H) 7.83 (d,J=7.62 Hz, 1 H) 7.74 (d, J=7.62 Hz, 1 H) 7.65 (d, J=8.21 Hz, 1 H)7.31-7.45 (m, 2 H) 7.10-7.21 (m, 2 H) 6.56 (br, s., 1 H) 6.27 (br, s., 3H) 3.89 (d, J=12.90 Hz, 2 H) 2.92 (t, J=12.31 Hz, 2 H) 2.49 (d, =−6.74Hz, 2 H) 1.53-1.72 (m, 3 H) 1.12-1.34 (m, 2 H). MS m/z (M+H) 557.1.

Example 542-(1H-indol-6-yl)-3-((4-((1-(isopropylsulfonyl)piperidin-4-yl)methyl)phenyl) ethynyl) benzoic acid

2-(1H-indol-6-yl)-3-((4-((1-(isopropylsulfonyl)piperidin-4-yl)methyl)phenyl)ethynyl) benzoic acid was prepared by the same procedure as Example 52.¹H NMR (300 MHz, CDCl₃) δ ppm 8.25 (br, s., 1 H) 7.83 (d, J=7.62 Hz, 1H) 7.74 (d, J=7.62 Hz, 1 H) 7.65 (d, J=7.92 Hz, 1 H) 7.33-7.42 (m, 2 H)7.09-7.22 (m, 2 H) 6.56 (br, s., 1 H) 5.90 (br, s., 2 H) 3.74 (d,J=12.61 Hz, 2 H) 3.13 (quin, J=6.82 Hz, 1 H) 2.74 (t, J=11.87 Hz, 2 H)2.46 (d, J=6.74 Hz, 2 H) 1.49-1.63 (m, 3 H) 1.12-1.36 (m, 8 H). MS m/z(M+H) 541.

Example 553-((4-((1-acetylpiperidin-4-yl)methyl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid

3-((4-((1-acetylpiperidin-4-yl)methyl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid was prepared by the same procedure as Example 52. ¹H NMR (300 MHz,CDCl₃) δ ppm 8.24 (br, s., 1 H) 7.83 (d, J=7.62 Hz, 1 H) 7.74 (d, J=7.62Hz, 1 H) 7.65 (d, J=7.92 Hz, 1 H) 7.33-7.41 (m, 2 H) 7.16-7.19 (m, 2 H)6.96-6.93 (m, 4 H) 6.55 (s, 1 H) 4.49-4.52 (m, 1H) 3.71-3.75 (m, 1 H)2.90-2.98 (m, 2 H) 2.44-2.46 (m, 3H) 2.07 (s, 3 H) 1.61-1.64 (m, 3 H)1.08-1.12 (m, 2 H). MS m/z (M+H) 477.2.

Example 56 3-((2-acetylisoindolin-5-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid

3-((2-acetylisoindolin-5-yl)ethynyl)-2-(1H-indol-6-yl)benzoic acid wasprepared by the same procedure as Example 52. ¹H NMR (300 MHz, CD₃OD) δppm 7.77 (d, J=7.92 Hz, 2 H) 7.64 (d, J=7.92 Hz, 1 H) 7.44-7.54 (m, 2 H)7.37 (br, s., 1 H) 7.22 (d, J=4.69 Hz, 1 H) 7.02-7.12 (m, 2 H) 6.98 (br,s., 1 H) 6.55 (br, s., 1 H) 2.63 (d, J=1.47 Hz, 4 H) 2.15 (s, 3 H). MSm/z (M+H) 421.1.

Example 572-(1H-indol-6-yl)-3-((2-(isopropylsulfonyl)isoindolin-5-yl)ethynyl)benzoicacid

2-(1H-indol-6-yl)-3-((2-(isopropylsulfonyl)isoindolin-5-yl)ethynyl)benzoicacid was prepared by the same procedure as Example 52. ¹H NMR (300 MHz,CDCl₃)δ ppm 8.21 (br, s., 1 H) 7.89 (d, J=7.92 Hz, 1 H) 7.75 (d, =7.62Hz, 1 H) 7.68 (d, J=8.21 Hz, 1 H) 7.37-7.48 (m, 3 H) 7.15 (d, J=8.21 Hz,1 H) 6.99-7.07 (m, 1 H) 6.89-6.98 (m, 1 H) 6.71 (s, 1 H) 6.61 (br, s., 1H) 4.68 (s, 2 H) 4.59 (s, 2 H) 3.31 (dt, J=13.71, 6.78 Hz, 1 H) 1.38 (d,J=7.04 Hz, 6 H). MS m/z (M+H) 485.2.

Example 582-(1H-indol-6-yl)-3-((2-(1-(methylsulfonyl)pyrrolidin-3-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoicacid

7-Bromo-2-(pyrrolidin-3-yl)-1,2,3,4-tetrahydroisoquinoline:7-Bromo-1,2,3,4-tetrahydro-isoquinoline (211 mg, 1 mmol) and tert-butyl3-oxopyrrolidine-1-carboxylate (185 mg, 1 mmol) were dissolved in1,2-dichloroethane at room temperature. NaBH(OAc)₃ (254 mg, 1.2 mmol)and 1 drop of acetic acid was added to the mixture. The reaction wasstirred at room temperature for 18 hours. Then, saturated sodiumbicarbonate solution was added to quench the reaction. Ethyl acetate wasadded to reaction mixture and layers were separated. The organic layerwas combined and concentrated to give crude material. The crude materialwas stirred with 4N HCl in dioxane (2 mL) for 18 hours. The reaction wasbasified with 2N sodium hydroxide solution until pH=10. Then thereaction was extracted with 3×10 ml methylene chloride. The combinedmethylene chloride was dried with sodium sulfate and removed undervacuum. The crude product was used in next step without furtherpurification.

7-Bromo-2-(1-methanesulfonyl-pyrrolidin-3-yl)-1,2,3,4-tetrahydroisoquinoline:To the dichloromethane (2 mL) solution of7-bromo-2-(pyrrolidin-3-yl)-1,2,3,4-tetrahydroisoquinoline (280 mg, 1mmol) and triethylamine (80 mg, 1.2 mmol) at 0° C., methanesulfonylchloride (171 mg, 1.5 mmol) was added slowly. The reaction was warmed toroom temperature and stirred for 16 hours. Water (2 mL) was added andthe layers were separated. The water layer was extracted 2×3 mLdichloromethane. The combined solvent was dried with sodium sulfate andremoved under vacuum, the crude material used in next step withoutfurther purifications.

2-(1H-indol-6-yl)-3-((2-(1-(methylsulfonyl)pyrrolidin-3-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoicacid:7-Bromo-2-(1-methanesulfonyl-pyrrolidin-3-yl)-1,2,3,4-tetrahydroisoquinolineand 3-ethynyl-2-(1H-indol-6-yl)-benzoic acid methyl ester were reactedfollowing the same procedure as Example 1. ¹H NMR (300 MHz, CD₃OD) δ ppm7.72 (dd, J=15.83, 7.62 Hz, 2 H) 7.59 (d, J=7.92 Hz, 1 H) 7.27-7.49 (m,3 H) 6.96-7.19 (m, 3 H) 6.63 (s, 1 H) 6.53 (d, J=3.22 Hz, 1 H) 4.26 (d,J=2.35 Hz, 2 H) 4.01-4.15 (m, 1 H) 3.85 (dd, J=10.85, 7.62 Hz, 1 H)3.49-3.68 (m, 4 H) 3.33-3.47 (m, 1 H) 3.13 (t, J=6.16 Hz, 2 H) 2.98 (s,3 H) 2.47-2.63 (m, 1 H) 2.17-2.36 (m, 1 H). MS m/z (M+H) 540.2.

Example 592-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)piperidin-4-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoicacid

2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)piperidin-4-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoicacid was prepared by the same procedure as Example 58. ¹H NMR (300 MHz,CD₃OD) δ ppm 7.72 (dd, J=9.97, 7.92 Hz, 2 H) 7.58 (d, J=8.21 Hz, 1 H)7.36-7.49 (m, 2 H) 7.29 (d, J=3.23 Hz, 1 H) 6.90-7.11 (m, 3 H) 6.76 (s,1 H) 6.51 (d, J=2.93 Hz, 1 H) 4.35 (br, s., 1 H) 3.72 (d, J=12.02 Hz, 2H) 3.49 (br, s., 1 H) 3.12 (d, J=6.74 Hz, 2 H) 2.97 (br, s., 2 H)2.59-2.88 (m, 5 H) 2.05 (dd, J=10.85, 7.33 Hz, 1 H) 1.86 (d, J=12.61 Hz,2 H) 1.34 (qd, J=12.22, 3.81 Hz, 2 H). MS m/z (M+H) 568.2.

Example 60 2-(1H-indol-6-yl)-3-((2-(1methylsulfonyl)azetidin-3-yl)-1,3,4-tetrahydro isoquinolin-6-yl)ethynyl)benzoic acid

2-(1H-indol-6-yl)-3-((2-(1-(methylsulfonyl)azetidin-3-yl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoic acid was prepared by the same procedure as Example 58.¹H NMR (300 MHz, CD3OD) δ ppm 7.73 (dd, J=12.17, 7.77 Hz, 2 H) 7.58 (d,J=8.21 Hz, 1 H) 7.38-7.50 (m, 2 H) 7.28 (d, J=2.93 Hz, 1 H) 6.92-7.07(m, 3 H) 6.77 (s, 1 H) 6.50 (d, J=3.22 Hz, 1 H) 4.29 (s, 2 H) 4.11-4.26(m, 5 H) 3.41 (t, J=6.16 Hz, 2 H) 2.92-3.03 (m, 5 H). MS m/z (M+H)526.1.

Example 612-(1H-indol-1-yl)-3-((2-((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoicacid

2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl)ethynyl)benzoicacid was prepared by the same procedure as Example 58. ¹H NMR (300 MHz,CD₃OD) δ ppm 7.72 (dd. J=10.85, 7.92 Hz, 2 H) 7.58 (d, J=8.21 Hz, 1 H)7.39-7.48 (m, 2 H) 7.29 (d, J=2.93 Hz, 1 H) 6.90-7.10 (m, 3 H) 6.76 (s,1 H) 6.50 (d, J=2.64 Hz, 1 H) 4.38 (br, s., 2 H) 3.40-3.69 (m, 5 H)2.95-3.14 (m, 4 H) 2.89 (s, 3 H) 2.71-2.84 (m, 1 H) 2.14-2.35 (m, 1 H)1.67-1.83 (m, 1 H). MS m/z (M+H) 554.2.

Example 622-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoicacid

2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)-1,2,3,4-tetrahydro-isoquinolin-7-yl)ethynyl)benzoicacid was prepared by the same procedure as Example 58. ¹H NMR (300 MHz,CD₃OD) δ ppm 7.71 (dd, J=12.31, 7.62 Hz, 2 H) 7.58 (d, J=7.92 Hz, 1 H)7.37-7.49 (m, 2 H) 7.25-7.36 (m, 1 H) 6.95-7.12 (m, 3 H) 6.69 (s, 1 H)6.52 (d, J=3.22 Hz, 1 H) 4.22 (br, s., 2 H) 3.62 (dd, J=9.97, 7.33 Hz, 1H) 3.47 (td, J=9.16, 3.37 Hz, 3 H) 2.98-3.14 (m, 3 H) 2.90 (s, 3 H)2.71-2.87 (m, 1 H) 2.15-2.28 (m, 1 H) 1.64-1.85 (m, 1 H). MS m/z (M+H)554.2.

Example 63 3-((2-((1-acetylpyrrolidin-3-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)-2-(H-indol-6-yl)benzoic acid

3-((2-((1-acetylpyrrolidin-3-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid was prepared by the same procedure as Example 58. ¹H NMR (300 MHz,CD30OD) δ ppm 7.71 (dd, J=11.58, 7.77 Hz, 2 H) 7.58 (d, J=8.21 Hz, 1 H)7.34-7.47 (m, 2 H) 7.24-7.33 (m, 1 H) 6.94-7.15 (m, 3 H) 6.72 (d,J=15.83 Hz, 1 H) 6.39-6.55 (m, 1 H) 4.23 (br, s., 2 H) 3.73-3.87 (m, 1H) 3.43-3.69 (m, 4 H) 3.15-3.25 (m, 1 H) 2.95-3.15 (m, 3 H) 2.57-2.88(m, 1 H) 2.11-2.32 (m, 1 H) 2.04 (m, 3 H) 1.60-1.90 (m 1 H). MS m/z(M+H) 518.2.

Example 642-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)azetidin-3-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoicacid

2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)azetidin-3-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoic acid was prepared by the same procedure asExample 58. ¹H NMR (300 MHz, CD₃OD) δ ppm 7.68-7.79 (m, 2 H) 7.58 (d,J=−8.21 Hz, 1 H) 7.35-7.49 (m, 2 H) 7.28 (d, J=2.93 Hz, 1H) 6.99-7.08(m, 2 H) 6.88-6.99 (m, 1 H) 6.76 (s, 1 H) 6.50 (d, J=2.93 Hz, 1 H) 4.34(s, 2 H) 4.10 (t, J=8.21 Hz, 2 H) 3.78 (dd, J=7.92, 6.45 Hz, 2 H)3.38-3.61 (m, 4 H) 3.09-3.25 (m, 1 H) 2.99 (t, J=6.16 Hz, 2 H) 2.94 (s,3 H). MS m/z (M+H) 540.2.

Example 652-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)azetidin-3-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoicacid

2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)azetidin-3-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoic acid was prepared by the same procedure asExample 58. ¹H NMR (300 MHz, CD₃OD) δ ppm 7.67-7.78 (m, 2 H) 7.59 (d,J=7.92 Hz, 1 H) 7.36-7.47 (m, 2 H) 7.31 (d, J=2.93 Hz, 1 H) 6.89-7.13(m, 3 H) 6.71 (s, 1 H) 6.52 (d, J=2.93 Hz, 1 H) 4.05-4.24 (m, 4 H) 3.79(dd, J=8.06, 6.60 Hz, 2 H) 3.43-3.59 (m, 4 H) 3.05-3.24 (m, 3 H) 2.96(s, 3 H). MS m/z (M+H) 540.2.

Example 662-(1H-indol-6-yl)-3-((2-(3-(methylsulfonamido)benzyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoicacid

2-(1H-indol-6-yl)-3-((2-(3-(methylsulfonamido)benzyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoicacid was prepared by the same procedure as Example 58. ¹H NMR (300 MHz,CD₃OD) δ ppm 7.768-7.75 (m, 2 H) 7.57 (d, J=8.21 Hz, 1 H) 7.38-7.50 (m,4 H) 7.23-7.35 (m, 3 H) 6.90-7.03 (m, 3 H) 6.75 (s, 1 H) 6.49 (d, =−2.64Hz, 1 H) 4.39 (s, 2 H) 4.29 (s, 2 H) 3.50 (br, s., 2 H) 2.91-3.06 (m, 5H). MS m/z (M+H) 576.2.

Example 672-(1H-indol-6-yl)-3-((2-(3-(methylsulfonamido)benzyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoic

2-(1H-indol-6-yl)-3-((2-(3-(methylsulfonamido)benzyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoic acid was prepared by the same procedure as Example 58.¹H NMR (300 MHz, CD₃OD) δ ppm 7.74 (dd, J=7.77, 1.03 Hz, 1 H) 7.67 (dd,J=7.77, 1.03 Hz, 1 H) 7.50-7.57 (m, 2 H) 7.48 (s, 1 H) 7.34-7.46 (m, 3H) 7.30 (d, J=7.62 Hz, 1 H) 7.17 (d, J=2.93 Hz, 1 H) 7.04-7.12 (m, 1 H)6.91-7.04 (m, 2 H) 6.33-6.45 (m, 2 H) 4.40 (s, 2 H) 4.08 (s, 2 H) 3.53(br, s., 2 H) 3.09 (1, J=6.16 Hz, 2 H) 2.99-3.05 (m, 3 H). MS m/z (M+H)576.2.

Example 682-(1H-indol-6-yl)-3-((2-(1-(methylsulfonyl)pyrrolidin-3-yl)isoindolin-5-yl)ethynyl)benzoicacid

2-(1H-indol-6-yl)-3-((2-(1-(methylsulfonyl)pyrrolidin-3-yl)isoindolin-5-yl)ethynyl)benzoicacid was prepared by the same procedure as Example 58. ¹H NMR (30×) MHz,CD₃OD) δ ppm 7.73 (t, J=7.92 Hz, 2 H) 7.58 (d, J=8.21 Hz, 1 H) 7.37-7.50(m, 2 H) 7.27-7.31 (m, 1 H) 7.23 (d, J=7.92 Hz, 1 H) 7.00-7.12 (m, 2 H)6.97 (s, 1 H) 6.50 (d, J=2.93 Hz, 1 H) 4.54-4.72 (m, 4 H) 4.12-4.31 (m,1 H) 3.76 (dd, J=11.29, 6.89 Hz, 1 H) 3.51-3.67 (m, 2 H) 3.34-3.47 (m, 1H) 2.96 (s, 3 H) 2.43-2.65 (m, 1 H) 2.14-2.36 (m, 1 H). MS m/z (M+H)556.3.

Example 692-(1H-indol-6-yl)-3-((2-(1-(methylsulfonyl)azetidin-3-yl)isoindolin-5-yl)ethynyl)benzoicacid

2-(1H-indol-6-yl)-3-((2-(1-(methylsulfonyl)azetidin-3-yl)isoindolin-5-yl)ethynyl)benzoicacid was prepared by the same procedure as Example 58. ¹H NMR (300 MHz,CD₃OD) δ ppm 7.73 (t, J=7.77 Hz, 2 H) 7.57 (d, J=8.21 Hz, 1 H) 7.35-7.48(m, 2 H) 7.17-7.31 (m, 2 H) 6.90-7.12 (m, 3 H) 6.49 (d, J=3.22 Hz, 1 H)4.62 (s, 2 H) 4.55 (s, 2 H) 4.19-4.33 (m, 3 H) 4.05-4.19 (m, 2 H)2.91-3.05 (m, 3 H). MS m/z (M+H) 512.

Example 70 2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)isoindolin-5-yl)ethynyl)benzoic acid

2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)isoindolin-5-yl)ethynyl)benzoic acid was prepared by the same procedure as Example 58. ¹H NMR(300 MHz, CD₃OD) δ ppm 7.73 (t, J=7.92 Hz, 2 H) 7.58 (d, J=7.92 Hz, 1 H)7.39-7.49 (m, 2 H) 7.21-7.34 (m, 2 H) 6.86-7.15 (m, 3 H) 6.50 (d, J=2.93Hz, 1 H) 4.51-4.73 (m, 3 H) 3.63 (dd, J=9.82, 7.48 Hz, 1 H) 3.44-3.57(m, 3 H) 3.34-3.42 (m, 1 H) 3.05-3.16 (m, 1 H) 2.91 (s, 3 H) 2.64-2.83(m, 1 H) 2.15-2.36 (m, 1 H) 1.70-1.94 (m, 1 H). MS m/z (M+H) 540.2.

Example 712-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)azetidin-3-yl)methyl)isoindolin-5-yl)ethynyl)benzoic acid

2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)azetidin-3-yl)methyl)isoindolin-5-yl)ethynyl)benzoic acid was prepared by the same procedure as Example 58. ¹H NMR(300 MHz, CD₃OD) δ ppm 7.73 (t, J=8.21 Hz, 2 H) 7.58 (d, J=8.21 Hz, 1 H)7.37-7.48 (m, 2 H) 7.18-7.32 (m, 2 H) 7.01-7.12 (m, 2 H) 6.95 (s, 1 H)6.50 (d, J=2.93 Hz, 0 H) 4.64 (br, s., 2 H) 4.57 (br, s., 2 H) 4.09 (t,J=8.21 Hz, 2 H) 3.79 (dd, J=8.06, 6.30 Hz, 2 H) 3.70 (d, J=7.04 Hz, 2 H)3.03-3.16 (m, 1 H) 2.95 (s, 3 H). MS m/z (M+H) 526.2.

Example 72 2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)piperidin-4-yl)methyl)isoindolin-5-yl)ethynyl)benzoic acid

2-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)piperidin-4-yl)methyl)isoindolin-5-yl)ethynyl)benzoic acid was prepared by the same procedure as Example 58. ¹H NMR(300 MHz, CD₃OD) δ ppm 7.74 (t, J=7.92 Hz, 2 H) 7.58 (d, J=8.21 Hz, 1 H)7.37-7.50 (m, 2 H) 7.18-7.33 (m, 2 H) 7.01-7.15 (m, 2 H) 6.98 (s, 1 H)6.50 (d, J=2.93 Hz, 1 H) 4.65 (d, J=19.06 Hz, 2 H) 3.78 (d, J=11.73 Hz,2 H) 3.36 (d, J=7.04 Hz, 2 H) 2.72-2.89 (m, 5 H) 1.86-2.08 (m, 3 H)1.30-1.49 (m, 2 H). MS m/z (M+H) 554.2.

Example 732-(1H-indol-6-yl)-3-((2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoic acid

2-(1H-indol-6-yl)-3-((2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoicacid was prepared by the same procedure as Example 52. ¹H NMR (300 MHz,CD₃OD) δ ppm 7.71 (dd, J=10.11, 7.77 Hz, 2 H) 7.59 (d, J=8.21 Hz, 1 H)7.37-7.47 (m, 2 H) 7.30 (s, 1 H) 7.00 (d, J=9.67 Hz, 2 H) 6.83-6.93 (m,1 H) 6.56 (s, 1 H) 4.18 (s, 2 H) 3.45 (t, J=5.86 Hz, 2 H) 2.82-2.91 (m,5 H). MS m/z (M+H) 471.2.

Example 742-(1H-indol-6-yl)-3-((2-(isopropylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoic acid

2-(1H-indol-6-yl)-3-((2-(isopropylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoic acid was prepared by the same procedure as Example 52. ¹H NMR(30×) MHz, CD₃OD) δ ppm 7.63-7.75 (m, 2 H) 7.58 (d, J=8.21 Hz, 1 H)7.24-7.47 (m, 3 H) 7.01 (dd, J=8.21, 1.17 Hz, 1 H) 6.79-6.96 (m, 2 H)6.48 (s, 1 H) 4.22 (s, 2 H) 3.49 (t, J=5.86 Hz, 2 H) 2.77 (t, J=5.86 Hz,2 H) 1.17-1.36 (m, 6 H). MS m/z (M+H) 499.1.

Example 752-(1H-indol-1-yl)-3-((2-propionyl-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoic acid

2-(1H-indol-6-yl)-3-((2-propionyl-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoicacid was prepared by the same procedure as Example 52. ¹H NMR (30×) MHz,CD₃OD) δ ppm 7.63-7.75 (m, 2 H) 7.58 (dd, J=8.06, 2.78 Hz, 1 H)7.35-7.49 (m, 2 H) 7.30 (s, 1 H) 7.01 (d, J=8.21 Hz, 1 H) 6.89-6.98 (m,1 H) 6.75-6.89 (m, 1 H) 6.49-6.66 (m, 1 H) 4.39 (d, J=18.47 Hz, 2 H)3.66 (t, J=5.86 Hz, 1 H) 3.58 (t, J=5.86 Hz, 1 H) 2.64-2.80 (m, 2 H)2.41 (qd, J=7.43, 2.93 Hz, 2 H) 1.11 (t, J=7.48 Hz, 3 H). MS m/z (M+H)449.3.

Example 762-(1H-indol-6-yl)-3-((2-(methylsulfonyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl)ethynyl)benzoicacid

2-(1H-indol-6-yl)-3-((2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoicacid was prepared by the same procedure as Example 52. ¹H NMR (300 MHz,CD3OD) δ ppm 7.63-7.74 (m, 2 H) 7.58 (d, J=8.21 Hz, 1 H) 7.34-7.48 (m, 2H) 7.28 (s, 1 H) 7.02 (dd, J=8.21, 1.17 Hz, 1 H) 6.87 (q, J=8.60 Hz, 2H) 6.66 (s, 1 H) 4.28 (s, 2 H) 3.38 (t, J=5.86 Hz, 2 H) 2.81 (s, 3 H)2.70 (t, J=5.86 Hz, 2 H). MS m/z (M+H) 471.1.

Example 772-(1H-indol-6-yl)-3-((2-(isopropylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoic acid

2-(1H-indol-6-yl)-3-((2-(isopropylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoic acid was prepared by the same procedure as Example 52. ¹H NMR(300 MHz, CD₃OD) δ ppm 7.35-7.77 (m, 5 H) 7.28 (s, 1 H) 7.02 (dd,J=8.06, 1.32 Hz, 1 H) 6.82-6.96 (m, 2 H) 6.66 (s, 1 H) 4.40 (s, 2 H)3.51 (t, J=6.01 Hz, 2 H) 2.68 (t, J=5.86 Hz, 2 H) 1.27 (d, J=6.74 Hz, 6H). MS m/z (M+H) 499.2.

Example 783-((2-acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid

3-((2-acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid was prepared by the same procedure as Example 52. ¹H NMR (300 MHz,CD₃OD) δ ppm 7.70 (t, J=8.06 Hz, 2 H) 7.58 (d, J=7.92 Hz, 1 H) 7.35-7.51(m, 2 H) 7.28 (s, 1 H) 6.83-7.08 (m, 3 H) 6.68 (s, 1 H) 4.57 (br, s., 2H) 3.48-3.77 (m, 2 H) 2.69 (t, J=5.57 Hz, 1 H) 2.61 (t, J=5.72 Hz, 1 H)2.12 (s, 3 H). MS nm/z (M+H) 435.2.

Example 792-(1H-indol-6-yl)-3-((2-propionyl-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoic acid

2-(1H-indol-6-yl)-3-((2-propionyl-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoicacid was prepared by the same procedure as Example 52. ¹H NMR (300 MHz,CD₃OD) δ ppm 7.63-7.75 (m, 2 H) 7.58 (d, J=8.21 Hz, 1 H) 7.34-7.48 (m, 2H) 7.28 (s, 1 H) 7.02 (d, J=8.21 Hz, 1 H) 6.80-6.98 (m, 2 H) 6.66 (s, 1H) 4.53 (d, J=4.98 Hz, 2 H) 3.64 (t, J=6.01 Hz, 1 H) 3.57 (t, J=5.86 Hz,1 H) 2.60 (dt, J=16.93, 5.75 Hz, 2 H) 2.40 (q, J=7.33 Hz, 2 H) 1.08 (q,J=7.52 Hz, 3 H). MS m/z (M+H) 449.2.

Example 803-[4-(4-cyano-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

2-Bromo-3-(4-formyl-phenylethynyl)-benzoic acid methyl ester: A solutionof methyl 2-bromo-3-iodobenzoate (1.5 g, 4 mmol) and4-ethynyl-benzaldehyde (0.51 g, 4 mmol) in tetrahydrofuran:triethylamine(8:8 mL) was deaerated using a N₂ gas balloon for 15 minutes. To thissolution were added bis(triphenylphosphine) palladium(II) dichloride(310 mg, 0.04 mmol) and copper (I) iodide (50 mg, 0.3 mmol) and stirredfor 16 hours at ambient temperature. The reaction mixture was thenfiltered through celite using ethyl acetate (50 mL). The resultantsolution was the concentrated under reduced pressure and purifiedthrough silica gel cartridge eluting with ethyl acetate/hexanes to givea pale yellow solid in 67% yield.

3-(4-Formyl-phenylethynyl)-2-(1H-indol-6-yl)-benzoic acid methyl ester:To a stirring solution of 2-bromo-3-(4-formyl-phenylethynyl)-benzoicacid methyl ester (250 mg, 0.95 mmol) in 1,4-dioxane:water (2.5:2.5 mL)were added 6-indole boronic acid (277 mg, 1.13 mmol),[1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complexwith dichloromethane (78 mg, 0.095 mmol), potassium carbonate (321 mg,2.4 mmol) and resulting mixture was heated to 90° C. for 3 h. Theresultant mixture was then allowed to cool to ambient temperature andwas diluted with ethyl acetate (50 mL) and filtered through celite. Theaqueous layer was separated and extracted with ethyl acetate (2×25 mL)and then the combined organic layer was washed with water (20 mL), brine(20 mL), dried (sodium sulfate), filtered and concentrated under reducedpressure. The resultant crude product was purified through silica gelcartridge eluting with ethyl acetate/hexanes to give a yellow solid in70% yield. ¹H NMR (400 MHz, DMSO-d₆) δ 11.22 (s, 1H), 9.95 (s, 1H), 7.87(dd, J=8.0, 1.6 Hz, 1H), 7.81 (d, J=8.4 Hz, 2H), 7.75 (dd, J=7.6, 1.2Hz, 1H), 7.61 (d, J=8.4 Hz, 1H), 7.53 (t, J=8.0 Hz, 1H), 7.44-7.41 (m,2H), 7.33 (d, J=8.0 Hz, 2H), 6.98 (dd, J=8.0, 1.6 Hz, 1H), 6.49 (dd,J=2.0, 0.8 Hz, 1H), 3.49 (s, 3H). MS m/z (M−H) 378.2.

3-(4-Hydroxymethyl-phenylethynyl)-2-(1H-indol-6-yl)-benzoic acid methylester: To a stirring solution of3-(4-formyl-phenylethynyl)-2-(1H-indol-6-yl)-benzoic acid methyl ester(2 g, 5.26 mmol) in methanol (40 mL) was added sodium borohydride (0.234mg, 6.32 mmol) at 0-5° C., and stirred for 1 h at ambient temperature.The reaction mixture was then diluted with ethyl acetate (300 mL) andwashed with water (2×50 mL). The organic layer was washed with brine (50mL), dried (sodium sulfate), filtered and concentrated under reducedpressure. The resultant crude product was purified through silica gelcartridge eluting with ethyl acetate/hexanes to give a pale yellow solidin 90% yield. ¹H NMR (400 MHz, DMSO-d₆) δ 11.20 (s, 1H), 7.79 (d, J=8.0Hz, 1H), 7.68 (d, J=7.6 Hz, 1H), 7.58 (d, J=8.4 Hz, 1H), 7.49 (t, J=7.6Hz, 1H), 7.42-7.40 (m, 2H), 7.21 (d, J=7.6 Hz, 2H), 7.09 (d, J=8.0 Hz,2H), 6.95 (d, J=8.0 Hz, 1H), 6.47 (bs, 1H), 5.23 (t, J=5.6 Hz, 1H), 4.44(d, J=5.2 Hz, 2H), 3.49 (s, 3H). MS m/z (M−H) 380.0.

3-[4-(4-Cyano-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid methyl ester: To a stirring solution of3-(4-hydroxymethyl-phenylethynyl)-2-(1H-indol-6-yl)-benzoic acid methylester (400 mg, 1.06 mmol) in tetrahydrofuran (6 mL) were added1,1′-(azodicarbonyl)-dipiperidine (400 mg, 1.60 mmol), tributylphosphine(0.8 mL, 1.6 mmol), 4-cyanophenol (116 mg, 1.06 mmol) and stirred for 12hours at ambient temperature. The reaction mixture was then diluted withethyl acetate (100 mL) and washed with water (2×20 mL). The organiclayer was washed with brine (10 mL), dried (sodium sulfate), filteredand concentrated under reduced pressure. The resultant crude product waspurified through silica gel cartridge eluting with ethyl acetate/hexanesto give an off-white solid in 50% yield. ¹H NMR (400 MHz, DMSO-d₆) δ11.21 (s, 1H), 7.79-7.75 (m, 3H), 7.71 (dd, J=7.6, 1.2 Hz, 1H), 7.59 (d,J=8.4 Hz, 1H), 7.42 (s, 1H), 7.40 (t, J=2.8 Hz, 2H), 7.37 (d, J=8.0 Hz,2H), 7.18-7.13 (m, 4H), 6.96 (dd, J=8.0, 1.6 Hz, 1H), 6.48 (bs, 1H),5.17 (s, 2H), 3.48 (s, 3H). MS m/z (M−H) 483.1.

3-[4-(4-Cyano-phenoxymethyl)-phenylethenyl]-2-(1H-indol-6-yl)-benzoicacid: To a solution of3-[4-(4-cyano-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid methyl ester (200 mg, 0.42 mmol) in tetrahydrofuran:methanol (1:1mL) was added 2N sodium hydroxide (aq) (84 mg, 2.1 mmol) and theresulting solution was stirred for about 24 hours at ambienttemperature. The reaction mixture was then concentrated and the pHadjusted to 4 using 1 N hydrochloric acid solution. The aqueous layerwas then extracted using ethyl acetate (2×25 mL) and washed with water(20 mL) and brine (10 mL). The organic layers were combined, dried(sodium sulfate), filtered and concentrated under reduced pressure. Theresulting crude product was then purified using reversed phase HPLC togive an off-white solid in 70% yield. ¹H NMR (400 MHz, DMSO-d₆) δ 12.80(bs, 1H), 11.19 (s, 1H), 7.77-7.74 (m, 3H), 7.68 (dd. J=7.6, 1.2 Hz,1H), 7.58 (d, J=8.0 Hz, 1H), 7.46 (t, J=8.0 Hz, 1H), 7.42 (s, 1H), 7.39(t, J=2.8 Hz, 1H), 7.37 (d, J=7.6 Hz, 2H), 7.17-7.13 (m, 4H), 7.03 (dd,J=8.4, 1.6 Hz, 1H), 6.47 (t, J=2 Hz, 1H), 5.17 (s, 2H). MS m/z (M−H)469.0.

Example 81 3-[4-(3-cyano-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoic acid

3-[4-(3-cyano-phenoxymethyl)-phenyl ethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) δ 12.77 (s, 1H), 11.20 (s, 1H), 7.75 (dd, J=7.7, 1.4 Hz, 1H),7.66 (dd, J=7.8, 1.4 Hz, 1H), 7.58 (d, J=8.1 Hz, 1H), 7.53-7.29 (m, 9H),7.19-7.12 (m, 2H), 7.03 (dd, J=8.1, 1.6 Hz, 1H), 6.47 (s, 1H), 5.14 (s,2H). MS m/z (M+H) 469.1.

Example 823-[4-carbamoyl-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(3-carbamoyl-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) δ 11.19 (t, J=2.2 Hz, 1H), 7.95 (s, 1H), 7.72 (dd, J=7.7, 1.4Hz, 1H), 7.63 (dd. J=7.7, 1.4 Hz, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.48 (t,J=2.0 Hz, 1H), 7.49-7.39 (m, 3H), 7.43-7.30 (m, 5H), 7.19-7.08 (m, 3H),7.04 (dd, J=8.2, 1.6 Hz, 1H), 6.47 (s, 1H), 5.11 (s, 2H). MS m/z (M+H)487.1.

Example 832-(1H-indol-6-yl)-3-[4-(4-trifluoromethyl-phenoxymethyl)-phenylethynyl]-benzoic acid

2-(1H-indol-6-yl)-3-[4-(4-trifluoromethyl-phenoxymethyl)-phenylethynyl]-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) δ 12.75 (s, 1H), 11.19 (s, 1H), 7.74 (d, J=7.8 Hz, 1H), 7.65(dd, J=8.5, 6.7 Hz, 3H), 7.57 (d, J=8.1 Hz, 1H), 7.50-7.33 (m, 5H), 7.16(d, J=8.1 Hz, 4H), 7.03 (dd, J=8.1, 1.6 Hz, 1H), 6.47 (t, J=2.3 Hz, 1H),5.17 (s, 2H). MS m/z (M−H) 510.1.

Example 842-(1H-indol-6-yl)-3-[4-(3-trifluoromethyl-phenoxymethyl)-phenylethynyl]-benzoic acid

2-(1H-indol-6-yl)-3-[4-(3-trifluoromethyl-phenoxymethyl)-phenylethynyl]-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) δ 12.75 (s, 1H), 11.20 (d, J=2.6 Hz, 1H), 7.75 (dd, J=7.7, 1.4Hz, 1H), 7.67 (dd, J=7.7, 1.4 Hz, 1H), 7.58 (d, J=8.2 Hz, 1H), 7.56-7.44(m, 1H), 7.47-7.36 (m, 3H), 7.37 (s, 2H), 7.29 (d, J=8.1 Hz, 3H), 7.16(d, J=8.2 Hz, 2H), 7.03 (dd, J=8.2, 1.6 Hz, 1H), 6.47 (s, 1H), 5.16 (s,2H). MS m/z (M−H) 510.9.

Example 85 2-(1H-indol-1-yl)-3-[4-(4-methoxy-phenoxymethyl)-phenylethynyl]-benzoic acid

2-(1H-indol-6-yl)-3-[4-(4-methoxy-phenoxymethyl)-phenylethynyl]-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) δ 12.73 (s, 1H), 11.20 (t, J=2.2 Hz, 1H), 7.75 (dd, J=7.7, 1.4Hz, 1H), 7.67 (dd, J=7.8, 1.4 Hz, 1H), 7.58 (d, J=8.2 Hz, 1H), 7.51-7.36(m, 3H), 7.36-7.29 (m, 2H), 7.17-7.10 (m, 2H), 7.02 (dd, J=8.2, 1.6 Hz,1H), 6.94-6.85 (m, 2H), 6.88-6.79 (m, 2H), 6.50-6.44 (m, 1H), 5.00 (s,2H), 3.68 (s, 3H). MS m/z (M−H) 472.1.

Example 863-[4-(4-carbamoyl-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(4-carbamoyl-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) δ 12.81 (s, 1H), 11.17 (s, 1H), 7.86-7.77 (m, 3H), 7.69 (d,J=7.5 Hz, 1H), 7.58 (dd, J=18.2, 7.7 Hz, 1H), 7.44 (s, 1H), 7.44-7.32(m, 5H), 7.16 (dd, J=10.4, 8.5 Hz, 3H), 7.10-6.97 (m, 3H), 6.46 (s, 1H),5.13 (s, 2H). MS m/z (M+H) 487.0.

Example 87 2-(1H-indol-6-yl)-3-[4-(3-methoxy-phenoxymethyl)-phenylethynyl]-benzoic acid

2-(1H-indol-6-yl)-3-[4-(3-methoxy-phenoxymethyl)-phenylethynyl]-benzoicacid was by the same procedure as Example 80. ¹H NMR (400 MHz, DMSO-d₆)δ 12.76 (s, 1H), 11.21 (t, J=2.3 Hz, 1H), 7.75 (dd, J=7.7, 1.4 Hz, 1H),7.67 (dd, J=7.8, 1.4 Hz, 1H), 7.58 (d, J=8.1 Hz, 1H), 7.51-7.36 (m, 3H),7.35 (d, J=8.1 Hz, 2H), 7.21-7.11 (m, 3H), 7.02 (dd, J=8.1, 1.6 Hz, 1H),6.59-6.47 (m, 3H), 6.47 (s, 1H), 5.05 (s, 2H), 3.71 (s, 3H). MS m/z(M+H) 474.1.

Example 88 2-(1H-indol-6-yl)-3-(4-phenoxymethyl-phenylethynyl)-benzoicacid

2-(1H-indol-6-yl)-3-(4-phenoxymethyl-phenylethynyl)-benzoic acid wasprepared by the same procedure as Example 80. ¹H NMR (400 MHz, DMSO-d₆)δ 12.74 (s, 1H), 11.20 (s, 1H), 7.75 (d, J=7.7 Hz, 1H), 7.67 (d, J=7.5Hz, 1H), 7.58 (d, J=8.1 Hz, 1H), 7.46 (t, J=7.7 Hz, 1H), 7.45-7.32 (m,4H), 7.27 (t, J=8.0 Hz, 2H), 7.15 (d, J=8.0 Hz, 2H), 7.02 (dd, J=8.1,1.6 Hz, 1H), 6.94 (dd, J=19.2, 7.8 Hz, 3H), 6.47 (s, 1H), 5.06 (s, 2H).MS m/z (M+H) 444.0.

Example 893-[4-(2-fluoro-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(2-fluoro-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) δ 12.74 (s, 1H), 11.21 (d, J=2.3 Hz, 1H), 7.76 (dd, J=7.7, 1.4Hz, 1H), 7.68 (dd, J=7.8, 1.4 Hz, 1H), 7.58 (d, J=8.2 Hz, 1H), 7.46 (dd,J=15.9, 8.1 Hz, 2H), 7.43-7.32 (m, 3H), 7.26-7.12 (m, 4H), 7.14-7.05 (m,1H), 7.02 (dd, J=8.1, 1.6 Hz, 1H), 6.93 (tdd, J=7.7, 4.6, 1.6 Hz, 1H),6.47 (s, 1H), 5.14 (s, 2H). MS m/z (M+H) 462.0.

Example 902-(1H-indol-6-yl)-3-[4-(pyridin-3-yloxymethyl)phenylethynyl]-benzoicacid

2-(1H-indol-6-yl)-3-[4-(pyridin-3-yloxymethyl)-phenylethynyl]-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) 12.72 (s, 1H), 11.19 (s, 1H), 8.33 (d, J=2.9 Hz, 1H), 8.16 (dd.J=4.6, 1.3 Hz, 1H), 7.76 (dd, J=7.8, 1.4 Hz, 1H), 7.68 (dd, J=7.8, 1.4Hz, 1H), 7.58 (d, J=8.1 Hz, 1H), 7.51-7.24 (m, 7H), 7.19-7.12 (m, 2H),7.02 (dd, J=8.1, 1.6 Hz, 1H), 6.47 (s, 1H), 5.15 (s, 2H). MS m/z (M+H)445.0.

Example 913-[4-(3-chloro-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

-[4-(3-chloro-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) δ 12.75 (s, 1H), 11.20 (s, 1H), 7.75 (dd, J=7.6, 1.4 Hz, 1H),7.70-7.63 (m, 1H), 7.58 (d, J=8.2 Hz, 1H), 7.51-7.25 (m, 6H), 7.15 (d,J=7.9 Hz, 2H), 7.11-6.91 (m, 4H), 6.47 (t, J=2.5 Hz, 1H), 5.10 (s, 2H).MS m/z (M+H) 478.0.

Example 923-[4-(3,4-dichloro-phenoxymethyl)-phenylethynyl]-2-(H-indol-6-yl)-benzoicacid

3-[4-(3,4-dichloro-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) δ 12.76 (s, 1H), 11.20 (s, 1H), 7.75 (d, J=7.6 Hz, 1H), 7.67(d, J=7.6 Hz, 1H), 7.58 (d, J=8.2 Hz, 2H), 7.55-7.27 (m, 6H), 7.15 (d,J=7.8 Hz, 2H), 7.06-6.96 (m, 2H), 6.47 (t, J=2.3 Hz, 1H), 5.11 (s, 2H).MS m/z (M, 512.0 and (M+2) 514.0.

Example 932-(1H-indol-6-yl)-3-[4-(2-trifluoromethyl-phenoxymethyl)-phenylethynyl]-benzoicacid

2-(1H-indol-6-yl)-3-[4-(2-trifluoromethyl-phenoxymethyl)-phenylethynyl]-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) δ 12.74 (s, 1H), 11.20 (d, J=2.3 Hz, 1H), 7.75 (dd, J=7.7, 1.4Hz, 1H), 7.71-7.55 (m, 4H), 7.51-7.36 (m, 3H), 7.34 (d, J=8.0 Hz, 2H),7.28 (d, J=8.4 Hz, 1H), 7.16 (d, J=8.1 Hz, 2H), 7.10 (t, J=7.6 Hz, 1H),7.02 (dd, J=8.2, 1.6 Hz, 1H), 6.47 (s, 1H), 5.24 (s, 2H). MS m/z (M+H)512.0.

Example 943-[4-(2-cyano-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(2-cyano-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) δ 12.74 (s, 1H), 11.20 (t, J=2.2 Hz, 1H), 7.75 (ddd, J=7.6,3.9, 1.5 Hz, 2H), 7.65 (ddd, J=16.4, 7.7, 1.6 Hz, 2H), 7.58 (d, J=8.2Hz, 1H), 7.55-7.35 (m, 5H), 7.27 (d, J=8.4 Hz, 1H), 7.21-7.14 (m, 2H),7.10 (td, J=7.6, 0.9 Hz, 1H), 7.02 (dd, J=8.1, 1.6 Hz, 1H), 6.47 (s,1H), 5.26 (s, 2H). MS m/z (M+H) 469.2.

Example 952-(1H-indol-6-yl)-3-[4-(4-methanesulfonyl-phenoxymethyl)-phenylethynyl]-benzoicacid

2-(1H-indol-6-yl)-3-[4-(4-methanesulfonyl-phenoxymethyl)-phenylethynyl]-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) 11.18 (d, J=2.6 Hz, 1H), 7.87-7.78 (m, 2H), 7.69 (d, J=7.7 Hz,1H), 7.58 (dd, J=16.6, 7.9 Hz, 2H), 7.47-7.33 (m, 5H), 7.24-7.13 (m,4H), 7.04 (dd, J=8.2, 1.6 Hz, 1H), 6.46 (s, 1H), 5.19 (s, 2H), 3.14 (s,3H). MS m/z (M+H) 522.0.

Example 962-(1H-indol-6-yl)-3-[4-(pyrimidin-5-yloxymethyl)-phenylethynyl]-benzoicacid

2-(1H-indol-6-yl)-3-[4-(pyrimidin-5-yloxymethyl)-phenylethynyl]-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) δ 12.74 (s, 1H), 11.20 (s, 1H), 8.81 (s, 1H), 8.59 (s, 2H),7.76 (dd, J=7.7, 1.4 Hz, 1H), 7.68 (dd. J=7.8, 1.4 Hz, 1H), 7.58 (d,J=8.2 Hz, 1H), 7.47 (t, J=7.7 Hz, 1H), 7.45-7.35 (m, 4H), 7.16 (d, J=8.2Hz, 2H), 7.02 (dd, J=8.1, 1.6 Hz, 1H), 6.51-6.44 (m, 1H), 5.24 (s, 2H).MS m/z (M+H) 446.1.

Example 972-(1H-indol-6-yl)-3-[4-(2-methanesulfonyl-phenoxymethyl)-phenylethynyl]-benzoicacid

2-(1H-indol-6-yl)-3-[4-(2-methanesulfonyl-phenoxymethyl)-phenylethynyl]-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) δ 12.74 (s, 1H), 11.20 (t, J=2.3 Hz, 1H), 7.79 (ddd, J=24.5,7.7, 1.6 Hz, 2H), 7.67 (ddd, J=8.2, 6.4, 1.6 Hz, 2H), 7.58 (d, J=8.1 Hz,1H), 7.51-7.36 (m, 5H), 7.31 (d, J=8.4 Hz, 1H), 7.18 (d, J=7.8 Hz, 3H),7.03 (dd, J=8.1, 1.6 Hz, 1H), 6.47 (s, 1H), 5.31 (s, 2H), 3.20 (s, 3H).MS m/z (M+H) 522.0.

Example 982-(1H-indol-6-yl)-3-[4-(3-methanesulfonyl-phenoxymethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(3-methanesulfonyl-phenoxymethyl)-phenylethynyl]-benzoicacid was prepared by the same procedure as Example 80. ¹H NMR (400 MHz,DMSO-d₆) δ 12.75 (s, 1H), 11.21 (t, J=2.2 Hz, 1H), 7.76 (dd, J=7.7, 1.4Hz, 1H), 7.68 (dd, J=7.8, 1.4 Hz, 1H), 7.62-7.52 (m, 2H), 7.53-7.29 (m,8H), 7.20-7.13 (m, 2H), 7.03 (dd, J=8.1, 1.6 Hz, 1H), 6.47 (s, 1H), 5.18(s, 2H), 3.21 (s, 3H). MS mm/z (M+H) 522.1.

Example 992-(1H-Indol-6-yl)-3-{2-[3-(3-methanesulfonamidophenyl)phenyl]ethynyl}benzoicacid

2-(1H-Indol-6-yl)-3-{2-[3-(3-methanesulfonamidophenyl)phenyl]ethynyl}benzoic acid was prepared by the same procedure as Example 1. ¹H NMR(300 MHz, DMSO-d6) δ 11.16 (s, 1 H), 9.81 (s, 1 H), 7.64-7.80 (m, 2 H),7.32-7.62 (m, 7 H), 7.10-7.29 (m, 4 H), 7.02 (dd, J=8.21, 1.47 Hz, 2 H),6.46 (br s, 1 H), 3.01 (s, 3 H), 2.50-2.78 (m, 1 H). MS m/z (M+H) 507.4.

Example 1002-(1H-Indol-6-yl)-3-{2-[6-(oxan-4-yloxy)pyridin-3-yl]ethynyl}benzoicacid

2-(1H-Indol-6-yl)-3-{2-[6-(oxan-4-yloxy)pyridin-3-yl]ethynyl}benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d6) δ 11.16 (br s, 1 H), 7.90 (d, J=2.35 Hz, 1 H), 7.59-7.80 (m, 2H), 7.55 (d, J=8.21 Hz, 1 H), 7.22-7.50 (m, 4 H), 6.99 (dd, J=8.06, 1.32Hz, 1 H), 6.71 (d, J=8.50 Hz, 1 H), 6.44 (br s, 1 H), 5.10 (td, J=8.87,4.25 Hz, 1 H), 3.70-3.83 (m 2 H), 3.64 (br s, 1 H) 3.19-3.47 (m, 2 H),1.91 (br d, J=10.55 Hz, 2 H), 1.37-1.75 (m, 2 H). MS m/z (M+H) 439.5.

Example 1012-(1H-Indol-6-yl)-3-{2-[2-(propylcarbamoyl)-1H-indol-6-yl]ethynyl}benzoicacid

2-(1H-Indol-6-yl)-3-{2-[2-(propylcarbamoyl)-1H-indol-6-yl]ethynyl}benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d6) δ 11.60-11.65 (m, 1 H), 11.13-11.16 (m, 1 H), 8.44-8.50 (m, 1H), 7.80-7.83 (m, 1 H), 7.67-7.76 (m, 1 H), 7.51-7.62 (m, 1 H),7.26-7.48 (m, 3 H), 6.91-7.08 (m, 2 H), 6.80-6.90 (m, 1 H), 6.67-6.78(m, 1 H), 6.45 (br d, J=2.05 Hz, 1 H) 2.89-3.23 (m, 2 H), 1.44-1.59 (m,2 H), 1.11-1.27 (bs, 1 H), 0.77-0.94 (m, 3 H). MS m/z (M+H) 462.6.

Example 1022-(1H-Indol-6-yl)-3-{2-[3-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)phenyl]ethynyl}benzoicacid

2-(1H-Indol-6-yl)-3-{2-[3-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)phenyl]ethynyl}benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (30×) MHz,DMSO-d6) δ 11.15 (br s, 1 H), 7.58-7.92 (m, 4 H), 7.19-7.55 (m, 7 H),6.86-7.14 (m, 4 H), 6.39 (br s, 1 H), 3.41-3.72 (m, 4 H), 2.65-2.98 (m,2 H), 2.51-2.64 (m, 2 H). MS m/z (M+H) 483.2.

Example 1033-{2-[3-Cyano-4-(oxan-4-yloxy)phenyl]ethynyl}-2-(1H-indol-6-yl)benzoicacid

3-{2-[3-Cyano-4-(oxan-4-yloxy)phenyl]ethynyl}-2-(1H-indol-6-yl)benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d6) δ 12.74 (br s, 1 H), 11.17 (br s, 1 H), 7.50-7.80 (m, 3 H),7.20-7.50 (m, 5 H), 6.86-7.16 (m, 2 H), 6.45 (br s, 1 H), 4.56-4.84 (m,1 H), 3.64-3.91 (m, 2 H), 3.36-3.60 (m, 2 H), 1.86-2.08 (m, 2 H), 1.57(ddt, J=12.94, 8.61, 4.18, 4.18 Hz, 2 H). MS m/z (M+H) 463.5.

Example 104 3-[2-(3-{[4-(Ethoxycarbonyl)piperazin-1-yl]methyl}phenyl)ethynyl]-2-(1H-indol-6-yl)benzoic acid

3-[2-(3-{[4-(Ethoxycarbonyl)piperazin-1-yl]methyl}phenyl)ethynyl]-2-(1H-indol-6-yl)benzoic acid was prepared by the same procedure as Example 1. ¹H NMR(300 MHz, DMSO-d6) δ 11.16 (br s, 1 H), 7.60-7.75 (m, 2 H), 7.55 (d,J=7.92 Hz, 1 H), 7.28-7.48 (m, 2 H), 7.21 (br d, J=4.40 Hz, 3 H),6.77-7.11 (m, 3 H), 6.43 (br s, 1 H), 4.00 (q, J=7.04 Hz, 2 H), 3.39 (s,2 H) 2.07-2.44 (m, 8 H), 1.15 (t, J=7.04 Hz, 3 H). MS m/z (M+H) 508.3.

Example 1053-(2-{4-[3-(Hydroxymethyl)oxetan-3-yl]phenyl}ethynyl)-2-(1H-indol-6-yl)benzoicacid

3-(2-{4-[3-(Hydroxymethyl)oxetan-3-yl]phenyl}ethynyl)-2-(1H-indol-6-yl)benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d6) δ 11.15 (br s., 1 H), 7.59-7.93 (m, 2 H), 7.29-7.49 (m, 2 H),7.20 (br d, J=7.92 Hz, 1 H), 6.92-7.14 (m, 4 H), 6.84 (br s, 2 H), 6.44(br s, 1 H), 5.06 (br s, 1 H), 4.37-4.73 (m, 4 H), 3.36-3.74 (m, 2 H).MS m/z (M+H) 424.0.

Example 1063-{2-[3-(5-Amino-1H-pyrazol-3-yl)phenyl]ethynyl}-2-(1H-indol-6-yl)benzoicacid

3-{2-[3-(5-Amino-1H-pyrazol-3-yl)phenyl]ethynyl}-2-(1H-indol-6-yl)benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d6) δ 11.18 (br s, 1 H), 7.51-7.88 (m, 4 H), 7.27-7.51 (m, 3 H),7.14 (m, 2 H), 7.01 (br d, J=9.09 Hz, 2 H), 6.46 (br s, 1 H), 6.12 (s, 1H), 3.60 (br s, 3 H). MS m/z (M+) 418.9.

Example 1072-(1H-Indol-6-yl)-3-{2-[3-(1,3-oxazol-5-yl)phenyl]ethynyl}benzoic acid

2-(1H-Indol-6-yl)-3-{2-[3-(1,3-oxazol-5-yl)phenyl]ethynyl} benzoic acidwas prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d6) δ 12.62-12.97 (bs, 1 H), 11.18 (br s, 1 H), 8.31-8.54 (m, 1 H),8.23 (br s, 1 H), 7.55-7.77 (m, 4 H), 7.34-7.52 (m, 4 H), 7.10 (br d,J=7.33 Hz, 1 H), 6.70-7.05 (m, 2 H), 6.47 (s, 1 H). MS m/z (M+H) 406.0.

Example 1082-(1H-Indol-6-yl)-3-{2-[4-(oxane-4-carbonyl)phenyl]ethynyl}benzoic acid

2-(1H-Indol-6-yl)-3-{2-[4-(oxane-4-carbonyl)phenyl]ethynyl}benzoic acidwas prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d6) δ 11.17 (br s, 1 H), 7.63-7.96 (m, 4 H), 7.30-7.60 (m, 4 H),7.22 (d, J=8.21 Hz, 2 H), 7.02 (d, J=8.21 Hz, 1 H), 6.46 (br s, 1 H),3.81-3.85 (bs, 1 H), 3.40-3.60 (m, 4 H), 1.39-1.74 (m, 4 H). MS m/z(M+H) 450.1.

Example 109 2-(7-Fluoro-1H-indol-6-yl)-3-(phenylethynyl) benzoic acid

7-Fluoro-6-(4,4,5,5-tetramethyl-[1.3.2]dioxaborolan-2-yl)-1H-indole: Astirring suspension of 6-bromo-7-fluoro-1H-indole (PCT Int. Appl.,2014151005) (1.25 g, 5.8 mmol), potassium acetate (1.14 g, 11.68 mmol),bis(pinacolato)diboron (1.9 g, 7.54 mmol) in dry 1,4-dioxane (18 mL) wasdeaerated using an argon gas balloon for 15 minutes. To the resultingsuspension, [1,1′-bis (diphenylphosphino) ferrocene]palladium (II)dichloride complexed with dichloromethane (473 mg, 0.58 mmol) was addedand reaction was heated to 100° C. for 12 hours. The resultant reactionmixture was then allowed to cool to ambient temperature, diluted withethyl acetate (150 mL) and filtered through celite. The organic layerthus obtained washed with water (2×50 mL), brine (50 mL), dried(anhydrous sodium sulfate), filtered and concentrated under reducedpressure to obtain crude product as a brown liquid. The resultant crudeproduct was taken to next step as such without characterization.

2-(7-Fluoro-1H-indol-6-yl)-3-(phenylethynyl)benzoic acid methyl ester: Astirring suspension of7-fluoro-6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indole (1.2g, 4.5 mmol), 2-bromo-3-(phenylethynyl)benzoic acid methyl ester (1.4 g,4.5 mmol) and potassium carbonate (1.2 g, 9.0 mmol) in 1,4-dioxane:water(4:1) (20 mL) was deaerated using an argon gas balloon for 15 minutes.To the resulting suspension, [1,1′-bis (diphenylphosphino)ferrocene]palladium(II) dichloride complexed with dichloromethane (440mg, 0.45 mmol) was added and reaction mixture was refluxed at 100° C.for 4 hours. The resultant reaction mixture was then allowed to cool toambient temperature, diluted with ethyl acetate (250 mL) and filteredthrough celite bed. The organic layer thus obtained washed with water(2×50 mL), brine (50 mL), dried (anhydrous sodium sulfate), filtered andconcentrated under reduced pressure to obtain crude product as a brownliquid. The crude product thus obtained was purified by preparative HPLCto give a pale yellow solid with 35% yield. ¹H NMR (400 MHz, DMSO-d₆) δ11.65 (s, 1H), 7.86 (d, J=7.8 Hz, 2H), 7.58 (t, J=7.8 Hz, 1H), 7.48-7.37(m, 2H), 7.35-7.20 (m, 3H), 7.05-6.97 (m, 2H), 6.86 (dd, J=8.1, 6.5 Hz,1H), 6.57 (td, J=3.3, 1.9 Hz, 1H), 3.55 (s, 3H). MS m/z (M−H) 368.2.

2-(7-Fluoro-1H-indol-6-yl)-3-(phenylethynyl) benzoic acid: To a solutionof 2-(7-fluoro-1H-indol-6-yl)-3-(phenylethynyl) benzoic acid methylester (200 mg, 0.42 mmol) in terahydrofuran:methanol (1:1 mL) was added2 N NaOH (aq) (84 mg, 2.1 mmol) and the resulting solution was stirredfor about 24 hours at ambient temperature. The reaction mixture was thenconcentrated and neutralized to pH 4 using 1 N hydrochloric acidsolution. The aqueous layer was then extracted with ethyl acetate (2×25mL), washed with water (20 mL) and brine (10 mL). The organic layerswere combined, dried (sodium sulfate), filtered and concentrated underreduced pressure. The resulting crude product was then purified usingreverse phase HPLC to give the2-(7-fluoro-1H-indol-6-yl)-3-phenylethynyl-benzoic acid as an off-whitesolid in 70%6 yield. ¹H NMR (400 MHz, DMSO-d₆) δ 11.61 (s, 1H), 7.79(dd, J=12.9, 7.8 Hz, 2H), 7.52 (t, J=7.8 Hz, 1H), 7.46-7.34 (m, 2H),7.25 (dt, J=14.7, 7.1 Hz, 3H), 7.02-6.95 (m, 2H), 6.89 (dd, J=8.0, 6.4Hz, 1H), 6.55 (q, J=2.6 Hz, 1H). MS m/z (M+H) 356.4.

Example 110 2-Benzothiazol-6-yl-3-phenylethynyl-benzoic acid

2-Benzothiazol-6-yl-3-phenylethynyl-benzoic acid was prepared by thesame procedure as Example 109. ¹H NMR (400 MHz, DMSO-d₆) δ 12.89 (s,1H), 9.44 (s, 1H), 8.22-8.11 (m, 2H), 7.83 (dq, J=7.9, 1.4 Hz, 2H),7.61-7.47 (m, 2H), 7.36-7.22 (m, 3H), 7.05 (dt, J=6.7, 1.6 Hz, 2H). MSm/z (M+H) 356.5.

Example 111 2-Benzothiazol-5-yl-3-phenylethynyl-benzoic acid

2-Benzothiazol-5-yl-3-phenylethynyl-benzoic acid was prepared by thesame procedure as Example 109. ¹H NMR (400 MHz, DMSO-d₆) δ 13.00 (s,1H), 9.44 (s, 1H), 8.22 (d, J=8.3 Hz, 1H), 8.04 (s, 1H), 7.78 (t, J=6.8Hz, 2H), 7.57-7.45 (m, 2H), 7.27 (dt, J=14.5, 7.0 Hz, 3H), 7.04 (d,J=7.3 Hz, 2H). MS m/z (M+H) 356.5.

Example 112 2-(2-Methyl-benzothiazol-5-yl)-3-phenylethynyl-benzoic acid

2-(2-Methyl-benzothiazol-5-yl)-3-phenylethynyl-benzoic acid was preparedby the same procedure as Example 109. ¹H NMR (400 MHz, DMSO-d₆) δ 12.87(s, 1H), 8.09 (d, J=8.2 Hz, 1H), 7.87-7.77 (m, 3H), 7.55 (t, J=7.8 Hz,1H), 7.39 (dd, J=8.2, 1.7 Hz, 1H), 7.29 (qd, J=8.7, 7.8, 3.6 Hz, 3H),7.07 (dt, J=6.5, 1.7 Hz, 2H), 2.82 (s, 3H). MS m/z (M+H) 370.3.

Example 113 2-(5-Fluoro-1H-indol-yl)-3-phenylethynyl-benzoic acid

2-(5-Fluoro-1H-indol-6-yl)-3-phenylethynyl-benzoic acid was prepared bythe same procedure as Example 109. ¹H NMR (400 MHz, DMSO-d₆) δ 12.80 (s,1H), 11.21 (s, 1H), 7.81 (ddd, J=11.9, 7.8, 1.4 Hz, 2H), 7.53 (t, J=7.8Hz, 1H), 7.44 (t, J=2.8 Hz, 1H), 7.39-7.20 (m, 5H), 7.07-6.98 (m, 2H),6.47 (s, 1H). MS m/z (M+H) 356.3.

Example 114 2-(6-Fluoro-1H-indol-5-yl)-3-phenylethynyl-benzoic acid

2-(6-Fluoro-1H-indol-5-yl)-3-phenylethynyl-benzoic acid was prepared bythe same procedure as Example 109. ¹H NMR (400 MHz, DMSO-d₆) δ 11.17 (s,1H), 7.81-7.72 (m, 2H), 7.53-7.42 (m, 2H), 7.35 (t, J=2.7 Hz, 1H),7.32-7.17 (m, 4H), 7.04 (dt, J=6.7, 1.6 Hz, 2H), 6.46 (d, J=2.5 Hz, 1H).MS m/z (M+H) 356.5.

Example 115 2-[1,8]Naphthyridin-3-yl-3-(phenylethynyl) benzoic acid

3-Phenylethynyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzoicacid methyl ester: A stirring suspension of2-iodo-3-phenylethynyl-benzoic acid methyl ester (US 20080153802) (4 g,11.05 mmol), potassium acetate (2.16 g, 22.1 mmol),bis(pinacolato)diboron (3.06 g, 12.16 mmol) in dry dimethylformamide (40mL) was deaerated using an argon gas balloon for 15 minutes. To theresulting suspension, [1,1′-bis (diphenylphosphino) ferrocene] palladium(11) dichloride complexed with dichloromethane (897 mg, 1.1 mmol) wasadded and reaction mixture was heated to 90° C. for 12 hours. Theresultant reaction mixture was then allowed to cool to ambienttemperature, diluted with ethyl acetate (300 mL) and filtered throughpre packed celite pad. The organic layer thus obtained was washed withwater (2×100 mL), brine (100 mL), dried (anhydrous sodium sulfate),filtered and concentrated under reduced pressure to obtain crude productas a brown liquid which was purified through silica gel cartridgeeluting with hexane/ethyl acetate to give3-phenylethynyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoicacid methyl ester as a pale yellow solid in 50% yield. ¹H NMR (400 MHz,DMSO-d₆) δ 7.96 (dd, J=7.8, 1.1 Hz, 1H), 7.80 (dd, J=7.7, 1.1 Hz, 1H),7.64-7.47 (m, 3H), 7.45 (dd, J=5.0, 2.0 Hz, 3H), 3.88 (s, 3H), 1.32 (s,12H). MS m/z (M+Na) 385.7.

2-1,8-Naphthyridin-3-yl-3-(phenylethynyl) benzoic acid methyl ester: Astirring suspension of3-phenylethynyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzoicacid methyl ester (500 mg, 1.38 mmol), 3-bromo-1,8-naphthyridine (289mg, 1.38 mmol) and potassium carbonate (380 mg, 2.76 mmol) in1,4-dioxane:water (4:1) (10 mL) was deaerated using an argon gas balloonfor 15 minutes. To the resulting suspension, [1, l-bis(diphenylphosphino) ferrocene]palladium(II) dichloride complexed withdichloromethane (112 mg, 0.138 mmol) was added and reaction mixture wasrefluxed at 100° C. for 4 h. The resultant reaction mixture was thenallowed to cool to ambient temperature, diluted with ethyl acetate (150mL) and filtered through celite bed. The organic layer thus obtainedwashed with water (2×30 mL), brine (30 mL), dried (anhydrous sodiumsulfate), filtered and concentrated under reduced pressure to obtaincrude product as a brown liquid. The crude product thus obtained waspurified using silica gel cartridge eluting with hexane/ethyl acetate togive a pale yellow solid with 40% yield.

2-1,8-Naphthyridin-3-yl-3-(phenylethynyl) benzoic acid: To a solution of2-1,8-naphthyridin-3-yl-3-phenylethynyl-benzoic acid methyl ester (200mg, 0.55 mmol) in terahydrofuran:methanol (1:1 mL) was added 2 N NaOH(aq) (110 mg, 2.75 mmol) and the resulting solution was stirred forabout 24 hours at ambient temperature. The reaction mixture was thenconcentrated and neutralized to pH 4 using 1 N hydrochloric acidsolution. The aqueous layer was then extracted using ethyl acetate (2×25mL) and washed with water (20 mL) and brine (10 mL). The organic layerswere combined, dried (sodium sulfate), filtered and concentrated underreduced pressure. The resulting crude product was then purified usingreverse phase HPLC to give the product as an off-white solid in 15%yield. ¹H NMR (400 MHz, DMSO-d₆) δ 13.11 (s, 1H), 9.12 (dd. J=4.2, 2.0Hz, 1H), 9.03 (d, J=2.5 Hz, 1H), 8.59-8.47 (m, 2H), 8.01 (dd, J=7.8, 1.4Hz, 1H), 7.92 (dd, J=7.8, 1.3 Hz, 1H), 7.73-7.61 (m, 2H), 7.34-7.19 (m,3H), 7.04-6.96 (m, 2H). MS m/z (M+H) 351.3.

Example 1162-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-phenylethynyl-benzoic acid

2-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-phenylethynyl-benzoic acidwas prepared by the same procedure as Example 115. ¹H NMR (400 MHz,DMSO-d₆) δ 12.60 (s., 1H), 8.06 (d, J=8.0 Hz, 1H), 7.78 (ddd, J=15.0,7.7, 1.4 Hz, 2H), 7.59-7.50 (m, 2H), 7.43 (d, J=8.1 Hz, 1H), 7.39-7.27(m, 3H), 7.21-7.13 (m, 2H), 6.52 (d, J=3.4 Hz, 1H), 3.77 (s, 3H). MS m/z(M+H) 353.5.

Example 117 2-[1,8]Naphthyridin-2-yl-3-phenylethynyl-benzoic acid

2-[1,8]Naphthyridin-2-yl-3-phenylethynyl-benzoic acid was prepared bythe same procedure as Example 115. ¹H NMR (400 MHz, DMSO-d₆) δ 12.85 (s,1H), 9.08 (dd, J=4.2, 2.0 Hz, 1H), 8.58-8.48 (m, 2H), 7.93 (d, J=7.6 Hz,1H), 7.82 (t, J=7.8 Hz, 2H), 7.71-7.57 (m, 2H), 7.33-7.24 (m, 1H),7.27-7.18 (m, 2H), 6.97 (d, J=7.4 Hz, 2H). MS m/z (M+H) 351.4.

Example 118 3-Phenylethynyl-2-(1H-pyrrolo[2,3-b]pyridin-6-yl)-benzoicacid

3-Phenylethynyl-2-(1H-pyrrolo[2,3-b]pyridin-6-yl)-benzoic acid wasprepared by the same procedure as Example 115. ¹H NMR (400 MHz, DMSO-d₆)δ 12.64 (s, 1H), 11.68 (d, J=2.4 Hz, 1H), 8.04 (d, J=8.1 Hz, 1H),7.84-7.74 (m, 2H), 7.58-7.45 (m, 2H), 7.37-7.25 (m, 4H), 7.18-7.10 (m,2H), 6.50 (dd, J=3.4, 1.8 Hz, 1H). MS m/z (M+H) 339.1.

Example 119 2-(4-methoxy-1H-indol-6-yl)-3-(2-phenylethynyl)-benzoic acid

2-(4-methoxy-1H-indol-6-yl)-3-(2-phenylethynyl)-benzoic acid wasprepared by the same procedure as Example 109. ¹H NMR (300 MHz, DMSO-d₆)δ ppm 11.18 (br, s., 1 H), 7.73 (d, J=6.74 Hz, 1 H), 7.61 (br, s., 1 H),7.45 (d, J=7.62 Hz, 1 H), 7.29 (s, 2 H), 7.25 (s, 2 H), 7.14 (br, s., 2H), 7.02 (br, s., 1 H), 6.52 (br, s., 1 H), 6.44 (br, s., 1 H), 3.80(br, s., 3 H). MS m/z (M+H) 368.4.

Example 1203-(2-(4-(2-hydroxypropan-2-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid

3-(2-(4-(2-hydroxypropan-2-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 11.17 (br, s., 1 H), 7.60-7.74 (m, 2 H), 7.55 (d, J=7.33Hz, 1 H), 7.30-7.46 (m, 5 H), 6.95-7.09 (m, 3 H), 6.45 (br, s., 1 H),3.48 (br, s., 2 H), 1.33 (br, s., 5 H) MS m/z (M+H) 396.4.

Example 1213-(2-(4-(2-aminothiazol-4-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid

3-(2-(4-(2-aminothiazol-4-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 11.17 (s, J=3.72 Hz, 1 H), 7.62-7.74 (m, 4 H), 7.55 (d,J=8.21 Hz, 1 H), 7.36-7.47 (m, 3 H), 7.05-7.11 (m, 3 H), 6.99 (dd,J=8.21, 1.47 Hz, 1 H), 6.45 (t, J=3.20 Hz, 1 H). MS m/z (M+H) 436.02.

Example 122 2-(1H-Indol-6-yl)-3-(3-sulfamoyl-phenylethynyl)-benzoic acid

2-(1H-Indol-6-yl)-3-(3-sulfamoyl-phenylethynyl)-benzoic acid wasprepared by the same procedure as Example 1. ¹H NMR (300 MHz, DMSO-d₆) δppm 12.73 (br, s., 1 H), 11.16 (s, 1 H), 7.67-7.81 (m, 4 H), 7.58 (d,J=8.08 Hz, 1 H), 7.48 (t, J=7.74 Hz; 2 H), 7.36-7.41 (m, 4 H), 7.25 (dt,J=7.62, 1.17 Hz, 1 H), 7.05 (dd, J=8.21, 1.76 Hz, 1 H), 6.45 (t, J=2.05Hz, 1 H) MS m/z (M+H) 416.9.

Example 1233-(4-Amino-3-sulfamoyl-phenylethynyl)-2-(1H-indol-6-yl)-benzoic acid

3-(4-Amino-3-sulfamoyl-phenylethynyl)-2-(1H-indol-6-yl)-benzoic acid wasprepared by the same procedure as Example 1. ¹H NMR (300 MHz, DMSO-d₆) δppm 8.68 (br, s., 1 H), 8.11 (d, J=8.79 Hz, 1 H), 8.00 (dd, J=−7.92,1.47 Hz, 1 H), 7.78 (d, J=−8.79 Hz, 1 H), 7.62-7.70 (m, 3 H), 7.52-7.58(m, 1 H), 7.24-7.37 (m, 4 H), 6.96 (d, J=8.21 Hz, 1 H), 6.55 (dd,J=2.78, 1.91 Hz, 1 H). MS m/z (M−H) 431.9.

Example 1242-(4H-indol-6-yl)-3-(Spiro[2H-1-benzopyran-2,1′-4-piperidine-1-t-butylcarboxylate]-4(3H)-one)ethynyl)benzoic acid

2-(1H-indol-6-yl)-3-(Spiro[2H-1-benzopyran-2,1′-4-piperidine-1-t-Butylcarboxylate]-4(3H)-one)ethynyl)benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 11.00-11.22 (m, 1 H), 7.74 (dd, J=7.77, 1.32 Hz, 1 H),7.42-7.70 (m, 3 H), 7.34-7.38 (m, 2 H), 7.19-7.32 (m, 1 H), 7.01 (t,J=8.75 Hz, 2 H), 6.30-6.51 (m, 1 H), 3.38-3.71 (m, 4 H), 3.07 (br, s., 2H), 2.82 (s, 2 H), 1.81 (d, J=13.78 Hz, 2 H), 1.49-1.66 (m, 2 H), 1.37(s, 9 H) MS m/z (M+H) 577.2.

Example 1253-(2-(3-(2-aminothiazol-4-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid

3-(2-(3-(2-aminothiazol-4-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 11.08-11.28 (m, 1 H), 7.72-7.78 (m, 1 H), 7.63-7.72 (m, 2H), 7.55-7.62 (m, 1 H), 7.39-7.51 (m, 3 H), 7.33-7.38 (m, 1 H),7.19-7.30 (m, 1 H), 6.93-7.07 (m, 2 H), 6.78-6.85 (m, 1 H), 6.41-6.51(m, 1 H). MS m/z (M+H) 436.0.

Example 126 3-(2-(4-(5-(methoxycarbonyl)-2-aminothiazol-4-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoic acid

3-(2-(4-(5-(methoxycarbonyl)-2-aminothiazol-4-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 11.05-11.30 (m, 1 H), 7.70-7.75 (m, 1 H), 7.61-7.68 (m, 2H), 7.53-7.60 (m, 1 H), 7.42-7.49 (m, 3 H), 7.39-7.42 (m, 1 H),7.35-7.39 (m, 1 H), 7.05-7.11 (m, 1 H), 6.96-7.02 (m, 2 H), 6.42-6.49(m, 1 H), 2.80-2.92 (m, 3 H). MS m/z (M+H) 479.8.

Example 1273-(2-(4-(5-amino-1,3,4-thiadiazol-2-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid

3-(2-(4-(5-amino-1,3,4-thiadiazol-2-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 12.73 (m, 1 H), 11.17-11.23 (m, 1 H), 7.78 (d, J=7.44 Hz,1 H), 7.58-7.71 (m, 4 H), 7.39-7.54 (m, 5 H), 7.20 (s, 1 H), 7.18 (s, 1H), 7.04 (d, J=7.98 Hz, 1 H), 6.49 (m, 1 H). MS m/z (M+H) 437.1.

Example 1283-(2-(4-(3-amino-1H-pyrazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid

3-(2-(4-(3-amino-1H-pyrazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 11.11-11.30 (m, 1 H), 7.73-7.80 (m, 1 H), 7.55-7.72 (m, 4H), 7.37-7.53 (m, 3 H), 7.10-7.21 (m, 2 H), 6.99-7.08 (m, 1 H),6.41-6.52 (m, 1 H), 6.06-6.20 (m, 1 H). MS m/z (M+H) 419.2.

Example 1292-Amino-4-{4-[3-carboxy-2-(1H-indol-6-yl)-phenylethynyl]-phenyl}-thiazole-5-carboxylicacid

2-Amino-4-{4-[3-carboxy-2-(1H-indol-6-yl)-phenylethynyl]-phenyl}-thiazole-5-carboxylicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 11.12-11.33 (m, 1 H), 10.64-10.98 (m, 1 H), 7.74-7.82 (m,1 H), 7.67-7.74 (m, 1 H), 7.56-7.61 (m, 1 H), 7.36-7.53 (m, 4 H),7.29-7.34 (m, 1 H), 7.14-7.24 (m, 2 H), 7.00-7.12 (m, 2 H), 6.45-6.50(m, 1 H). MS m/z (M+H) 558.6.

Example 1303-(2-(4-(2-aminooxazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid

3-(2-(4-(2-aminooxazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 12.61-12.76 (m, 1 H), 11.16-11.21 (m, 1 H), 7.74 (d,J=7.55 Hz, 1 H), 7.67 (d, J=−7.70 Hz, 1 H), 7.59 (d, J=−8.09 Hz, 1 H),7.46-7.50 (m, 1 H), 7.39-7.44 (m, 2 H), 7.31-7.37 (m, 3 H), 7.15-7.28(m, 2 H), 7.00-7.12 (m, 3 H), 6.48 (m, 1 H). MS m/z (M+H) 420.3.

Example 1312-(1H-Indol-6-yl)-3-[4-(2-methanesulfonylamino-thiazol-4-yl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(2-methanesulfonylamino-thiazol-4-yl)-phenylethynyl]-benzoicacid was prepared by the same procedure as Example 52. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 10.90-11.27 (m, 1 H), 7.59-7.74 (m, 5 H), 7.49-7.56 (m, 1H), 7.32-7.46 (m, 4 H), 7.18-7.30 (m, 1 H), 7.07-7.15 (m, 2 H),6.92-7.02 (m, 1 H), 6.38-6.47 (m, 1 H), 2.84-2.99 (m, 3 H). MS m/z (M+H)514.0.

Example 1322-(1H-Indol-6-yl)-3-[3-(2-methanesulfonylamino-thiazol-4-yl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[3-(2-methanesulfonylamino-thiazol-4-yl)-phenylethynyl]-benzoicacid was prepared by the same procedure as Example 52. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 11.09-11.31 (m, 1 H), 7.78-7.84 (m, 1 H), 7.58-7.75 (m, 3H), 7.48-7.56 (m, 2 H), 7.42-7.46 (m, 1 H), 7.32-7.42 (m, 2 H),7.07-7.15 (m, 1 H), 6.95-7.01 (m, 1 H), 6.45-6.51 (m, 1 H), 3.49 (s, 3H). MS m/z (M+H) 514.1.

Example 1333-(2-(1,4-dihydro-2-((4-methoxypiperidin-1-yl)methyl)-4-oxoquinazolin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid

3-(2-(1,4-dihydro-2-((4-methoxypiperidin-1-yl)methyl)-4-oxoquinazolin-6-yl)ethynyl)-2-(lH-indol-6-yl)benzoic acid was prepared by the same procedure asExample 1. ¹H NMR (300 MHz, CD₃OD) δ ppm 8.02 (d, J=2.05 Hz, 1 H),7.74-7.86 (m, 2 H), 7.59 (m, 2 H), 7.43-7.50 (m, 2 H), 7.34 (d, J=8.61Hz, 1 H), 4.86 (s, 153 H), 4.72-4.83 (m, 3 H), 4.34 (s, 2 H), 3.44-3.61(m, 4 H), 3.38 (s, 3 H), 2.08 (m, 4 H). MS m/z (M+H) 533.1.

Example 1343-(2-(1,4-dihydro-2-((4-thiomorpholine-1,1dioxide-1-yl)methyl)-4-oxoquinazolin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoic acid

3-(2-(1,4-dihydro-2-((4-thiomorpholine-1,1dioxide-1-yl)methyl)-4-oxoquinazolin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoic acid was prepared by the sameprocedure as Example 1. ¹H NMR (300 MHz, CD₃OD) δ 11.66-12.14 (m, 1 H),8.67-8.72 (m, 1 H), 8.58-8.64 (m, 1 H), 8.46-8.52 (m, 1 H), 8.36-8.43(m, 1 H), 8.15-8.34 (m, 5 H), 7.84-7.90 (m, 1 H), 7.27 (br, s., 1 H),4.45 (s, 2 H), 3.95 (br, s., 4 H), 3.83 (br, s., 4 H). MS m/z (M+H)553.1.

Example 1353-(2-(2-(trifluoromethyl)-3,4-dihydro-4-oxoquinazolin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid

3-(2-(2-(trifluoromethyl)-3,4-dihydro-4-oxoquinazolin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d₆) δ ppm 7.94 (d, J=1.76 Hz, 1 H), 7.83 (dd, J=7.92, 1.32 Hz, 1H), 7.68-7.72 (m, 2 H), 7.52-7.61 (m, 2 H), 7.37-7.49 (m, 3 H), 7.07(dd, J=8.14, 1.54 Hz, 1 H), 6.47 (br, s., 1 H). MS m/z (M+H) 474.1.

Example 1363-(2-(3,4-dihydro-3-(2-methoxyethyl)-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid

3-(2-(3,4-dihydro-3-(2-methoxyethyl)-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,CD₃OD) δ ppm 8.18 (s, 1H), 8.03 (d, J=1.76 Hz, 1H), 7.75 (t, J=7.98 Hz,2H), 7.61 (d, J=8.21 Hz, 1H), 7.41-7.50 (m, 3H), 7.27-7.33 (m, 2H), 7.07(dd, J=8.21, 1.47 Hz, 1H), 6.50 (d, J=3.27 Hz, 1H), 4.91-5.04 (m, 3H),4.19 (t, J=4.98 Hz, 3H), 3.65 (t, J=4.98 Hz, 3H), MS m/z (M+H) 464.1.

Example 1372-(1H-Indol-6-yl)-3-[3-(2-methoxy-6-methyl-phenylcarbamoyl)-phenylethynyl]-benzoicacid

2-Bromo-3-(3-carboxy-phenylethynyl)-benzoic acid methyl ester: Asolution of 2-bromo-3-iodo-benzoic acid methyl ester (1.5 g, 4.4 mmol),3-ethynyl-benzoic acid (0.65 g, 4.4 mmol), potassium carbonate (1.2 g,8.8 mmol) in dimethoxyethane (15 mL) and water (5 mL) was degassed underN₂ for 10 minutes, palladium(II) tetrakis(triphenylphosphine) (254 mg,0.22 mmol) and copper (I) iodide (84 mg, 0.44 mmol) was added and thereaction mixture was degassed under N₂ for 10 minutes and then heated at45° C. for 4 hours. After cooling to ambient temperature, the crudemixture was partitioned between ethyl acetate (30 mL) and water (20 mL).The organic layer was dried (sodium sulfate), filtered, concentrated andpurified through silica gel cartridge eluting with ethylacetate/dichloromethane to give the product as a white solid in 83%yield.

2-Bromo-3-[3-(2-methoxy-6-methyl-phenylcarbamoyl)-phenylethynyl]-benzoic acid methyl ester: A mixture of2-bromo-3-(3-carboxy-phenylethynyl)-benzoic acid methyl ester (150 mg,0.41 mmol), 2-methoxy-6-methyl-phenylamine (100 mg, 0.73 mmol),1-[Bis(dimethylamino) methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxid hexafluorophosphate (HAT (276 mg, 0.73 mmol) and triethylamine(0.156 ml, 1.12 mmol) in tetrahydrofuran (1 mL) was stirred at roomtemperature for 24 hours. The reaction mixture was concentrated andpurified through preparative thin layered chromatography to give thedesired product.

2-(1H-Indol-6-yl)-3-[3-(2-methoxy-6-methyl-phenylcarbamoyl)-phenylethynyl]-benzoic acid was prepared by the sameprocedure as Example 1. ¹H NMR (300 MHz, DMSO-d₆) δ=11.16 (s, 1H), 9.59(s, 1H), 7.91-7.76 (m, 3H), 7.68 (d, J=7.7 Hz, 1H), 7.58 (d, J=8.3 Hz,1H), 7.51-7.32 (m, 4H), 7.30-7.05 (m, 3H), 6.90-6.82 (m, 2H), 6.21 (s,1H), 3.65 (s, 3H), 2.05 (s, 3H). MS (ESI) m/z 501.3 (M+1)⁺.

Example 1383-{3-[4-(1,1-Dioxo-1-thiomorpholin-4-yl)-phenylcarbamoyl]-phenylethynyl}-2-(1H-indol-6-yl)-benzoicacid

3-{3-[4-(1,1-Dioxo-1-thiomorpholin-4-yl)-phenylcarbamoyl]-phenylethynyl}-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 137. ¹H NMR (300 MHz,CD₃OD) δ =11.15 (br, s., 1H), 10.11 (s, 1H), 7.85-7.75 (m, 3H),7.70-7.56 (m, 3H), 7.51-7.38 (m, 2H), 7.34 (t, J=4.7 Hz, 1H), 7.24 (d,J=7.6 Hz, 1H), 7.03 (t, J=8.7 Hz, 3H), 6.44-6.40 (m, 1H), 3.75-3.70 (m,4H), 3.19-3.02 (m, 4H). MS (ESI) m/z 590.33 (M+1)⁺.

Example 139 3-Phenylethynyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid

3-Phenylethynyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoic acid wasprepared by the same procedure as Example 1. ¹H NMR (300 MHz, DMSO-d₆) δ8.11 (d, J=0.88 Hz, 1 H), 7.72-7.82 (m, 3 H), 7.46-7.55 (m, 2 H),7.22-7.32 (m, 3 H), 7.02-7.11 (m, 3 H). MS (ESI) m/z 339 (M+1)⁺.

Example 1403-(4-Fluoro-phenylethynyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid

3-(4-Fluoro-phenylethynyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d₆) δ 11.73 (br, s., 1 H), 8.17 (d, J=2.05 Hz, 1 H), 7.97 (d,J=2.05 Hz, 1 H), 7.79-7.84 (m, 2 H), 7.51-7.55 (m, 2 H), 7.15-7.17 (m, 4H), 6.52 (dd, J=3.37, 1.91 Hz, 1 H). MS (ESI) m/z 357 (M+1)⁺.

Example 1413-(4-Methoxy-phenylethynyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid

3-(4-Methoxy-phenylethynyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,CD₃OD) δ 8.59 (d, J=1.47 Hz, 1 H), 8.39 (d, J=1.47 Hz, 1 H), 8.06 (dd,=7.92, 1.17 Hz, 1 H), 7.85 (dd, J=7.77, 1.32 Hz, 1 H), 7.72 (d, J=3.52Hz, 1 H), 7.61 (t, J=7.75 Hz, 1 H), 6.94-6.99 (m, 2 H), 6.89 (d, J=3.52Hz, 1 H), 6.74-6.79 (m, 2 H), 3.75 (s, 3 H). MS (ESI) m/z 369 (M+1)⁺.

Example 1422-(1H-Pyrrolo[2,3-b]pyridin-5-yl)-3-[4-(tetrahydro-pyran-4-yloxy)-phenylethynyl]-benzoicacid

2-(1H-Pyrrolo[2,3-b]pyridin-5-yl)-3-[4-(tetrahydro-pyran-4-yloxy)-phenylethynyl]-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,DMSO-d₆) δ 11.80 (br s, 2 H), 8.19 (br d, 0.1-2.05 Hz, 1 H), 8.00 (br d,J=1.47 Hz, 1 H), 7.78-7.97 (m, 2 H), 7.51-7.69 (m, 2 H), 6.98-7.30 (m, 3H), 6.90 (d, J=8.50 Hz, 1 H), 6.55 (dd, J=3.37, 1.61 Hz, 1 H), 4.54-4.75(m 1 H), 3.75-3.85 (m, 2 H), 3.20-3.40 (m, 2 H), 1.90-1.98 (m, 2 H),1.49-1.61 (m, 2 H). MS (ESI) m/z 439 (M+1)⁺.

Example 1432-(1H-Indol-6-yl)-3-{4-[2-(tetrahydro-pyran-4-yl)-ethoxy]-phenylethynyl}-benzoicacid

2-(1H-Indol-6-yl)-3-({4-[2-(tetrahydro-pyran-4-yl)-ethoxy]-phenylethynyl}-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,CD₃OD) δ 7.50-7.81 (m, 3 H), 7.32-7.50 (m, 2 H), 7.26 (br s, 1 H), 7.04(br d, J=8.21 Hz, 1 H), 6.93 (br d, J=8.21 Hz, 2 H), 6.69 (br d, J=8.21Hz, 2 H), 6.42-6.5 (m, 1 H), 3.67-3.97 (m, 4 H), 3.32-3.62 (m, 2 H),1.44-1.78 (m, 5 H), 1.07-1.36 (m, 2 H). MS (ESI) m/z 466.3 (M+1)⁺.

Example 1443-[4-(1,1-Dioxo-hexahydro-1-thiopyran-4-yloxy)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(1,1-Dioxo-hexahydro-1-thiopyran-4-yloxy)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,CD₃OD) δ 7.51-7.70 (m, 3 H), 7.47 (s, 1 H), 7.30-7.43 (m, 1 H), 7.25 (d,J=3.22 Hz, 1 H), 7.09 (br d, J=8.21 Hz, 1 H), 6.90-7.04 (m, 2 H), 6.83(m, J=8.79 Hz, 2 H), 6.47 (d, J=2.93 Hz, 1 H), 4.62-4.74 (m, 1 H),3.19-3.34 (m 2 H), 2.92-3.10 (m, 2 H), 2.21-2.38 (m, 4 H). MS (ESI) m/z486.45 (M+1)⁺.

Example 1452-(1H-Indol-6-yl)-3-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoic acid

2-(1H-Indol-6-yl)-3-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoic acid;A mixture of 3-(4-formyl-phenylethynyl)-2-(l H-indol-6-yl)-benzoic acidmethyl ester (60 mg, 0.158 mmol), morpholine (28 mg, 0.32 mmol) intetrahydrofuran (1 mL) was stirred at room temperature for 30 minutes.NaB(OAc)₃H (47 mg, 0.22 mmol) was added and the reaction mixture wasstirred at room temperature for 24 hours. The reaction mixture waspartitioned between ethyl acetate (3 mL) and saturated NaHCO₃ solution(3 mL). The organic layer was dried (sodium sulfate), filtered,concentrated and purified over silica gel eluting with ethylacetate/dichloromethane to give the ester intermediate. To thisintermediate in tetrahydrofuran/methanol (1 mL/0.2 mL) was added sodiumhydroxide solution (2 N in water, 0.2 mL, 0.4 mmol) and the solution wasstirred at room temperature for 18 hours. 1 N hydrochloric acid aqueoussolution was added dropwise until pH=5 and the reaction mixture waspurified through preparative HPLC to give 9 mg (17% for 2 steps) of thepure product as a white solid. ¹H NMR (300 MHz, CD₃OD) δ 7.74 (ddd,J=7.70, 6.38, 1.47 Hz, 2 H), 7.57 (d, J=7.92 Hz, 1 H), 7.38-7.48 (m, 2H), 7.20-7.35 (m, 3 H), 6.92-7.20 (m, 3 H), 6.48 (d, J=3.18 Hz, 1 H),4.27 (s, 2 H), 3.95-4.10 (m, 2 H), 3.60-3.75 (m, 2 H), 3.05-3.62 (m, 4H). MS (ESI) m/z 437.50 (M+1)⁺.

Example 1463-[4-(4-Ethyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(4-Ethyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid acid was prepared by same procedure as Example 145. ¹H NMR (300MHz, CD₃OD) δ=7.67-7.79 (m 2 H), 7.57 (d, J=8.2 Hz, 1 H), 7.38-7.48 (m,2 H), 7.17-7.29 (m 3 H), 7.01-7.07 (m, 3 H), 6.49 (d, J=3.1 Hz, 1 H),3.74 (s, 2 H), 3.13-3.28 (m, 6 H), 2.85 (br s, 4 H), 1.31 (t, J=7.2 Hz,3 H). MS (ESI) m/z 464.63 (M+1)⁺.

Example 1472-(1H-Indol-6-yl)-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.63-7.80 (m, 2 H), 7.57 (d, J=8.21 Hz, 1 H), 7.34-7.51 (m, 2H), 7.13-7.34 (m, 3 H), 6.74-7.13 (m, 3 H), 6.49 (d, J=3.22 Hz, 1H),3.72 (s, 2 H), 3.33-3.54 (m, 4 H), 2.69-3.07 (m, 7 H). MS (ESI) m/z450.56 (M+1)⁺.

Example 1483-[4-(1,1-Dioxo-thiomorpholin-4-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(1,1-Dioxo-thiomorpholin-4-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.64-8.04 (m, 2 H), 7.57 (d, J=8.21 Hz, 1 H), 7.35-7.50 (m, 2H), 7.18-7.35 (m, 3 H), 6.92-7.18 (m 3 H), 6.49 (d, J=3.17 Hz, 1 H),4.13 (s, 2 H), 3.45 (dd, J=6.74, 3.52 Hz, 4 H), 3.28-3.33 (m, 4 H). MS(ESI) m/z 495.5 (M+1)⁺.

Example 1493-(4-{[(2-Dimethylamino-ethyl)-methyl-amino]-methyl}-phenylethynyl)-2-(1H-indol-6-yl)-benzoicacid

3-(4-{[(2-Dimethylamino-ethyl)-methyl-amino]-methyl}-phenylethynyl)-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.75-7.69 (min, 2 H), 7.58 (d, J=8.21 Hz, 1 H), 7.50-7.64 (m, 2H), 7.18-7.46 (m, 3 H), 6.99-7.14 (m, 3 H), 6.34-6.51 (m 1 H), 4.23 (s,2 H), 3.42-3.58 (m, 4 H), 2.85 (s, 6 H), 2.69 (s, 3 H). MS (ESI) m/z452.46 (M+1)⁺.

Example 1503-{4-[4-(2-Hydroxy-ethyl)-piperidin-1-ylmethyl]-phenylethynyl}-2-(1H-indol-6-yl)-benzoicacid

3-{4-[4-(2-Hydroxy-ethyl)-piperidin-1-ylmethyl]-phenylethynyl}-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.66 (ddd, J=7.70, 6.23, 1.32 Hz, 2 H), 7.50 (d, J=8.21 Hz, 1H), 7.29-7.41 (m, 2 H), 7.14-7.27 (m, 3 H), 6.89-7.11 (m, 3 H), 6.41(dd, J=−3.22, 0.88 Hz, 1 H), 4.09 (s, 2 H), 3.35-3.66 (m, 2 H),3.16-3.29 (m, 4 H), 2.72-2.94 (m, 2 H), 1.84 (br d, J=13.78 Hz, 2 H),1.16-1.50 (m, 3 H). MS (ESI) m/z 479.58 (M+1)⁺.

Example 1513-[4-(4-Hydroxymethyl-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(4-Hydroxymethyl-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.74 (ddd, J=7.48, 5.86, 1.03 Hz, 2 H), 7.58 (d, J=8.21 Hz, 1H), 7.37-7.49 (m, 2 H), 7.22-7.35 (m, 3 H), 6.94-7.20 (m, 3 H), 6.49 (d,J=3.22 Hz, 1 H), 4.21 (s, 2 H), 3.33-3.59 (m 4 H), 2.86-3.03 (m, 2 H),1.68-2.04 (m, 2 H), 1.29-1.45 (m, 2 H). MS (ESI) m/z 465.58 (M+1)⁺.

Example 1522-(1H-Indol-6-yl)-3-[4-(4-methyl-[1,4]diazepan-1-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(4-methyl-[1,4]diazepan-1-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.65-7.84 (m, 2 H), 7.57 (d, J=7.92 Hz, 1 H), 7.37-7.50 (m, 2H), 7.19-7.36 (m, 3 H), 6.91-7.19 (m, 3 H), 6.48 (dd, J=3.22, 0.88 Hz, 1H), 4.18 (s, 2 H), 3.53-3.88 (m, 6 H), 3.38-3.52 (m, 2 H), 2.92 (s, 3H), 2.11-2.20 (m, 2 H). MS (ESI) m/z 464.56 (M+1)⁺.

Example 1533-[4-(3-Hydroxy-azetidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(3-Hydroxy-azetidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.69-7.80 (m, 2 H), 7.57 (d, J=7.92 Hz, 1 H), 7.38-7.45 (m, 2H), 7.21-7.36 (m, 3 H), 6.91-7.19 (m, 3 H), 6.48 (dd, J=3.22, 0.88 Hz, 1H), 4.62-4.52 (m, 1 H), 4.18-4.30 (m, 4 H), 3.82-3.90 (m, 2 H). MS (ESI)m/z 423 (M+1)⁺.

Example 1543-[4-(4-Hydroxy-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(4-Hydroxy-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.65-7.84 (m, 2 H), 7.57 (d, J=7.92 Hz, 1 H), 7.37-7.50 (m, 2H), 7.19-7.36 (m, 3 H), 6.98-7.19 (m, 3 H), 6.45 (dd, J=−3.22, 0.88 Hz,1 H), 4.18 (d, J=6.8 Hz, 2 H), 3.98-4.05 (m, 1 H), 3.70-3.81 (m, 1 H),2.92-3.40 (m, 3 H), 2.10-2.00 (m, 1 H), 1.88-1.80 (m, 2 H), 1.58-1.65(m, 1 H). MS (ESI) m/z 451.51 (M+1)⁺.

Example 1552-(1H-Indol-6-yl-3-[4-(4-methoxy-piperidin-1-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(4-methoxy-piperidin-1-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.66-7.81 (m, 2 H), 7.25-7.59 (m, 6 H), 7.01-7.16 (m, 3 H),6.48 (d, J=3.11 Hz, 1 H), 4.19 (s, 2 H), 3.52-3.58 (m, 1 H), 3.30-3.38(m, 4 H), 3.05-3.28 (m, 3 H), 2.79-3.02 (m, 1 H), 1.95-2.23 (m, 2 H),1.67-1.89 (m, 1 H). MS (ESI) m/z 465.51 (M+1)⁺.

Example 1563-(4-Dimethylaminomethyl-phenylethynyl)-2-(1H-indol-6-yl)-benzoic acid

3-(4-Dimethylaminomethyl-phenylethynyl)-2-(1H-indol-6-yl)-benzoic acidwas prepared by same procedure as Example 145. ¹H NMR (300 MHz, CD₃OD) δ7.66-7.80 (m, 2 H), 7.58 (d, J=8.21 Hz, 1 H), 7.38-7.50 (m, 2 H),7.22-7.38 (m, 3 H), 7.05-7.18 (m, 3 H), 6.48 (dd, J=3.22, 0.88 Hz, 1 H),4.15 (s, 2 H), 2.76 (s, 6 H). MS (ESI) m/z 395 (M+1)⁺.

Example 1572-(1H-Indol-6-yl)-3-(4-{[(2-methoxy-ethyl)methyl-amino]-methyl}-phenylethynyl)-benzoicacid

2-(1H-Indol-6-yl)-3-(4-{[(2-methoxy-ethyl)-methyl-amino]-methyl}-phenylethynyl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.70-7.77 (m, 2 H), 7.58 (d, J=8.03 Hz, 1 H), 7.38-7.48 (m, 2H), 7.25-7.34 (m, 3 H), 7.03-7.14 (m, 3 H), 6.48 (dd, J=3.22, 0.88 Hz, 1H), 4.18-4.34 (m, 2 H), 3.66 (t, J=4.98 Hz, 2 H), 3.48 (s, 3 H),3.30-3.35 (m, 2 H), 2.76 (s, 3 H). MS (ESI) m/z 439.47 (M+1)⁺.

Example 1583-[4-(4,4-Difluoro-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(4,4-Difluoro-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.74 (ddd, J=7.77, 6.60, 1.17 Hz, 2 H), 7.57 (d, J=8.21 Hz, 1H), 7.37-7.51 (m, 2 H), 7.21-7.37 (m, 3 H), 7.11 (d, J=7.92 Hz, 2 H),7.03 (dd, J=8.06, 1.61 Hz, 1 H), 6.48 (d, J=3.27 Hz, 1 H), 4.29 (s, 2H), 3.12-3.50 (m, 4 H), 2.14-2.44 (m, 4 H). MS (ESI) m/z 471.49 (M+1)⁺.

Example 1593-[4-(3,3-Difluoro-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(3,3-Difluoro-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.64-7.87 (m, 2 H), 7.51-7.64 (m, 1 H), 7.38-7.51 (m, 2 H),7.22-7.38 (m 3 H), 7.13 (br d, J=6.45 Hz, 2 H), 7.04 (br d, J=6.74 Hz, 1H), 6.48 (br s, 1 H), 3.46 (br t, J=10.99 Hz, 2 H), 3.26-3.38 (m 2 H),3.02-3.26 (m, 2 H), 1.82-2.22 (m, 4 H). MS (ESI) m/z 471.5 (M+1)⁺.

Example 1603-[4-(3,4-Dihydro-1H-isoquinolin-2-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(3,4-Dihydro-1H-isoquinolin-2-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.70-7.80 (m, 2 H), 7.59 (d, J=8.21 Hz, 1 H), 7.32-7.50 (m, 5H), 7.20-7.32 (m, 4 H), 7.10-7.20 (m 3 H), 7.05 (dd, J=8.21, 1.47 Hz, 1H), 6.43-6.53 (m, 1 H), 4.41 (s, 2 H), 4.33 (s, 2 H), 3.09-3.21 (m, 2H). MS (ESI) m/z 483.5 (M+1)⁺.

Example 1612-(1H-Indol-6-yl)-3-[4-(4-methanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(4-methanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.74 (ddd, J=−7.70, 6.38, 1.47 Hz, 2 H), 7.57 (d, J=8.18 Hz, 1H), 7.39-7.47 (m, 2 H), 7.33 (d, J=7.59 Hz, 2 H), 7.27 (d, J=2.95 Hz, 1H), 7.12 (d, J=7.68 Hz, 2 H), 7.03 (dd, J=8.21, 1.47 Hz, 1 H), 6.48 (dd,J=3.22, 0.88 Hz, 1 H), 4.31 (s, 2 H), 3.28-3.55 (m 6 H), 2.92 (s, 3 H),2.65 (s, 2 H). MS (ESI) m/z 514.53 (M+1)⁺.

Example 1622-(1H-Indol-6-yl)-3-[4-(3-trifluoromethyl-piperidin-1-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(3-trifluoromethyl-piperidin-1-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.73 (br s, 2 H), 7.52-7.65 (m, 1 H), 7.37-7.51 (m, 2 H),7.19-7.37 (m, 3 H), 6.93-7.19 (m, 3 H), 6.48 (br s, 1 H), 4.20-4.44 (m,2 H), 3.58 (br d, J=11.14 Hz, 1 H), 3.16-3.47 (m, 1 H), 2.64-3.10 (m, 3H), 1.87-2.17 (m, 2 H), 1.46-1.87 (m, 2 H), 1.38-1.66 (m, 2 H). MS (ESI)m/z 503.58 (M+1)⁺.

Example 1632-(1H-Indol-6-yl)-3-[4-(3-methoxy-pyrrolidin-1-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(3-methoxy-pyrrolidin-1-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.70-7.75 (m, 2 H), 7.59 (d, J=8.2 Hz, 1 H), 7.39-7.45 (m, 2H), 7.27-7.35 (m, 3 H), 7.02-7.12 (m, 3 H), 6.48 (dd, J=2.93, 0.88 Hz, 1H), 4.30 (s, 2 H), 4.08-4.15 (m, 1 H), 3.06-3.60 (m, 7 H), 2.01-2.35 (m,2 H). MS (ESI) m/z 478.7 (M+1)⁺. MS (ESI) m/z 451.58 (M+1)⁺.

Example 1642-(1H-Indol-6-yl)-3-[4-(4-isopropyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(4-isopropyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.64-7.84 (m, 2 H), 7.59 (s, 1 H), 7.35-7.52 (m, 2 H),7.20-7.35 (m, 3 H), 6.94-7.11 (m, 3 H), 6.48 (dd, J=2.93, 0.88 Hz, 1 H),3.92 (s, 2 H), 3.30-3.57 (m, 5 H), 3.02-3.15 (m, 4 H), 1.32 (d, J=6.70Hz, 6 H). MS (ESI) m/z 478.7 (M+1)⁺.

Example 1653-[4-(4-cyclohexyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(4-Cyclohexyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz;CD₃OD) δ 7.68-7.76 (m 2 H), 7.56 (d, J=8.21 Hz, 1 H), 7.34-7.48 (m, 2H), 7.15-7.32 (m, 3 H), 6.95-7.06 (m, 3 H), 6.42-6.53 (m, 1 H), 3.91 (s,2 H), 3.32-3.60 (m, 3 H), 2.92-3.27 (m, 5 H), 2.02 (br s, 2 H),1.81-1.97 (m, 2 H), 1.68 (br d, J=12.02 Hz, 1 H), 1.23-1.49 (m, 5 H),1.19 (br s, 1 H). MS (ESI) m/z 518.74 (M+1)⁺.

Example 1663-[4-(4-Cyclopropanecarbonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(4-Cyclopropanecarbonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.66-7.86 (m, 2 H), 7.57 (d, J=8.21 Hz, 1 H), 7.37-7.51 (m, 2H), 7.20-7.37 (m, 3 H), 7.12 (d, J=8.21 Hz, 2 H), 7.03 (dd, J=8.21, 1.47Hz, 1 H), 6.40-6.53 (m, 1 H), 4.27 (s, 2 H), 3.11-3.28 (m, 8 H), 1.92(ddd, J=7.62, 4.84, 2.79 Hz, 1 H), 0.74-1.02 (m, 4 H). MS (ESI) m/z504.67 (M+1)⁺.

Example 1672-(1H-Indol-6-yl)-3-(4-piperazin-1-ylmethyl-phenylethynyl)-benzoic acid

2-(1H-Indol-6-yl)-3-(4-piperazin-1-ylmethyl-phenylethynyl)-benzoic acidwas prepared by same procedure as Example 145. ¹H NMR (300 MHz, CD₃OD) δppm 7.71-7.77 (m, 2 H), 7.57 (d, J=8.14 Hz, 1 H), 7.39-7.47 (m, 2 H),7.26-7.35 (m, 3 H), 7.12 (d, J=7.61 Hz, 2 H), 7.03 (dd, J=8.21, 1.47 Hz,1 H), 6.49 (d, J=3.05 Hz, 1 H), 4.27 (s, 2 H), 3.60-3.98 (m, 4 H),2.60-2.81 (m, 4 H). MS (ESI) m/z 436.62 (M+1)⁺.

Example 1683-[4-(4-Benzenesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(4-Benzenesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.69-7.83 (m, 4 H), 7.62-7.69 (m, 1 H), 7.52-7.62 (m, 3 H),7.35-7.49 (m, 2 H), 7.18-7.30 (m, 3 H), 7.05-7.11 (m, 2 H), 6.97-7.05(m, 1 H), 6.48 (dd, J=3.08, 0.88 Hz, 1 H), 4.22 (s, 2 H), 3.11-3.34 (m,8 H). MS (ESI) m/z 576 (M+1)⁺.

Example 1693-{4-[(1,1-Dioxo-hexahydro-1-thiopyran-4-ylamino)-methyl]-phenylethynyl}-2-(1H-indol-6-yl)-benzoicacid

3-{4-[(1,1-Dioxo-hexahydro-1-thiopyran-4-ylamino)-methyl]-phenylethynyl}-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.70-7.79 (m, 2 H), 7.58 (d, J=8.02 Hz, 1 H), 7.45-7.41 (m, 2H), 7.26-7.35 (m, 3 H), 7.08-7.14 (m, 2 H), 7.04 (dd, J=8.21, 1.47 Hz, 1H), 6.48 (dd, J=3.22, 0.88 Hz, 1 H), 4.20 (s, 2 H), 3.38-3.53 (m, 1 H),3.11-3.27 (m, 4 H), 2.46-2.55 (m, 2 H), 2.11-2.26 (m, 2 H). MS (ESI) m/z499 (M+1)⁺.

Example 1703-[4-(4-Cyclopentyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(4-Cyclopentyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(lH-indol-6-yl)-benzoic acid was prepared by the same procedure as Example145. ¹H NMR (300 MHz, CD₃OD) δ 7.64-7.84 (m, 2 H), 7.59 (s, 1 H),7.35-7.52 (m, 2 H), 7.24-7.35 (m, 1 H), 7.19 (d, J=7.92 Hz, 2 H),6.94-7.11 (m, 3 H), 6.48 (dd, =−2.93, 0.88 Hz, 1 H), 3.63 (s, 2 H),3.39-3.57 (m, 3 H), 2.55-2.95 (m, 4 H), 1.99-2.27 (m, 2 H), 1.54-1.91(m, 8 H). MS (ESI) m/z 504 (M+1)⁺.

Example 1713-[4-(4-Dimethylcarbamoyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(4-Dimethylcarbamoyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.63-7.77 (m, 2 H), 7.58 (d, J=7.33 Hz, 1 H), 7.38-7.45 (m, 2H), 7.25-7.32 (m, 3 H), 7.16 (d, J=8.21 Hz, 2 H), 6.96-7.12 (m, 1 H),6.49 (dd, J=3.22, 0.88 Hz, 1 H), 4.21 (s, 2 H), 3.11-3.30 (m, 8 H), 2.83(s, 6 H). MS (ESI) m/z 507 (M+1)⁺.

Example 1722-(1H-Indol-6-yl)-3-[4-(2,3,5,6-tetrahydro-[1,2′]bipyrazinyl-4-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(2,3,5,6-tetrahydro-[1,2′]bipyrazinyl-4-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 8.24 (s, 1 H), 8.16 (dd, J=2.49, 1.32 Hz, 1 H), 7.90 (br d,J=2.05 Hz, 1 H), 7.74 (ddd, J=7.70, 6.08, 1.47 Hz, 2 H), 7.57 (d, J=8.21Hz; 1 H), 7.36-7.49 (m, 2 H), 7.23-7.36 (m, 3 H), 7.11 (d, J=8.21 Hz, 2H), 7.02 (dd, J=8.06, 1.61 Hz, 1 H), 6.48 (dd, J=3.22, 0.88 Hz, 1 H),4.26 (s, 2 H), 3.14-3.34 (m, 8 H). MS (ESI) m/z 514 (M+1)⁺.

Example 1732-(1H-Indol-6-yl)-3-[4-(4-thiazol-2-yl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(4-thiazol-2-yl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 145. MS (ESI) m/z 519(M+1)⁺.

Example 1743-(4-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylamino)-methyl]-phenylethynyl-2-(1H-indol-6-yl)-benzoicacid

3-{4-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylamino)-methyl]-phenylethynyl}-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.73 (ddd, =7.70, 5.94, 1.32 Hz, 2 H), 7.57 (d, J=8.79 Hz, 1H), 7.38-7.51 (m, 2 H), 7.35 (d, J=8.21 Hz, 2 H), 7.26 (d, J=2.93 Hz, 1H), 6.99-7.20 (m, 3 H), 6.48 (dd, J=3.22, 0.88 Hz, 1 H), 4.25 (s, 2 H),2.57-2.84 (m, 5 H), 1.90-1.95 (m, 2 H). MS (ESI) m/z 519.13 (M+1)⁺.

Example 1753-(4-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylamino)-methyl]-phenylethynyl)-2-(1H-indol-6-yl)-benzoicacid

3-{4-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylamino)-methyl]-phenylethynyl}-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.63-7.81 (m, 2 H), 7.51-7.63 (m, 1 H), 7.38-7.51 (m, 2 H),7.33 (d, J=7.92 Hz, 2 H), 7.17-7.29 (m, 1 H), 6.93-7.17 (m, 3 H), 6.47(d, J=2.93 Hz, 1 H), 4.22 (s, 2 H), 3.46-3.73 (m, 1 H), 2.98-3.23 (m, 1H), 2.53-2.88 (m, 3 H), 2.25-2.49 (m, 1 H), 1.82-2.15 (m, 1 H). MS (ESI)m/z 519.14 (M+1)⁺.

Example 1763-[4-(4-Methyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid

3-[4-(4-Methyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CDCl₃) δ 8.40 (d, J=1.17 Hz, 1 H), 8.18 (d, J=1.47 Hz, 1 H), 8.02 (dd,J=7.62, 1.17 Hz, 1 H), 7.70-7.84 (m, 1 H), 7.42-7.58 (m, 2 H), 7.13 (d,J=8.21 Hz, 2 H), 6.98 (d, J=7.92 Hz, 2 H), 6.69 (d, J=3.52 Hz, 1 H),3.66 (s, 2 H), 3.07-3.47 (m, 4 H), 2.87 (br s, 4 H), 2.74 (s, 3 H). MS(ESI) m/z 451 (M+1)⁺.

Example 1773-[4-(4-Methoxy-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid

3-[4-(4-Methoxy-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CDCl₃) δ 8.43 (d, J=1.47 Hz; 1 H), 8.11-8.23 (m, 1 H), 8.05 (dd, J=7.92,1.17 Hz, 1 H), 7.79 (dd, J=7.62, 1.17 Hz, 1 H), 7.40-7.60 (m, 2 H),7.13-7.32 (m, 2 H), 7.04 (d, J=8.21 Hz, 2 H), 6.71 (d, J=3.22 Hz; 1 H),4.03 (s, 2 H), 3.70-3.81 (m, 4 H), 3.05-3.29 (m, 4 H), 1.79-2.09 (m, 4H). MS (ESI) m/z 466.1 (M+1)⁺.

Example 1782-(1H-Indol-5-yl)-3-[4-(4-methoxy-piperidin-1-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-5-yl)-3-[4-(4-methoxy-piperidin-1-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CDCl₃) δ 7.77-7.88 (m, 1 H), 7.63-7.74 (m, 1 H), 7.59 (d, J=0.88 Hz, 1H), 7.30-7.42 (m, 2 H), 7.05-7.22 (m, 4 H), 6.98 (d, J=8.21 Hz, 2 H),6.47 (br d, J=3.22 Hz, 1 H), 3.96 (s, 2 H), 3.47 (br d, J=1.47 Hz, 1 H),3.05-3.31 (m, 5 H), 2.60-2.95 (m, 2H), 1.73-2.06 (m, 4 H). MS (ESI) m/z465.23 (M+1)⁺.

Example 1792-(1H-Indol-5-yl)-3-[4-(4-methanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid

2-1H-Indol-5-yl)-3-[4-(4-methanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CDCl₃) δ 7.81 (dd, J=7.77, 1.32 Hz, 1 H), 7.68 (dd, J=7.77, 1.32 Hz, 1H), 7.53 (d, J=1.17 Hz, 1 H), 7.27-7.41 (m, 2 H), 7.17 (t, J=1.47 Hz, 1H), 7.02-7.12 (m, 3 H), 6.92-7.02 (m, 2 H), 6.44 (d, J=2.64 Hz, 1 H),3.95 (s, 2 H), 3.34 (br dd, J=3.22, 1.47 Hz, 2 H), 2.86-3.07 (m, 2 H),2.47-2.86 (m, 7 H). MS (ESI) m/z 514.10 (M+1)⁺.

Example 1803-[4-(4-Methanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid

3-[4-(4-Methanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CDCl₃) δ ppm 8.37-8.54 (m, 1 H), 8.21 (s, 1 H), 8.02-8.15 (m, 1 H), 7.82(dd, J=7.77, 1.32 Hz, 1 H), 7.44-7.64 (m, 2 H), 7.17-7.32 (m, 2 H), 7.08(d, J=7.92 Hz, 2 H), 6.73 (d, J=3.52 Hz, 1 H), 4.11 (s, 2 H), 3.53 (brs, 4 H), 3.00-3.31 (m, 4 H), 2.82 (s, 3 H). MS (ESI) m/z 515.17 (M+1)⁺.

Example 1813-[4-(4,4-Difluoro-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-5-yl)-benzoicacid

3-[4-(4,4-Difluoro-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-5-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CDCl₃) δ 7.78 (dd, J=7.77, 1.03 Hz, 1 H), 7.67 (dd, J=7.77, 1.03 Hz, 1H), 7.57 (d, J=1.47 Hz, 1 H), 7.30-7.41 (m, 2 H), 7.05-7.21 (m, 4 H),6.95-7.05 (m, 2 H), 6.44 (d, J=3.22 Hz, 1 H), 3.99 (s, 2 H), 3.18-3.55(m, 4 H), 2.81-3.17 (m, 2 H), 2.04-2.43 (m, 2 H). MS (ESI) m/z 471.08(M+1)⁺.

Example 1822-(1H-Indol-5-yl)-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-5-yl)-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CDCl₃) δ 7.89 (dd, J=7.77, 1.32 Hz, 1 H), 7.72 (dd. J=7.62, 1.47 Hz, 1H), 7.33-7.50 (m, 2 H), 7.19 (d, J=8.50 Hz, 1 H), 7.02-7.15 (m, 3 H),6.83-6.97 (m, 3 H), 6.36 (dd, J=3.22, 0.88 Hz, 1 H), 3.87 (s, 2 H), 2.97(br d, J=5.86 Hz, 8 H), 2.62 (s, 3 H). MS (ESI) m/z 450.17 (M+1)⁺.

Example 1833-[4-(4-Ethanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(4-Ethanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CDCl₃) δ=7.85 (d, J=7.9 Hz, 1 H), 7.74 (td, J=1.2, 7.8 Hz, 1 H), 7.66(d, J=7.8 Hz, 1 H), 7.37-7.49 (m, 2 H), 7.13-7.25 (m, 4 H), 7.03-7.10(m, 2 H), 6.45-6.49 (m, 1 H), 4.10 (s, 2 H), 3.56-3.69 (m, 4 H),2.96-3.12 (m, 6 H), 1.38 (t, J=7.6 Hz, 3 H). MS (ESI) m/z 528.33 (M+1)⁺.

Example 1843-[4-(1,1-Dioxo-hexahydro-1-thiopyran-4-yloxy)-phenylethynyl]-2-(1H-indol-5-yl)-benzoicacid

3-[4-(1,1-Dioxo-hexahydro-1-thiopyran-4-yloxy)-phenylethynyl]-2-(1H-indol-5-yl)-benzoicacid was prepared by same procedure as Example 1. ¹H NMR (300 MHz,CDCl₃) δ 8.22 (br s, 1 H), 7.62-7.81 (m, 3 H), 7.30-7.46 (m, 2 H),7.18-7.30 (m, 2 H), 6.98-7.18 (m, 2 H), 6.63-6.82 (m, 2 H), 6.57 (br s,1 H), 4.52-4.65 (m, 1 H), 3.25-3.41 (m, 2 H), 2.82-2.90 (m, 2 H),2.20-2.49 (m, 4 H). MS (ESI) m/z 486.14 (M+1)⁺.

Example 1853-[4-(1,1-Dioxo-hexahydro-thiopyran-4-yloxy)-phenylethynyl]-2-(1H-indazol-6-yl)-benzoicacid

3-[4-(1,1-Dioxo-hexahydro-thiopyran-4-yloxy)-phenylethynyl]-2-(1H-indazol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,CD₃OD) 5=8.08 (s, 1 H), 7.67-7.81 (m, 3 H), 7.42-7.55 (m, 2 H), 7.18 (d,J=8.2 Hz, 1 H), 6.91-6.96 (m, 2 H), 6.81-6.86 (m, 2 H), 4.62-4.70 (m, 1H), 3.20-3.26 (m, 2 H), 2.95-3.06 (m, 2 H), 2.22-2.36 (m, 4 H). MS (ESI)m/z 487.08 (M+1)⁺.

Example 1863-[2-Fluoro-4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[2-Fluoro-4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,CDCl₃) δ 8.25 (br s, 1 H), 7.89 (dd, J=7.77, 1.32 Hz, 1 H), 7.81 (dd,J=7.92, 1.47 Hz, 1 H), 7.67 (d, J=7.92 Hz, 1 H), 7.34-7.55 (m, 2 H),7.25-7.21 (m, 1 H), 7.15 (dd, J=8.06, 1.61 Hz, 1 H), 6.98 (br d, J=10.26Hz, 1 H), 6.83-6.93 (m, 2 H), 6.58 (dt, J=2.05, 1.03 Hz, 1 H), 4.47 (s,2 H), 3.96 (dt, J=11.87, 4.32 Hz, 2 H), 3.37-3.64 (m, 3 H), 1.77-1.98(m, 2 H), 1.48-1.77 (m, 2 H). MS (ESI) m/z 470 (M+1)⁺.

Example 1873-[4-(1,1-Dioxo-hexahydro-1-thiopyran-4-yloxymethyl)-2-fluoro-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(1,1-Dioxo-hexahydro-1-thiopyran-4-yloxymethyl)-2-fluoro-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by the same procedure as Example 1. ¹H NMR (300 MHz,CDCl₃) 7.79 (dd, J=10.41, 7.77 Hz, 2 H), 7.65 (d, J=8.21 Hz, 1 H), 7.48(d, J=1.47 Hz, 1 H), 7.40 (t, J=7.77 Hz, 1 H), 7.13-7.28 (m, 2 H),6.83-7.02 (m, 3 H), 6.48 (dt, J=2.05, 1.03 Hz, 1 H), 4.46 (s, 2 H),3.61-3.80 (m, 1 H), 3.20-3.40 (m, 2 H), 2.80-2.99 (m, 2 H), 2.06-2.44(m, 4 H). MS (ESI) m/z 518 (M+1)⁺.

Example 1882-(1H-Indol-6-yl)-3-[4-(2-methanesulfonyl-2,7-diaza-spiro[3.5]non-7-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(2-methanesulfonyl-2,7-diaza-spiro[3.5]non-7-ylmethyl)-phenylethynyl]-benzoic acid was prepared by the same procedure as Example 58.¹H NMR (300 MHz, CDCl₃) δ 7.84 (dd, J=7.62, 1.47 Hz, 2 H), 7.74 (dd,J=7.77, 1.32 Hz, 1 H), 7.64 (d, J=8.21 Hz, 1 H), 7.34-7.52 (m, 2 H),7.04-7.32 (m, 5 H), 6.49 (dd, J=3.22, 0.88 Hz, 1 H), 4.05 (s, 2 H),3.61-3.68 (m, 2 H), 3.41 (dt, J=3.22, 1.61 Hz, 2 H), 2.86 (s, 3 H),2.13-2.44 (m, 4 H), 1.77-2.13 (m, 4 H). MS (ESI) m/z 554.2 (M+1)⁺.

Example 1892-(1H-Indol-6-yl)-3-[4-(5-methanesulfonyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(5-methanesulfonyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 58. ¹H NMR (300 MHz,CD₃OD) δ 7.74 (ddd, J=7.84, 6.38, 1.32 Hz, 2 H), 7.58 (d, J=8.21 Hz, 1H), 7.37-7.50 (m, 2 H), 7.34 (d, J=8.21 Hz, 2 H), 7.27 (d, J=2.93 Hz, 1H), 7.09-7.19 (m, 2 H), 7.01-7.09 (m, 1 H), 6.49 (dd, J=3.22, 0.88 Hz, 1H), 4.33 (s, 2 H), 3.75-3.63 (m, 2 H) 3.28-3.42 (m, 6 H), 3.15-3.00 (m,2 H), 2.87 (s, 3 H). MS (ESI) m/z 540.2 (M+1)⁺.

Example 190 3-[4-(4-Cyclopropanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoic acid

3-[4-(4-Cyclopropanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 58. ¹H NMR (300 MHz,CD₃OD) δ 7.65-7.88 (m, 2 H), 7.58 (dd, J=8.21, 0.88 Hz, 1 H), 7.38-7.51(m, 2 H), 7.21-7.38 (m, 3 H), 7.09-7.21 (m, 2 H), 7.04 (dd, J=8.21, 1.76Hz, 1 H), 6.49 (dd, J=3.22, 0.88 Hz, 1 H), 4.28 (s, 2 H), 3.60-3.42 (m,2 H), 3.17-3.12 (m, 6 H), 2.56-2.49 (m, 1 H), 1.05-1.11 (m, 4 H). MS(ESI) m/z 540.24 (M+1)⁺.

Example 1912-(1H-Indol-6-yl)-3-(4-[4-(propane-2-sulfonyl)-piperazin-1-ylmethyl]-phenylethynyl)-benzoicacid

2-(1H-Indol-6-yl)-3-{4-[4-(propane-2-sulfonyl)-piperazin-1-ylmethyl]-phenylethynyl}-benzoicacid was prepared by same procedure as Example 58. ¹H NMR (300 MHz,CD₃OD) δ 7.74 (ddd, J=7.84, 6.52, 1.17 Hz, 2 H), 7.49-7.65 (m, 1 H),7.38-7.49 (m, 2 H), 7.30-7.38 (m, 2 H), 7.24-7.30 (m, 1 H), 7.08-7.19(m, 2 H), 7.04 (dd, J=8.21, 1.47 Hz, 1 H), 6.49 (dd, J=3.22, 0.88 Hz, 1H), 4.30 (s, 2 H), 3.62-3.45 (m, 4 H), 3.29-3.36 (m, 1 H), 3.13-3.29 (m,4 H), 1.31 (d, J=6.74 Hz, 6 H). MS (ESI) m/z 542.13 (M+1)⁺.

Example 1922-(1H-Indol-6-yl)-3-[4-(7-methanesulfonyl-2,7-diaza-spiro[3.5]non-2-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(7-methanesulfonyl-2,7-diaza-spiro[3.5]non-2-ylmethyl)-phenylethynyl]-benzoic acid was prepared by same procedure as Example 58. ¹HNMR (300 MHz, CD₃OD) δ 7.74 (td, J=−7.62, 1.47 Hz, 2 H), 7.57 (d, J=8.21Hz, 1 H), 7.37-7.51 (m, 3 H), 7.21-7.37 (m, 2 H), 7.08-7.21 (m, 2 H),7.04 (dd, =8.06, 1.61 Hz, 1 H), 6.48 (dd, J=3.22, 0.88 Hz, 1 H), 4.33(s, 2 H), 3.94 (s, 4 H), 3.10-3.24 (m, 4 H), 2.80 (s, 3 H), 1.86-2.05(m, 4 H). MS (ESI) m/z 554.16 (M+1)⁺.

Example 1932-(1H-Indol-5-yl)-3-[4-(tetrahydro-pyran-4-yloxy)-phenylethynyl]-benzoicacid

2-(1H-Indol-5-yl)-3-[4-(tetrahydro-pyran-4-yloxy)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 1. H NMR (300 MHz, CD₃OD)7.53-7.74 (m, 3H), 7.30-7.49 (m, 2 H), 7.25 (t, J=1.61 Hz, 1 H), 7.14(dd, J=8.35, 1.61 Hz, 1 H), 6.91-7.05 (m, 2 H), 6.67-6.77 (m, 2 H), 6.47(dd, J=3.22, 0.88 Hz, 1 H), 4.45 (tt, J=8.03, 3.99 Hz, 1 H), 3.76-3.97(m, 2 H), 3.51 (ddd, J=11.73, 8.65, 3.08 Hz, 2 H), 1.79-2.03 (m, 2 H),1.61 (dtd, J=12.94, 8.56, 8.56, 3.96 Hz, 2 H). MS (ESI) m/z 438.15(M+1)⁺.

Example 194-(N,N-dimethylsulfamoyl)-2-(1H-indol-6-yl)-3-((4-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)phenyl)ethynyl)benzamide

2-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-benzoicacid (45.1 mg, 0.1 mmol) and dimethylsulfamoyl amine (149 mg, 0.14 mmol)were dissolved in N,N-dimethylformamide (1 mL), followed by the additionof 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (1.2eq), 4-dimethylaminopyridine (2 eq) and hydroxybenzotriazole (1.2 eq).The reaction was stirred at room temperature for 16 hours. The solventwas then evaporated to dryness and reaction mixture was purified bypreparative HPLC to give product as an off-white solid in 68% yield. ¹HNMR (300 MHz, CDCl₃) δ ppm 8.39 (br, s., 1 H) 7.71-7.86 (m, 3 H) 7.54(s, 1 H) 7.39-7.51 (m, 2 H) 7.20-7.33 (m, 4 H) 7.16 (d, J=7.92 Hz, 2 H)7.01 (d, J=8.21 Hz, 2 H) 6.63 (br, s., 1 H) 4.49 (s, 2 H) 3.88-4.06 (m,2 H) 3.37-3.61 (m, 3 H) 2.56 (s, 6 H) 1.82-1.99 (m, 2 H) 1.54-1.75 (m, 2H). MS m/z (M+H) 558.2.

Example 1952-(1H-indol-6-yl)-N-(methylsulfonyl)-3-((4-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)phenyl)ethynyl)benzamide

2-(1H-indol-6-yl)-N-(methylsulfonyl)-3-((4-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)phenyl)ethynyl)benzamide was prepared by same procedure as Example 194. ¹H NMR(300 MHz, DMSO-d₆) δ ppm 12.18 (br, s., 1 H) 11.34 (br, s., 1 H) 7.84(dd, J=7.48, 1.32 Hz, 1 H) 7.68 (d, J=7.92 Hz, 1 H) 7.52-7.64 (m, 3 H)7.48 (t, J=2.64 Hz, 1 H) 7.29-7.37 (m, 2 H) 7.14-7.27 (m, 3 H) 6.54 (br,s., 1 H) 4.55 (s, 2 H) 3.85 (dt, J=11.58, 4.18 Hz, 2 H) 3.58 (tt,J=8.80, 4.25 Hz, 1 H) 3.31-3.45 (m, 2 H) 2.95 (s, 3 H) 1.91 (dd,J=12.90, 3.52 Hz, 2 H) 1.40-1.60 (m, 2 H). MS m/z (M+H) 529.2

Example 1966-[2-[4-(Tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-6-(1H-tetrazol-5-yl)-phenyl]-1H-indole

N-(2-Cyanoethyl)-2-(1H-indol-6-yl)-3-((4-(((tetrahydro-2H-pyran-4-yl)oxy)methyl) phenyl)ethynyl)benzamide:2-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]benzoic acid (451 mg, 1 mmol) and 3-aminopropanenitrile (77 mg, 1.1mmol) were dissolved in DMF, followed by the addition of1-ethyl-3-(3-dirmethylamino propyl) carbodiimide hydrochloride (1.2 eq),N,N-diisopropylethylamine (2 eq) and hydroxybenzo triazole (1.2 eq). Thereaction was stirred at room temperature for 16 hours. The solvent wasevaporated and reaction mixture was purified by preparative HPLC to giveproduct as a white solid in 98% yield.

6-[2-[4-(Tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-6-(1H-tetrazol-5-yl)-phenyl]-1H-indole:N-(2-cyanoethyl)-2-(1H-indol-6-yl)-3-((4-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)phenyl) ethynyl)benzamide (500 mg, 1 mmol), diisopropylazodicarboxylate (808 mg, 4 mmol) triphenylphosphine (1048 mg, 4 mmol)and trimethylsilyl azide (460 mg, 4 mmol) and tetrahydrofuran (5 mL)were added to a vial under nitrogen. After stirring for 24 hours atambient temperature, 4 additional equivalents of diisopropylazodicarboxylate (808 mg, 4 mmol) triphenylphosphine (1048 mg, 4 mmol)and trimethylsilyl azide were added to reaction mixture and stirred foran additional 24 hours. The reaction was concentrated at reducedpressure behind a shield. Tetrahydrofuran (5 mL) and 2 M aqueous sodiumhydroxide (5 mL) was added to the reaction mixture and stirred for 4hours. The tetrahydrofuran was removed by evaporation. 10 ml water and10 ml diethyl ether were added and layer is separated. The aqueous layerwas washed with 3×2 mL diethyl ether. 2 M aqueous hydrogen chloride (5mL) was added to the aqueous layer to acidify the solution. Water wasremoved by evaporation and the resulting material was dissolved inN,N-dimethylformamide and purified via preparative HPLC to yield productas white foam in 48% yield. ¹H NMR (300 MHz, CDCl₃) δ ppm 9.71 (br, s.,1 H) 8.50 (br, s., 1 H) 8.30 (d, J=7.92 Hz, 1 H) 7.81 (t, J=−8.06 Hz, 2H) 7.46-7.60 (m, 1 H) 7.31-7.38 (m, 2 H) 7.06-7.22 (m, 3 H) 6.93 (d,J=8.21 Hz, 2 H) 6.68 (br, s., 1 H) 4.48 (s, 2 H) 3.86-4.13 (m, 2 H)3.31-3.72 (m, 3 H) 1.82-1.98 (m, 2 H) 1.53-1.73 (m, 2 H). MS m/z (M+H)476.2

Example 1973-[4-(Benzoylamino-methyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoic acid

3-[4-(Benzoylamino-methyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoic acidwas prepared by same procedure as Example 1. ¹H NMR (300 MHz, CD₃OD) δ7.75-7.85 (m, 2 H), 7.70 (d, J=7.62 Hz, 2 H), 7.30-7.60 (m, 6 H),7.23-7.28 (m 1 H), 7.17 (d, J=7.92 Hz, 2 H), 6.95-7.10 (m, 3 H), 6.48(d, J=3.15 Hz, 1 H), 4.49 (s, 2 H). MS (ESI) m/z 471.49 (M+1)⁺.

Example 1982-(1H-Indol-6-yl)-3-(4-{[(4-oxo-cyclohexanecarbonyl)-amino]-methyl}-phenylethynyl)-benzoicacid

2-(1H-Indol-6-yl)-3-(4-{[(4-oxo-cyclohexanecarbonyl)-amino]-methyl}-phenylethynyl)-benzoicacid; A was prepared by same procedure as Example 1. ¹H NMR (300 MHz,CD₃OD) δ 7.69 (d, J=7.62 Hz, 2 H), 7.57 (d, J=7.92 Hz, 1 H), 7.33-7.48(m, 2 H), 7.26 (t, J=1.61 Hz, 1 H), 6.91-7.13 (m, 5 H), 6.48 (d, J=2.93Hz, 1 H), 4.26 (s, 2 H), 2.18-2.25 (m, 1 H), 1.97-2.12 (m, 2 H),1.54-1.75 (m, 4 H), 1.18-1.44 (m, 2 H). MS (ESI) m/z 490.86 (M+H)⁺.

Example 199 2-(1H-Indol-6-yl)-3-[4-(4-oxo-cyclohexylcarbamoyl)-phenylethynyl]-benzoic acid

2-(1H-Indol-6-yl)-3-[4-(4-oxo-cyclohexylcarbamoyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 1. ¹H NMR (300 MHz,CD₃OD) δ 7.67-7.82 (m, 2 H), 7.50-7.67 (m, 3 H), 7.36-7.50 (m, 2 H),7.21-7.31 (m, 1 H), 6.94-7.14 (m, 3 H), 6.41-6.56 (m, 1 H), 3.80-3.94(m, 1 H), 2.44-2.67 (m, 1 H), 2.09-2.44 (m, 2 H), 1.67-2.07 (m 3 H),1.36-1.67 (m, 2 H). MS (ESI) m/z 477.19 (M+1)⁺.

Example 2003-[4-(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylcarbamoyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylcarbamoyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid was prepared by same procedure as Example 1. ¹H NMR (300 MHz,CD₃OD) δ 7.67-7.82 (m, 2 H), 7.53-7.67 (m, 3 H), 7.37-7.53 (m, 2 H),7.22-7.33 (m, 1 H), 6.98-7.16 (m, 3 H), 6.49 (d, J=3.21 Hz, 1 H),4.18-4.45 (m, 1 H), 2.90 (br dd, J=15.83, 5.28 Hz, 1 H), 2.65 (br s, 2H), 2.42

Example 2013-[4-(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylcarbamoyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoicacid

3-[4-(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylcarbamoyl)-phenylethynyl1]-2-(1H-indol-6-yl)-benzoic acid was prepared by same procedure asExample 1. ¹H NMR (300 MHz, CD₃OD) δ 7.68-7.80 (m, 2 H), 7.54-7.67 (m, 3H), 7.32-7.50 (m, 2 H), 7.21-7.32 (m, 1 H), 6.98-7.15 (m, 3 H), 6.49(dd, J=3.22, 0.88 Hz, 1 H), 4.26-4.42 (m, 1 H), 2.87 (br dd, J=15.98,5.13 Hz, 1 H), 2.63 (br s, 2 H), 2.51 (br dd, J=15.83, 8.79 Hz, 1 H),2.02-2.19 (m, 1 H), 1.81-2.02 (m, 1 H). MS (ESI) m/z 533.18 (M+1)⁺.

Example 2022-(1H-Indol-6-yl)-3-[4-(4-methyl-piperazine-1-carbonyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(4-methyl-piperazine-1-carbonyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 1. ¹H NMR (300 MHz,CDCl₃) δ 7.85 (dt, J=7.55, 1.21 Hz, 1 H), 7.70-7.81 (m, 1 H), 7.55-7.70(m, 1 H), 7.37-7.50 (m, 2 H), 7.14-7.26 (m 4 H), 7.09 (d, J=−7.33 Hz, 2H), 6.52 (br d, J=2.93 Hz, 1 H), 3.62-3.97 (m, 2 H), 3.41-3.45 (m, 2 H),2.88-3.26 (m, 4 H), 2.80 (s, 3 H). MS (ESI) m/z 464.28 (M+1)⁺.

Example 2032-(1H-Indol-6-yl)-3-[4-(4-methoxy-piperidine-1-carbonyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(4-methoxy-piperidine-1-carbonyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 1. ¹H NMR (300 MHz,CDCl₃) δ 8.25 (br s, 1 H), 7.83-7.98 (m 1 H), 7.77 (dt, J=7.48, 1.10 Hz;1 H), 7.68 (d, J=8.21 Hz; 1 H), 7.33-7.50 (m, 2 H), 7.09-7.23 (m, 4 H),6.92-7.09 (m, 2 H), 6.58 (ddd, J=3.22, 2.05, 0.88 Hz, 1 H), 3.50-3.41 (m3 H), 3.35 (s, 3 H), 2.38-2.53 (m, 6 H). MS (ESI) m/z 479.4 (M+1)⁺.

Example 2042-(1H-Indazol-6-yl)-3-[4-(4-methanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indazol-6-yl)-3-[4-(4-methanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CDCl₃) δ 8.12 (br d, J=2.05 Hz, 1 H), 7.70-7.94 (m, 3 H), 7.37-7.55 (m,2 H), 7.09-7.26 (m, 3 H), 7.04 (d, J=8.21 Hz, 2 H), 4.12 (s, 2 H),3.52-3.67 (m, 4 H), 3.04-3.31 (m, 4 H), 2.87 (s, 3 H). MS (ESI) m/z515.2 (M+1)*.

Example 2052-(1H-Indol-6-yl)-3-[4-(4-sulfamoyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid

2-(1H-Indol-6-yl)-3-[4-(4-sulfamoyl-piperazin-1-ylmethyl)-phenylethynyl]-benzoicacid was prepared by same procedure as Example 145. ¹H NMR (300 MHz,CD₃OD) δ 7.74 (ddd, J=7.62, 6.16, 1.17 Hz, 2 H), 7.58 (d, J=7.92 Hz, 1H), 7.39-7.49 (m, 2 H), 7.26-7.37 (m, 3 H), 7.11-7.17 (m, 2 H), 7.05(dd, J=8.21, 1.47 Hz, 1 H), 6.49 (dd, J=3.08, 1.03 Hz, 1 H), 4.30 (s, 3H). MS (ESI) m/z 515.23 (M+1)⁺.

Example 206 Inhibition of 5′-Biotin-oPL4624 Binding to his-EBNA1 UsingAlpha Screen Technology

Assays were performed using the DNA binding domain of EBNA1 (amino acids459-607), which was His-tagged (His-EBNA1) and the self-complementarybiotinylated (bt) oligonucleotide with the sequence5′-bt-GGGTAGCATATGCTATCTAGATAGCAT-ATGCTACCC-3′ (bt-oPL4624; or 5′-bt-SEQID NO: 1). The protein was expressed in E. coli and purified accordingto Barwell, et al., 1995, J Biol Chem. 270:20556-9.). The bt-oPL4624oligonucleotide was purchased from Integrated DNA Technologies, Inc(IDT). AlphaScreen donor, acceptor beads and white, opaque 384-wellassay plates were purchased from PerkinElmer, Inc.

Assays contained 15 nM His-EBNA1, 0.2 nM bt-oPL4624, 5 μg/mL AlphaScreenstreptavidin donor beads and nickel chelate acceptor beads, and a seriesof concentrations of test compound ranging from 3.2 nM to 100 μM in atotal volume of 40 μL assay buffer (25 mM Tris, pH 7.2, 160 mM NaCl, 1mM MgCl₂). His-EBNA1 (30 nM) and bt-oPL4624 (0.4 nM) were preincubatedwith 10 μg/mL nickel chelate AlphaScreen acceptor bead, or 10 μg/mLstreptavidin AlphaScreen donor bead, respectively, for 30 minutes atroom temperature in assay buffer. Twenty microliters ofHis-EBNA1/acceptor bead mix and bt-oPL4624/donor bead mix weretransferred to assay plates containing 0.4 μL of 1:3 serial dilutions oftest compounds previously prepared in DMSO at concentrations rangingfrom 0.32 μM to 10 mM. Non-specific binding was determined with 5 μg/mLAlphaScreen acceptor bead in the absence of His-EBNA1. After 2 hrincubation at room temperature, the AlphaScreen signal was measured onthe Envision plate reader (PerkinElmer, Inc.) at 680 nm excitation and570 nm emission. Inhibition values at each concentration of testcompound were determined by setting 100% equal to raw data values in theabsence of EBNA1 and 0% equal to the raw data values in the presence ofEBNA1. Nonlinear regression fits of the inhibition values to a one-sitedose-response equation were performed using GraphPad Prism.

Example 207 Cell Based Luciferase Assay of EBNA1 Inhibition

In vivo inhibition of EBNA1 was determined for compounds of thedisclosure using a cell based luciferase reporter assay. EBNA1 bindingto the Family of Repeat (FR) region is essential for EBV latentinfection and host-cell viability, thus providing a physiologicallymeaningful cell-based readout. A derivative of EBNA1, which isfunctionally equivalent to full-length EBNA1 and lacks the GGA repeats(90-325), was cloned into p3×FLAG-Myc-CMV™-24 (Sigma-Aldrich Co., LLC)(N803). To make the assay more sensitive by reducing the expressionlevels of EBNA1, the CMV promoter was excised and the TK promoterinserted upstream of EBNA1. To enhance the EBNA1-driven luciferasesignal, the activation domain of herpes virus VP16 (411-490) was fusedto the C-terminus of EBNA1 using SacII and BamHI restriction sites,resulting in the plasmid pTK-3×FLAG-Myc-EBNA1-VP16AD. Empty vectorp3×FLAG-Myc-CMV-24 was used as a control. To create luciferase reporterplasmid, the FR region, a locus of 21 contiguous EBNA1 binding sites(7421-8042), was PCR amplified from EBV genomic DNA and cloned into thepGLuc-Basic 2 (New England Biolabs) using the KpnI and HindIIIrestriction sites, resulting in plasmid pGLuc2-21×FR.

For the transient transfection assay. HEK293T cells were seeded at aconcentration of 4-8×10⁶ cells in a 10 cm plate in Delbecco's ModifiedEagle Medium (DMEM) (Life Technologies Corp.) supplemented with 10%Fetal Bovine Serum (FBS) (Gemini Bio-Products). After overnightincubation, the transfection was performed using Lipofectamine 2000(Life Technologies). 3 μg of pGLuc2-21×FR and 0.6 μg ofpTK-3×FLAG-Myc-EBNA1-VP16AD or p3×FLAG-Myc-CMV-24 (empty vector) wereadded to 0.5 ml Optimem buffer (Life Technologies Corp.). 30 μlLipofectamine was added to a separate 0.5 ml Optimem buffer andincubated for 5 minutes. The DNA and lipofectamine mixtures werecombined and incubated for 20 minutes at room temperature and added dropwise to the 10 cm plate. The cells were then incubated for 6 hours at37° C. The cells were harvested, counted and re-suspended at aconcentration of 2×10⁵ cells/ml and distributed using a MicroFlodispenser (BioTek) in 384-well tissue culture plate (Greiner BioOne), 40μl (8000 cells) per well. 160 nl of solutions of compounds of thedisclosure in DMSO at concentrations ranging from 50 mM to 976 μM wereadded to the cells (10-point 2-fold dilution series, final concentration200 uM-390 nM) using a Janus modular Nanohead dispenser (PerkinElmer,Inc.). Compounds and transfected cells were incubated overnight at 37°C. Gaussia luciferase is secreted into the medium. The top 10 μl of cellmedia from the 384-well tranfected HEK293T cells is transferred to awhite opaque 384-well development plate. 10 μl of substrate is added toeach well and incubated for 5 minutes. Bioluminescence is then measuredusing the Envision Multiplate Reader (Perkin Elmer, Inc.). To normalizethe activity of the compounds of the disclosure and to filter toxiccompound, the remaining 30 μl of cell media (including the cells) areincubated with 6 μl resazurin, incubated for 4-6 hours at 37° C., andmeasured using the Envision Multiplate Reader. Data analysis and IC₅₀curves are generated using Prism (GraphPad).

Example 208 Cell Viability Assay

To further evaluate the cell-based efficacy of EBNA1 inhibitors, a cellcytotoxicity assay was performed. EBNA1 inhibitors selectively killEBV-positive cell lines (Raji, LCL, C666-1) relative to EBV-negativecell lines (Bjab, DG75, HNE-1). Raji, Bjab, and DG75 were obtained fromAmerican Type Tissue Culture (ATCC), C666-1 and HNE-1 were a gift fromAnne Lee (Hong Kong University) and the Lymphoblastic Cell Line (LCL)was obtained by in vitro infection of B-cells with the B95.8 strain ofEBV.

To perform this assay, 40 μl of the different cell lines were seeded ata concentration of 1×10⁵ cells in a clear 384-well plate (4000cell/well). 160 nl of compound at concentrations ranging from 50 mM to976 μM were added to each well (10-point, 2-fold dilution series, finalconcentration 200 uM-390 nM) using a Janus modular Nanohead dispenser(PerkinElmer, Inc.). Cells were incubated for 72 hours in a humidified37° C. incubator 5% CO₂. The cell viability is inferred using theoxidation-reduction indicator, resazurin. 8 ul of resazurin was added toeach well and after 4-6 hours incubation at 37° C., the fluorescentsignal was monitored using 530-560 nm excitation wavelength and 590 nmemission wavelength using the Envision Multiplate Reader.

Data analysis and CC₅₀ (Cytotoxicity Concentration) curves are generatedusing Prism (GraphPad). A selectivity index is calculated by determiningthe ratio of the CC₅₀ from the EBV-negative cell line over the CC₅₀ fromthe EBV-positive cell line.

TABLE 2 Inhibition of 5′-biotin-oPL4624 binding to His-EBNA1 ofrepresentative compounds of the disclosure using Alpha Screentechnology: Alpha Screen Entry Compound Activity 12-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-indol-6-ylethynyl]-++ benzoic acid 23-[3-Acetylamino-4-(tetrahydro-pyran-4-yloxy)-phenylethynyl]-2-(1H- ++indol-6-yl)-benzoic acid 33-[4-(8-Acetyl-8-aza-bicyclo[3.2.1]oct-3-yl)-phenylethynyl]-2-(1H-indol-++ 6-yl)-benzoic acid 43-[1-(2-Dimethylamino-ethyl)-1H-pyrrolo(2,3-b]pyridin-5-ylethynyl]-2-+++ (1H-indol-6-yl)-benzoic acid 53-[1-(3-Dimethylamino-propyl)-1H-pyrrolo(2,3-b]pyridin-5-ylethynyl]-2-++ (1H-indol-6-yl)-benzoic acid 62-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-pyrrolo[2,3- +++b]pyridin-5-ylethynyl]-benzoic acid 72-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-pyrrolo[2,3- ++b]pyridin-3-ylethynyl]-benzoic acid 82-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-pyrrolo[2,3-b]pyridin-+++ 5-ylethynyl]-benzoic acid 93-{2-[3-(3,3-dimethyl-2-oxoazetidin-1-yl)phenyl]ethynyl}-2-(1H-pyrrol-1- +yl)benzoic acid3-[1-(2-Dimethylamino-ethyl)-1H-pyrrolo[2,3-b]pyridin-3-ylethynyl]-2-(1H-indol-6-yl)-benzoic acid 102-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-pyrrolo[2,3-b]pyridin-++ 3-ylethynyl]-benzoic acid 113-[1-(3-Dimethylamino-propyl)-1H-pyrrolo[2,3-b]pyridin-3-ylethynyl]-2- +(1H-indol-6-yl)-benzoic acid 123-{1-[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-ethyl]-1H-pyrrolo[2,3- ++b]pyridin-5-ylethynyl}-2-(1H-indol-6-yl)-benzoic acid 132-(1H-indol-6-yl)-3-[1-(2-morpholin-4-yl-ethyl)-1H-indol-5-ylethynyl]-++ benzoic acid 142-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-indol-5-ylethynyl]-++ benzoic acid 152-(1H-indol-6-yl)-3-[1-(3-morpholin-4-yl-propyl)-1H-indol-6-ylethynyl]-++ benzoic acid 162-(1H-Indol-6-yl)-3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-3-ylethynyl)-+++ benzoic acid 172-(1H-indol-6-yl)-3-[1-(tetrahydro-pyran-4-ylmethyl)-1H-pyrrolo[2,3- +++b]pyridin-5-ylethynyl]-benzoic acid 182-(1H-Indol-6-yl)-3-[1-(tetrahydro-pyran-4-ylmethyl)-1H-indol-5- +++ylethynyl]-benzoic acid 192-(1H-Indol-6-yl)-3-[1-(1-methanesulfonyl-piperidin-4-ylmethyl)-1H- +++indol-5-ylethynyl]-benzoic acid 202-(1H-Indol-6-yl)-3-[1-(1-methanesulfonyl-piperidin-4-ylmethyl)-1H- +++pyrrolo [2,3-b]pyridin-5-ylethynyl]-benzoic acid 213-[1-(1,1-Dioxo-hexahydro-1λ⁶-thiopyran-4-ylmethyl)-1H-pyrrolo [2,3- +++b]pyridin-5-ylethynyl]-2-(1H-indol-6-yl)-benzoic acid 223-{1-[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-ethyl]-1H-indol-5-yl- +++ethynyl}-2-(1H-indol-6-yl)-benzoic acid 233-{1-[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-ethyl]-1H-indol-6-ylethynyl}-++ 2-(1H-indol-6-yl)-benzoic acid 243-{1-[3-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-propyl]-1H-indol-5-yl- ++ethynyl}-2-(1H-indol-6-yl)-benzoic acid 253-{1-[3-(1,1-Dioxo-1λ⁶-thiomorpholin-4-yl)-propyl]-1H-indol-6-yl- +++ethynyl}-2-(1H-indol-6-yl)-benzoic acid 263-[4-(1,1-Dioxo-hexahydro-1λ⁶-thiopyran-4-yloxymethyl)-phenyethynyl]- ++2-(1H-indol-6-yl)-benzoic acid 272-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-++ benzoic acid 282-(1H-Indol-6-yl)-3-(4-isopropoxymethyl-phenylethynyl)-benzoic acid +++29 2-(1H-Indol-6-yl)-3-[4-(1-oxo-hexahydro-1λ⁴-thiopyran-4-yloxy)- ++phenylethynyl]-benzoic acid 302-(1H-indol-6-yl)-3-(3-morpholin-4-ylmethyl-1H-indol-6-ylethynyl)- ++benzoic acid 312-(1H-indol-6-yl)-3-[3-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H- +++indol-6-ylethynyl]-benzoic acid 323-[3-(1,1-Dioxo-1λ⁶-thiomorpholin-4-ylmethyl)-1H-indol-6-ylethynyl]-2-+++ (1H-indol-6-yl)-benzoic acid 332-(1H-indol-6-yl)-3-(2-morpholin-4-ylmethyl-1H-indol-6-ylethynyl)- ++benzoic acid 343-[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-ylmethyl)-1H-indol-6-ylethynyl]-2-+++ (1H-indol-6-yl)-benzoic acid 353-[1-(4-ethoxy-2-methyl-butyl)-6-fluoro-1H-indol-5-ylethynyl]-2-(1H- +++indol-6-yl)-benzoic acid 363-[7-fluoro-1-(tetrahydro-pyran-4-ylmethyl)-1H-indol-6-ylethynyl]-2-(1H-+++ indol-6-yl)-benzoic acid 373-[1-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-ylmethyl)-7-fluoro-1H-indol-+++ 6-ylethynyl]-2-(1H-indol-1)-benzoic acid 383-[1-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-ylmethyl)-6-fluoro-1H-indol-+++ 5-ylethynyl]-2-(1H-indol-6-yl)-benzoic acid 393-(7-fluoro-3-morpholin-4-ylmethyl-1H-indol-6-ylethynyl)-2-(1H-indol-6-+++ yl)-benzoic acid 403-(6-fluoro-3-morpholin-4-ylmethyl-1H-indol-5-ylethynyl)-2-(1H-indol-6-++ yl)-benzoic acid 413-((4-(2H-tetrazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoic acid++++ 42 3-((3-(2H-tetrazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)benzoicacid ++++ 43 2-(1H-indol-6-yl)-3-((4-(oxazol-5-yl)phenyl)ethynyl)benzoicacid +++ 442-(1H-indol-6-yl)-3-((4-(6-oxo-1,6-dihydropyridazin-3-yl)phenyl) +++ethynyl)benzoic acid 45 2-(1H-indol-6-yl)-3-((3-methoxy-4- ++(morpholinomethyl)phenyl)ethynyl)benzoic acid 463-((3-hydroxy-4-(morpholine-4-carbonyl)phenyl)ethynyl)-2-(1H-indol-6- ++yl)benzoic acid 472-(1H-Indol-6-yl)-3-{3-methoxy-4-(4-morpholin-4-yl-piperidin-1- +ylmethyl)-phenylethynyl]-benzoic acid 483-((4-((4,4-difluoropiperidin-1-yl)methyl)-3-methoxyphenyl)ethynyl)-2-+++ (1H-indol-6-yl)benzoic acid 493-((4-((4-(dimethylcarbamoyl)piperidin-1-yl)methyl)-3-methoxyphenyl)ethynyl)-2-(1H-indol-6-yl)benzoic acid 503-((3-hydroxy-4-(4-morpholinopiperidine-1-carbonyl)phenyl)ethynyl)-2-+++ (1H-indol-6-yl)benzoic acid 513-((4-(4,4-difluoropiperidine-1-carbony1)-3-hydroxyphenyl)ethynyl)-2-+++ (1H-indol-6-yl)benzoic acid 522-(1H-indol-6-yl)-3-((4-((1-(methylsulfonyl)piperidin-4- +++yl)methyl)phenyl)ethynyl) benzoic acid 532-(1H-indol-6-yl)-3-((4-((1-((trifluoromethyl)sulfonyl)piperidin-4- +++yl)methyl)phenyl)ethynyl)benzoic acid 542-(1H-indol-6-yl)-3-((4-((1-(isopropylsulfonyl)piperidin-4- +++yl)methyl)phenyl)ethynyl) benzoic acid 553-((4-((1-acetylpiperidin-4-yl)methyl)phenyl)ethynyl)-2-(1H-indol-6- +++yl)benzoic acid 563-((2-acetylisoindolin-5-yl)ethynyl)-2-(1H-indol-6-yl)benzoic acid +++572-(1H-indol-6-yl)-3-((2-(isopropylsulfonyl)isoindolin-5-yl)ethynyl)benzoic+++ acid 582-(1H-indol-6-yl)-3-((2-(1-(methylsulfonyl)pyrrolidin-3-yl)-1,2,3,4- ++tetrahydroisoquinolin-7-yl)ethynyl)benzoic acid 592-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)piperidin-4-yl)methyl)-1,2,3,4-++ tetrahydroisoquinolin-6-yl)ethynyl)benzoic acid 602-(1H-indol-6-yl)-3-((2-(1-(methylsulfonyl)azetidin-3-yl)-1,2,3,4- ++tetrahydroisoquinolin-6-yl) ethynyl)benzoic acid 612-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)- ++1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzoic acid 622-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)- ++1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl)benzoic acid 633-((2-((1-acetylpyrrolidin-3-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-7-++ yl)ethynyl)-2-(1H-indol-6-yl)benzoic acid 642-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)azetidin-3-yl)methyl)-1,2,3,4-++ tetrahydroisoquinolin-6-yl)ethynyl)benzoic acid 652-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)azetidin-3-yl)methyl)-1,2,3,4-++ tetrahydroisoquinolin-7-yl)ethynyl)benzoic acid 662-(1H-indol-6-yl)-3-((2-(3-(methylsulfonamido)benzyl)-1,2,3,4- +++tetrahydroisoquinolin-6-yl)ethynyl)benzoic acid 672-(1H-indol-6-yl)-3-((2-(3-(methylsulfonamido)benzyl)-1,2,3,4- +++tetrahydroisoquinolin-7-yl)ethynyl)benzoic acid 682-(1H-indol-6-yl)-3-((2-(1-(methylsulfonyl)pyrrolidin-3-yl)isoindolin-5-+++ yl)ethynyl)benzoic acid 692-(1H-indol-6-yl)-3-((2-(1-(methylsulfonyl)azetidin-3-yl)isoindolin-5-+++ yl)ethynyl)benzoic acid 702-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)pyrrolidin-3- +++yl)methyl)isoindolin-5-yl)ethynyl)benzoic acid 712-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)azetidin-3- ++yl)methyl)isoindolin-5-yl)ethynyl)benzoic acid 722-(1H-indol-6-yl)-3-((2-((1-(methylsulfonyl)piperidin-4- ++yl)methyl)isoindolin-5-yl)ethynyl)benzoic acid 732-(1H-indol-6-yl)-3-((2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-7-+++ yl)ethynyl)benzoic acid 742-(1H-indol-6-yl)-3-((2-(isopropylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-+++ 7-yl)ethynyl)benzoic acid 752-(1H-indol-6-yl)-3-((2-propionyl-1,2,3,4-tetrahydroisoquinolin-7- ++yl)ethynyl) benzoic acid 762-(1H-indol-6-yl)-3-((2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-+++ yl)ethynyl)benzoic acid 772-(1H-indol-6-yl)-3-((2-(isopropylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-+++ 6-yl)ethynyl)benzoic acid 783-((2-acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)-2-(1H-indol-6-+++ yl)benzoic acid 792-(1H-indol-6-yl)-3-((2-propionyl-1,2,3,4-tetrahydroisoquinolin-6- +++yl)ethynyl)benzoic acid 803-[4-(4-cyano-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoic+++ acid 813-[4-(3-cyano-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoic+++ acid 823-[4-(3-carbamoyl-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)- +++benzoic acid 832-(1H-indol-6-yl)-3-[4-(4-trifluoromethyl-phenoxymethyl)-phenylethynyl]-+++ benzoic acid 842-(1H-indol-6-yl)-3-[4-(3-trifluoromethyl-phenoxymethyl)-phenylethynyl]-+++ benzoic acid 852-(1H-indol-6-yl)-3-[4-(4-methoxy-phenoxylmethyl)-phenylethynyl]- +++benzoic acid 863-[4-(4-carbamoyl-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)- +++benzoic acid 872-(1H-indol-6-yl)-3-[4-(3-methoxy-phenoxymethyl)-phenylethynyl]- +++benzoic acid 882-(1H-indol-6-yl)-3-(4-phenoxymethyl-phenylethynyl)-benzoic acid +++ 893-[4-(2-fluoro-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoic+++ acid 902-(1H-indol-6-yl)-3-[4-(pyridin-3-yloxymethyl)-phenylethynyl]-benzoic+++ acid 913-[4-(3-chloro-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoic+++ acid 923-[4-(3_(,)4-dichloro-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-+++ benzoic acid 932-(1H-indol-6-yl)-3-[4-(2-trifluoromethyl-phenoxymethyl)-phenylethynyl]-+++ benzoic acid 943-[4-(2-cyano-phenoxymethyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoic+++ acid 95 2-(1H-indol-6-yl)-3-[4-(4-methanesulfonyl-phenoxymethyl)-+++ phenylethynyl]-benzoic acid 962-(1H-indol-6-yl)-3-[4-(pyrimidin-5-yloxymethyl)-phenylethynyl]-benzoic+++ acid 97 2-(1H-indol-6-yl)-3-[4-(2-methanesulfonyl-phenoxymethyl)-+++ phenylethynyl]-benzoic acid 982-(1H-indol-6-yl)-3-[4-(3-methanesulfonyl-phenoxymethyl)- +++phenylethynyl]-benzoic acid 992-(1H-Indol-6-yl)-3-{2-[3-(3-methanesulfonamidophenyl)phenyl] +++ethynyl}benzoic acid 1002-(1H-Indol-6-yl)-3-{2-[6-(oxan-4-yloxy)pyridin-3-yl]ethynyl}benzoic +++acid 101 2-(1H-Indol-6-yl)-3-{2-[2-(propylcarbamoyl)-1H-indol-6- +++yl]ethynyl}benzoic acid 1022-(1H-Indol-6-yl)-3-{2-[3-(1,2,3,4-tetrahydroisoquinolin-2- +++ylmethyl)phenyl)ethynyl}benzoic acid 1033-{2-[3-Cyano-4-(oxan-4-yloxy)phenyl]ethynyl}-2-(1H-indol-6-yl)benzoic+++ acid 1043-[2-(3-{[4-(Ethoxycarbonyl)piperazin-1-yl]methyl}phenyl)ethynyl]-2- ++(1H-indol-6-yl)benzoic acid 1053-(2-{4-[3-(Hydroxymethyl)oxetan-3-yl]phenyl}ethynyl)-2-(1H-indol-6- +++yl)benzoic acid 1063-{2-[3-(5-Amino-1H-pyrazol-3-yl)phenyl]ethynyl}-2-(1H-indol-6- +++yl)benzoic acid 1072-(1H-Indol-6-yl)-3-{2-[3-(1,3-oxazol-5-yl)phenyl]ethynyl}benzoic acid+++ 108 2-(1H-Indol-6-yl)-3-{2-[4-(oxane-4-carbonyl)phenyl]ethynyl}benzoic acid +++ 109 2-(7-Fluoro-1H-indol-6-yl)-3-phenylethynyl-benzoicacid ++ 110 2-Benzothiazol-6-yl-3-phenylethynyl-benzoic acid ++ 1112-Benzothiazol-5-yl-3-phenylethynyl-benzoic acid ++ 1122-(2-Methyl-benzothiazol-5-yl)-3-phenylethynyl-benzoic acid ++ 1132-(5-Fluoro-1H-indol-6-yl)-3-phenylethynyl-benzoic acid +++ 1142-(6-Fluoro-1H-indol-5-yl)-3-phenylethynyl-benzoic acid ++ 1152-[1,8]Naphthyridin-3-yl-3-phenylethynyl-benzoic acid + 1162-(1-Methyl-1H-pyrrolo [2,3-b]pyridin-6-yl)-3-phenylethynyl-benzoic acid++ 117 2-[1,8]Naphthyridin-2-yl-3-phenylethynyl-benzoic acid ++ 1183-Phenylethynyl-2-(1H-pyrrolo [2,3-b]pyridin-6-yl)-benzoic acid + 1192-(4-methoxy-1H-indol-6-yl)-3-(2-phenylethynyl)-benzoic acid +++ 1203-(2-(4-(2-hydroxypropan-2-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoic+++ acid 1213-(2-(4-(2-aminothiazol-4-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoic+++ acid 122 2-(1H-Indol-6-yl)-3-(3-sulfamoyl-phenylethynyl)-benzoicacid ++ 1233-(4-Amino-3-sulfamoyl-phenylethynyl)-2-(1H-indol-6-yl)-benzoic acid ++124 2-(1H-indol-6-yl)-3-(Spiro[2H-1-benzopyran-2,1′-4-piperidine-1-t-+++ butylcarboxylate]-4(3H)-one)ethynyl)benzoic acid 1253-(2-(3-(2-aminothiazol-4-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoic+++ acid 1263-(2-(4-(5-(methoxycarbonyl)-2-aminothiazol-4-yl)phenyl)ethynyl)-2-(1H-++++ indol-6-yl)-benzoic acid 1273-(2-(4-(5-amino-1,3,4-thiadiazol-2-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-+++ benzoic acid 1283-(2-(4-(3-amino-1H-pyrazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)- +++benzoic acid 1292-Amino-4-{4-[3-carboxy-2-(1H-indol-6-yl)-phenylethynyl]-phenyl}- ++++thiazole-5-carboxylic acid 1303-(2-(4-(2-aminooxazol-5-yl)phenyl)ethynyl)-2-(1H-indol-6-yl)-benzoic+++ acid 1312-(1H-Indol-6-yl)-3-[4-(2-methanesulfonylamino-thiazol-4-yl)- ++++phenylethynyl]-benzoic acid 1322-(1H-Indol-6-yl)-3-[3-(2-methanesulfonylamino-thiazol-4-yl)- ++++phenylethynyl]-benzoic acid 1333-(2-(1,4-dihydro-2-((4-methoxypiperidin-1-yl)methyl)-4-oxoquinazolin-6-++ yl)ethynyl)-2-(1H-indol-6-yl)benzoic acid 1343-(2-(1,4-dihydro-2-((4-thiomorpholine-1,1dioxide-1-yl)methyl)-4- +++oxoquinazolin-6-yl)ethynyl)-2-(1H-indol-6-yl)benzoic acid 1353-(2-(2-(trifluoromethyl)-3,4-dihydro-4-oxoquinazolin-6-yl)ethynyl)-2-+++ (1H-indol-6-yl)benzoic acid 1363-(2-(3,4-dihydro-3-(2-methoxyethyl)-4-oxopyrido[2,3-d]pyrimidin-6- +++yl)ethynyl)-2-(1H-indol-6-yl)benzoic acid 1372-(1H-Indol-6-yl)-3-[3-(2-methoxy-6-methyl-phenylcarbamoyl)- +++phenylethynyl]-benzoic acid 1383-{3-[4-(1,1-Dioxo-1-thiomorpholin-4-yl)-phenylcarbamoyl]- +++phenylethynyl}-2-(1H-indol-6-yl)-benzoic acid 1393-Phenylethynyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoic acid ++++ 1403-(4-Fluoro-phenylethynyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoicacid ++ 1413-(4-Methoxy-phenylethynyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-benzoic ++acid 1422-(1H-Pyrrolo[2_(,)3-b]pyridin-5-yl)-3-[4-(tetrahydro-pyran-4-yloxy)- ++phenylethynyl]-benzoic acid 1432-(1H-Indol-6-yl)-3-{4-[2-(tetrahydro-pyran-4-yl)-ethoxy]-phenylethynyl}-+++ benzoic acid 1443-[4-(1,1-Dioxo-hexahydro-1-thiopyran-4-yloxy)-phenylethynyl]-2-(1H- ++indol-6-yl)-benzoic acid 1452-(1H-Indol-6-yl)-3-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoic acid+++ 1463-[4-(4-Ethyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)- ++benzoic acid 1472-(1H-Indol-6-yl)-3-[4-(4-methyl-piperazin-1-yimethyl)-phenylethynyl]-++ benzoic acid 1483-[4-(1,1-Dioxo-thiomorpholin-4-ylmethyl)-phenylethynyl]-2-(1H-indol-6-+++ yl)-benzoic acid 1493-(4-{[(2-Dimethylamino-ethyl)-methyl-amino]-methyl}-phenylethynyl)-2-++ (1H-indol-6-yl)-benzoic acid 1503-{4-[4-(2-Hydroxy-ethyl)-piperidin-1-ylmethyl]-phenylethynyl}-2-(1H-+++ indol-6-yl)-benzoic acid 1513-[4-(4-Hydroxymethyl-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-++ 6-yl)-benzoic acid 1522-(1H-Indol-6-yl)-3-[4-(4-methyl-[1,4]diazepan-1-ylmethyl)- +++phenylethynyl]-benzoic acid 1533-[4-(3-Hydroxy-azetidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-++ benzoic acid 1543-[4-(4-Hydroxy-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-yl)-++ benzoic acid 1552-(1H-Indol-6-yl)-3-[4-(4-methoxy-piperidin-1-ylmethyl)-phenylethynyl]-++ benzoic acid 1563-(4-Dimethylaminomethyl-phenylethynyl)-2-(1H-indol-6-yl)-benzoic acid++ 157 2-(1H-Indol-6-yl)-3-(4-{[(2-methoxy-ethyl)-methyl-amino]-methyl}-++ phenylethynyl)-benzoic acid 1583-[4-(4,4-Difluoro-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-+++ yl)-benzoic acid 1593-[4-(3,3-Difluoro-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-+++ yl)-benzoic acid 1603-[4-(3,4-Dihydro-1H-isoquinolin-2-ylmethyl)-phenylethynyl]-2-(1H- +++indol-6-yl)-benzoic acid 1612-(1H-Indol-6-yl)-3-[4-(4-methanesulfonyl-piperazin-1-ylmethyl)- ++phenylethynyl]-benzoic acid 1622-(1H-Indol-6-yl)-3-[4-(3-trifluoromethyl-piperidin-1-ylmethyl)- +++phenylethynyl]-benzoic acid 1632-(1H-Indol-6-yl)-3-[4-(3-methoxy-pyrrolidin-1-ylmethyl)-phenylethynyl]-++ benzoic acid 1642-(1H-Indol-6-yl)-3-[4-(4-isopropyl-piperazin-1-ylmethyl)-phenylethynyl]-++ benzoic acid 1653-[4-(4-Cyclohexyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-++ yl)-benzoic acid 1663-[4-(4-Cyclopropanecarbonyl-piperazin-1-ylmethyl)-phenylethynyl]-2- +++(1H-indol-6-yl)-benzoic acid 1672-(1H-Indol-6-yl)-3-(4-piperazin-1-ylmethyl-phenylethynyl)-benzoic acid++ 1683-[4-(4-Benzenesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H- +++indol-6-yl)-benzoic acid 1693-{4-[(1,1-Dioxo-hexahydro-1-thiopyran-4-ylamino)-methyl]- ++phenylethynyl}-2-(1H-indol-6-yl)-benzoic acid 1703-[4-(4-Cyclopentyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-6-++ yl)-benzoic acid 1713-[4-(4-Dimethylcarbamoyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H- ++indol-6-yl)-benzoic acid 1722-(1H-Indol-6-yl)-3-[4-(2,3,5,6-tetrahydro-[1,2′]bipyrazinyl-4-ylmethyl)-+++ phenylethynyl]-benzoic acid 1732-(1H-Indol-6-yl)-3-[4-(4-thiazol-2-yl-piperazin-1-ylmethyl)- +++phenylethynyl]-benzoic acid 1743-{4-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylamino)-methyl]- +++phenylethynyl}-2-(1H-indol-6-yl)-benzoic acid 1753-{4-[(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylamino)-methyl]- +++phenylethynyl}-2-(1H-indol-6-yl)-benzoic acid 1763-[4-(4-Methyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H-pyrrolo[2,3-++ b]pyridin-5-yl)-benzoic acid 1773-[4-(4-Methoxy-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-pyrrolo[2,3- +b]pyridin-5-yl)-benzoic acid 1782-(1H-Indol-5-yl)-3-[4-(4-methoxy-piperidin-1-ylmethyl)-phenylethynyl]-++ benzoic acid 1792-(1H-Indol-5-yl)-3-[4-(4-methanesulfonyl-piperazin-1-ylmethyl)- ++phenylethynyl]-benzoic acid 1803-[4-(4-Methanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2-(1H- +++pyrrolo[2,3-b]pyridin-5-yl)-benzoic acid 1813-[4-(4,4-Difluoro-piperidin-1-ylmethyl)-phenylethynyl]-2-(1H-indol-5-+++ yl)-benzoic acid 1822-(1H-Indol-5-yl)-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenylethynyl]-+++ benzoic acid 1833-[4-(4-Ethanesulfonyl-piperazin-1-ylmethyl)-phenylethyhyl]-2-(1H-indol-++ 6-yl)-benzoic acid 1843-[4-(1,1-Dioxo-hexahydro-1-thiopyran-4-yloxy)-phenylethynyl]-2-(1H- +++indol-5-yl)-benzoic acid 1853-[4-(1,1-Dioxo-hexahydro-thiopyran-4-yloxy)-phenylethynyl]-2-(1H- ++indazol-6-yl)-benzoic acid 1863-[2-Fluoro-4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-2-(1H- +++indol-6-yl)-benzoic acid 1873-[4-(1,1-Dioxo-hexahydro-1-thiopyran-4-yloxymethyl)-2-fluoro- ++phenylethynyl]-2-(1H-indol-6-yl)-benzoic acid 1882-(1H-Indol-6-yl)-3-[4-(2-methanesulfonyl-2,7-diaza-spiro[3.5]non-7- ++ylmethyl)phenylethynyl]-benzoic acid 1892-(1H-Indol-6-yl)-3-[4-(5-methanesulfonyl-hexahydro-pyrrolo[3,4- ++c]pyrrol-2-ylmethyl)-phenylethynyl]-benzoic acid 1903-[4-(4-Cyclopropanesulfonyl-piperazin-1-ylmethyl)-phenylethynyl]-2- ++(1H-indol-6-yl)-benzoic acid 1912-(1H-Indol-6-yl)-3-{4-[4-(propane-2-sulfonyl)-piperazin-1-ylmethyl]-+++ phenylethynyl}-benzoic acid 1922-(1H-Indol-6-yl)-3-[4-(7-methanesulfonyl-2,7-diaza-spiro[3.5]non-2- ++ylmethyl)-phenylethynyl]-benzoic acid 1932-(1H-Indol-5-yl)-3-[4-(tetrahydro-pyran-4-yloxy)-phenylethynyl]-benzoic+++ acid 194N-(N,N-dimethylsulfamoyl)-2-(1H-indol-6-yl)-3-((4-(((tetrahydro-2H- +++pyran-4-yl)oxy)methyl)phenyl)ethynyl)benzamide 1952-(1H-indol-6-yl)-N-(methylsulfonyl)-3-((4-(((tetrahydro-2H-pyran-4- ++yl)oxy)methyl)phenyl)ethynyl)benzamide 1966-[2-[4-(Tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-6-(1H-tetrazol-+++ 5-yl)-phenyl]-1H-indole 1973-[4-(Benzoylamino-methyl)-phenylethynyl]-2-(1H-indol-6-yl)-benzoic +++acid 1982-(1H-Indol-6-yl)-3-(4-{[(4-oxo-cyclohexanecarbonyl)-amino]-methyl}-++++ phenylethynyl)-benzoic acid 1992-(1H-Indol-6-yl)-3-[4-(4-oxo-cyclohexylcarbamoyl)-phenylethynyl]- ++++benzoic acid 2003-[4-(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylcarbamoyl)- +++phenylethynyl]-2-(1H-indol-6-yl)-benzoic acid 2013-[4-(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-ylcarbamoyl)- +++phenylethynyl]-2-(1H-indol-6-yl)-benzoic acid 2022-(1H-Indol-6-yl)-3-[4-(4-methyl-piperazine-1-carbonyl)-phenylethynyl]-++ benzoic acid 2032-(1H-Indol-6-yl)-3-[4-(4-methoxy-piperidine-1-carbonyl)-phenylethynyl]-+++ benzoic acid 2042-(1H-Indazol-6-yl)-3-[4-(4-methanesulfonyl-piperazin-1-ylmethyl)- ++phenylethynyl]-benzoic acid 2052-(1H-Indol-6-yl)-3-[4-(4-sulfamoyl-piperazin-1-ylmethyl)- +++phenylethynyl]-benzoic acid Alpha Screen Activity: IC₅₀ < 1 uM = ++++; 1uM < IC₅₀ < 10 uM = +++; 10 uM < IC₅₀ < 100 uM = ++; 100 uM < IC₅₀ < 1mM = +.

The disclosures of each and every patent, patent application, andpublication cited herein are hereby incorporated herein by reference intheir entirety.

While the invention has been disclosed with reference to specificembodiments, it is apparent that other embodiments and variations ofthis invention may be devised by others skilled in the art withoutdeparting from the true spirit and scope of the invention. The appendedclaims are intended to be construed to include all such embodiments andequivalent variations.

What is claimed is: 1.2-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-benzoicacid; or a salt thereof.
 2. A pharmaceutical composition comprising2-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-benzoicacid, or a salt thereof, and at least one pharmaceutically acceptablecarrier.
 3. The pharmaceutical composition of claim 2, furthercomprising at least one additional antiviral or anticancer agent. 4.2-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-benzoicacid.
 5. A pharmaceutical composition comprising2-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-benzoicacid and at least one pharmaceutically acceptable carrier.